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1 Introduction 
In order to multiply, pathogenic organisms or particles, such as bacteria or viruses, often 
interfere with cellular transcription regulation to successfully establish infection. They use 
different regulatory proteins which function like their cellular equivalents by specifically 
binding to the promoter regions of their target genes, the initiation and regulation points for 
the transcription process, to control their expression (for a recent review on eucaryotic 
promoters see (Smale and Kadonaga, 2003)). 
Transcriptional regulation must occur as soon as cells need to react to different 
environments and therefore to different signals which elicit specific responses that depend 
on the organ or organism to which the cells belong.  Regulation depends on specific 
transcriptional repressors or activators, which are brought to the nucleus where they are 
activated via the signal transduction pathways leading from the cell surface to the nucleus. 
Different stimuli thus lead to the production of different signalling proteins, which transfer 
the signal via a varying number of intermediate proteins to the nucleus. The last protein in 
this regulatory chain binds specifically to regulatory elements in the promoter region of its 
target genes, leading to repression or activation of transcription of the corresponding gene.  
The present work focuses on the human transcription factor RBP-Jκ and its direct 
interaction partners upstream of the signal transduction pathway. The best examined 
cellular interaction partner of RBP-Jκ is Notch1. A viral equivalent of this protein, EBNA2, 
is a key component in establishing the latency phase, leading to cell immortalization in 
host cells infected by the Epstein-Barr virus, which can cause infectious mononucleosis 
and is also associated with certain types of cancer. 
 
1.1 RBP-Jκ 
The transcription factor RBP-Jκ (recognition signal binding protein Jκ, also called CBF-1 
for Cp-binding factor 1) belongs to the family of CSL proteins (human C promoter binding 
factor, Drosophila melanogaster Suppressor of Hairless and Caenorhabditis elegans Lag-
1), members of which are evolutionarily conserved from nematodes to fruit flies and 
humans. They have a high sequence identity and bind to a core DNA sequence 
CGTGGGAA (Tun et al., 1994). Originally it was mistakenly identified as a protein 
involved in the recombination events necessary for the creation of antibody variety. 
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Human RBP-Jκ is ubiquitously expressed and mediates cellular as well as viral signal 
transduction in the cell. Apart from the DNA core sequence in the promoters of its target 
genes the protein binds to various protein interaction partners, such as the corepressor 
complexes SMRT/NcoR/HDAC1 and CIR/HDAC2/SAP30 (Hsieh et al., 1999; Kao et al., 
1998; Zhou and Hayward, 2001). A complex containing the intracellular domain of the 
Notch receptor and the scaffolding protein SKIP serves as an activator complex to enhance 
transcription of RBP-Jκ target genes (Zhou et al., 2000). Accordingly RBP-Jκ can act as 
transcriptional repressor (Dou et al., 1994; Hsieh et al., 1996; Waltzer et al., 1995) or 
activator (Kopan et al., 1996; Struhl and Adachi, 1998; Tamura et al., 1995) depending on 
its interaction partners or complexes. 
RBP-Jκ target genes have been studied in D. melanogaster, where several have been found 
(Jarriault et al., 1995; Jennings et al., 1994; Lecourtois and Schweisguth, 1995; Wettstein 
et al., 1997). RBP-Jκ binds to regulatory elements in the promoters of E(spl) genes 
(Enhancer of Split). These genes code for basic helix-loop-helix proteins (HLH) acting as 
transcriptional repressors of differential factors. They negatively regulate expression of 
proneural genes of the achaete-scute complex, which leads to inhibition of the 
differentiation of neuroblasts. 
Furthermore, RBP-Jκ regulates the expression of the control genes eyeless, vestial and 
distal-less, which are responsible for the correct formation of eyes, wings and extremities 
(reviewed in (Bray and Furriols, 2001)). 
In vertebrates, RBP-Jκ regulates genes of the HES family (Hairy Enhancer of Split), which 
are homologues of the E(spl) genes (Lecourtois and Schweisguth, 1995). HES1 is known to 
repress the expression of CD4, which is involved in T-cell development. RBP-Jκ binding 
sites have been found in the promoters of HES1 and HES5 (for a review see (Iso et al., 
2003)). The vertebrate homologue of Eyeless, Pax6, is also involved in eye development. 
RBP-Jκ binding sites have been found not only in cellular but also in viral promoters, for 
example in the Epstein-Barr virus genome, where they are present in promoters controlling 
the expression of immediate early genes. 
In mammalian promoters the last five base pairs of the binding site for RBP-Jκ (GGGAA) 
can overlap with the first four of the binding site of the transcription factor NFκB (GGGA). 
This combination has been found in the promoters of many genes, such as those encoding 
interleukin 6, major histocompatibility complex class1 (MHCI) and interferon β, leading to 
the hypothesis that repression of genes whose promoters contain this sequence overlap 
could also simply be counteracted by displacement of RBP-Jκ (Goodbourn and Maniatis, 
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1988; Kannabiran et al., 1997; Miyazawa et al., 1998; Plaisance et al., 1997; Shirakata et 
al., 1996). 
1.2 Protein interaction partners of RBP-Jκ 
RBP-Jκ possesses interaction sites for numerous proteins exhibiting different functions. 
The primary structure of RBP-Jκ and the binding regions of the most important interaction 
partners (coactivators or corepressors) introduced in the section below are shown in Figure 
1.1. 
Figure 1.1: Primary structure of RBP-Jκ with the binding regions of corepressors and coactivators introduced 
in section 1.2. Precise limits are only given if the binding region has been exactly determined, other binding 
regions are indicated by  braces. 
1.2.1 Cellular interaction partners 
Coactivators 
Notch1 
Notch proteins were discovered in fruit flies lacking one allele of the corresponding Notch 
gene, which display a phenotype with notches at the edges of the wings. A knockout of the 
gene is lethal in the embryonic state. To date, four members of the Notch receptor family 
have been identified in rodents and humans. All of them, Notch1 to Notch4, shown in 
Figure 1.2, bind to RBP-Jκ with different affinity, but their function is non-redundant 
(Mumm and Kopan, 2000).  Many cellular processes from embryonic development and 
differentiation to immortalisation of various tissues types rely on signal transduction 
involving members of the Notch receptor family. 
The loss of RBP-Jκ expression in mice is lethal to embryos at 10.5 days of gestation, an 
earlier stage than observed with Notch knock-out mice, suggesting that RBP-Jκ does not 
only function as a downstream target of Notch but also plays a unique role in development 
(Amakawa et al., 1993; Oka et al., 1995).  
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The human Notch1 receptor is the major upstream binding partner of RBP-Jκ and regulates 
its transactivation activity. It is a transmembrane receptor with a single membrane 
spanning region. The N-terminal extracellular domain of this 300 kDa molecule contains 
36 EGF tandem repeats, which play an important role during ligand binding. At the C-
terminal end of the EGF repeats there are three cysteine-rich NL regions (Notch-Lin-12; 
LNR), which are believed to negatively regulate the activity of the Notch intracellular 
domain (Mumm and Kopan, 2000). 
The intracellular region C-terminal to the transmembrane segment of Notch, which 
interacts directly with RBP-Jκ, is called RAM (RBP-Jκ Association Molecule). The 
following seven ankyrin repeats, which are flanked by a nuclear localization sequence 
(NLS), mediate interactions with various proteins (Lubman et al., 2004). The glutamine-
rich OPA domain forms an important part of the intrinsic transactivation domain (TAD) of 
the protein (Kurooka et al., 1998; Milner et al., 1996). The C-terminal PEST sequence is 
probably involved in the degradation of the protein for rapid termination of the signal 
(Kurooka et al., 1998). 
Figure 1.2: The four members of the Notch receptor family. The different protein domains are indicated at 
the top. Extracellular portion: N-terminal signal sequence followed by different numbers of EGF repeats and 
three NLRs (Notch-LIN regions); intracellular portion: Ram domain, followed by seven ankyrin repeats, 
flanked by a nuclear localization signal (NLS); the transactivation domain (TAD) including the glutamine-
rich OPA sequence is located at the C-terminus. A PEST sequence labels the protein for rapid degradation. 
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The activity of Notch proteins is regulated via posttranslational proteolysis. They are 
processed in the trans-Golgi by a furin-like convertase and presented on the cell surface as 
a dimer. The functional receptor consists of a 180 kDa N-terminal unit and a 120 kDa C-
terminal unit, which associate through a calcium dependent, non-covalent bond. 
As illustrated in Figure 1.3, a number of different transmembrane proteins belonging to the 
DSL family of conserved proteins (Delta, Serrate, Lag-2) located on the surface of 
neighbouring cells can serve as ligands mediating intercellular interactions. Upon ligand-
binding a two-step proteolytic cleavage takes place, which results in the release of the 
intracellular domain (Notch-IC) of the receptor. The first processing step occurs in the 
extracellular part of Notch, at the N-terminus of the transmembrane segment and involves a 
metalloprotease belonging to the ADAM family (a disintegrin and metalloprotease), 
followed by cleavage directly at the C-terminus of the transmembrane domain. Notch-IC 
possesses a nuclear localization sequence and translocates to the nucleus where it binds 
RBP-Jκ, which is present in different complexes with transactivation or repression 
functions (for recent reviews see (Hayward, 2004; Lai, 2002)).  
To form activation complexes Notch-IC displaces corepressors such as e.g. histone 
deacetylases (HDAC1 and HDAC6) or the SMRT corepressor complex from RBP-Jκ, 
which leads to upregulation of a number of target genes. The Notch signal transduction 
pathway is highly conserved throughout eucaryotic organisms.  
The homologues of Notch and RBP-Jκ in D. melanogaster are the expression products of 
the Notch and Suppressor of Hairless (Su(H)) genes, respectively, and the signalling 
pathway is also conserved in C. elegans where it involves the RBP-Jκ homologue Lag-1 
and the Notch homologue Lin-12 (Roehl et al., 1996). 
Notch is expressed in uncommitted proliferative cells during development and is believed 
to maintain the proliferative capacity of immature cells in the adult. Whereas in D. 
melanogaster the protein is only expressed in proliferating tissues, vertebrates also express 
it in differentiated tissues such as the adult brain or mature B- and T-cells. 
In vertebrates, the activated Notch gene inhibits neuronal and muscular differentiation and 
promotes adipogenesis. It plays an important role in hemapoietic differentiation: It is 
expressed in CD34-positive hematopoietic precursors as well as in lymphoid, myeloid and 
erythroid precursor populations and in B- and T-cells in the peripheral blood. Notch1 and 
Notch2 influence granulocyte differentiation and mediate cytokine specificity (Bigas et al., 
1998; Li et al., 1998; Milner et al., 1996). Whereas Notch1 plays an important role during 
the induction of T-cell maturation it simultaneously inhibits B-cell differentiation. It  
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influences the decision between CD4- and CD8-cells, the two functional T-cell subgroups, 
as well as between cells expressing the αβ- and γδ-receptors in favour of the CD8- and γδ- 
expressing populations (Robey et al., 1996; Washburn et al., 1997). Upon interaction with 
RBP-Jκ and NFκB, Notch1 represses the activity of the E47 protein, which is an essential 
transcription factor during early B-cell development. Notch proteins influence the decision 
of these cells for self-renovation or differentiation. This function predestines aberrant 
Notch proteins for an important role as oncogenes in cancer development. In fact, 
constitutively activated Notch has been found in a subset of T-cell leukemias and 
lymphomas in humans, cats and mice (Ellisen et al., 1991; Girard et al., 1996; Rohn et al., 
1996).  
Figure 1.3: Simplified scheme of the processing of Notch and of signal transduction via the Notch1-receptor. 
Before insertion into the cell membrane the Notch protein is processed in the Golgi apparatus, where the N-
terminal extracellular part of the protein is glycosylated and the pro-protein is proteolytically cleaved into the 
future extracellular and intracellular portions. When inserted into the membrane both parts associate at the C-
terminus of the extracellular and the N-terminus of the intracellular part through a calcium dependent, non-
covalent bond. Upon binding of a ligand belonging to the DSL family to the extracellular part of Notch the 
latter is proteolytically cleaved in two steps by a metalloprotease and a serine protease. The resulting 
intracellular domain translocates to the nucleus where it displaces corepressors from RBP-Jκ thus enabling 
transactivation of RBP-Jκ target genes. 
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SKIP as a link between transcription and splicing 
SKIP is a 60-80 kDa protein, which is expressed ubiquitously albeit in low abundance in 
the cell and is preferentially located in the nucleus. It is highly conserved and can be found 
throughout lower eucaryotes, plants, fungi and animals. A search in the Pfam protein 
domain database (Bateman et al., 2000) yields only one known domain in the amino acid 
sequence of SKIP, the SNW domain. This acronym stands for the absolutely conserved 
amino acid motif SNWKN. The remaining protein consists of N- and C-terminal domains 
separated by species-specific inserts. 
The three-dimensional structure of SKIP is so far unknown, but the protein may take part 
in various interactions depending on its functional status or way of assembly. 
SKIP is a constituent of many complexes that form at or bind close to the sites of 
preinitiation complex assembly, where it facilitates the correct sequence of events by 
bringing signalling partners into the vicinity of the appropriate target. It may also serve as 
scaffold for proteins with low mutual binding affinities at low concentrations. SKIP could 
also serve as decelerator for the regulatory components on their way through the nucleus, 
providing a means of compartmentalization by creating non-physically separated reaction 
compartments by binding to some interaction partners. 
Notch-IC binds to RBP-Jκ and this complex displaces the SMRT/HDAC corepressor 
complex allowing transcription to start from RBP-Jκ controlled promoters. This 
replacement seems to be assisted by SKIP, since its presence is necessary for Notch-IC to 
effectively activate CSL promoters (Leong et al., 2004). This was proven by mutation 
studies which revealed that after deletion/mutation of the fourth ANK repeat of Notch-IC, 
which binds to SKIP, Notch activity was abrogated. Apart from the physical interaction 
with Notch-ANK (Zhou et al., 2000), SKIP also binds to the N-terminal part (exons 1-5) of 
RBP-Jκ, SMRT, mSin3A, CIR and HDAC2. The Notch-IC mimicking Epstein-Barr virus 
protein EBNA2 binds to SKIP with its CR5 region.  
SKIP does not act as a general transcription factor. Human SKIP was found to coregulate 
only at certain promoters, whereas in Drosophila it associates only with a subset of 
transcriptionally active puffs of salivary polytene chromosomes. 
The function of SKIP proteins in the cell is not restricted to transcription and human SKIP 
was found among the ~100 protein constituents of speckles involved in splicing usually 
observed in higher eucaryotes (Nagai et al., 2004). The avidity of SNW proteins to splice 
factors U2, U4 and U5 and snRNAs and connectivity maps of their components suggest 
that these novel particles represent a part of the spliceosome or a temporary assembly 
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arising at a certain stage of its function (Nagai et al., 2004). Furthermore, SNW interacts 
with PABP2 (poly adenosine binding protein) and both proteins colocalize in nuclear 
speckles (Kim et al., 2001). PABP2 engages the nuclear export machinery and may 
contribute to mRNA export. It accompanies spliced mRNA on its route to the cytoplasm, 
where it is replaced by PABP1. Snw1p, the SKIP homologue in S. pombe, binds to the 
small subunit of the heterodimeric splicing factor U2AF, which shuttles continuously 
between nucleus and cytoplasm (Ambrozkova et al., 2001). This mechanism is independent 
of mRNA binding.  
 
Mastermind as coactivator 
Mastermind (MAML) was first identified in Drosophila and implicated as important 
positive regulator of Notch signalling (Artavanis-Tsakonas et al., 1995; Helms et al., 1999; 
Smoller et al., 1990; Petcherski and Kimble, 2000). In Drosophila the mastermind gene 
encodes a glutamine-rich nuclear protein. Mammalian MAML was shown to stabilize and 
participate in the DNA-binding complex of Notch-IC and RBP-Jκ during the activation of 
target promoters (Wu et al., 2000). A short protein fragment at the N-terminus of 
Mastermind comprising about 75 aa is required for binding the RBP-Jκ-Notch-IC complex 
(Nam et al., 2003). Mastermind plays dual roles of both activating Notch target gene 
transcription through the direct binding of CBP/p300 and promoting hyperphosphorylation 
and degradation of Notch-IC (Fryer et al., 2004; Wallberg et al., 2002).  
 
Corepressors 
The corepressor CIR 
Indirect evidence has implicated a corepressor in RBP-Jκ-mediated transcriptional 
repression. Yeast two-hybrid screens were used to identify a 450 aa protein, called CIR 
(CBF1 interacting protein), as corepressor and link between RBP-Jκ and 
histonedeacetylase complexes such as HDAC2-mSin3-SAP3 (Hsieh et al., 1999). The 
protein has a highly charged, serine-rich C-terminus. A 561 aa CIR homologue with a high 
sequence homology in the N-terminal part (aa 1-150) but not in the C-terminus exists in C. 
elegans, is also highly charged and contains numerous serines. In general, the protein is 
expressed at high levels in many different tissues such as heart, skeletal muscle or pancreas. 
The region responsible for RBP-Jκ interaction lies between aa 1 and 121. Within RBP-Jκ 
the interaction site with CIR could be mapped to aa 233 to 249 by yeast two-hybrid screens 
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(Hsieh et al., 1999). The protein also interacts with other RBP-Jκ binding proteins such as 
e.g. SKIP. 
 
The corepressor SMRT 
SMRT (silencing mediator of retinoic acid and thyroid hormone receptors) can form 
complexes with N-CoR and mSin3A as well as histonedeacetylase 1 (HDAC1) (Alland et 
al., 1997).  Yeast two-hybrid and in vitro interaction assays proved the interaction of 
SMRT with RBP-Jκ and the direct interaction was confirmed by GST-pull-down assays 
(Kao et al., 1998). Like CIR, it antagonizes the Notch-IC-mediated activation of RBP-Jκ 
and shares the same binding region on RBP-Jκ (amino acids 233 to 251) (Hsieh et al., 1999; 
Kao et al., 1998; Zhou and Hayward, 2001). In complex with other proteins (e.g. CIR and 
SKIP) SMRT appears to be responsible for the direction and relocalization of RBP-Jκ to 
the nucleus. 
 
The LIM protein KyoT2 
KyoT2 and its homologue KyoT1 share the first 167 aa. Whereas KyoT1 contains 280 aa, 
KyoT2 consists of only 194 aa. The different C-terminal portion of KyoT2 was shown to 
interact with RBP-Jκ. The protein is expressed in various tissues, such as heart, lung, liver, 
brain and skeletal muscle. It negatively regulates transcription by association with RBP-Jκ 
and expulsion of Notch-IC from RBP-Jκ (Taniguchi et al., 1998).  
 
The corepressor SHARP 
SHARP belongs to the Spen (split ends) family of proteins, which contain RNA 
recognition motifs (RRMs) in the N-terminal part. It was originally identified as SMRT-
associated protein in a yeast two-hybrid screen and implicated in nuclear receptor 
signalling (Shi et al., 2001). Its role as interaction partner of RBP-Jκ linking RBP-Jκ to 
HDAC corepressor complexes was only recently discovered (Oswald et al., 2002). Binding 
of Notch-IC and SHARP to RBP-Jκ is mutually exclusive; binding of SHARP to RBP-Jκ 
reduces transactivation.  The expression of SHARP overlaps with that of Notch, but the 
protein is also expressed in other tissues, suggesting other functions beside the modulation 
of Notch-signalling.  
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1.2.2 Viral interaction partners 
So far eight human Herpesviruses, which infect different organs (Varicella zoster), the 
lymphatic system (Epstein-Barr) or the central nervous system, are known. The Epstein-
Barr virus (EBV), which belongs to the family of gamma Herpesviruses, is distributed 
throughout the world with up to 95 % of the population being seropositive. An outbreak of 
the disease can, however, be effectively impeded by a functional cellular immune system, 
which prevents the uncontrolled reproduction of infected cells. As already mentioned, the 
virus can cause infectious mononucleosis and is associated with cancers in 
immunocompromised individuals.  
It infects either B-lymphocytes or T-cells and has the ability to reside latently in the 
organism. In this state the production of infectious particles is inhibited and the cells 
survive. The virus can repeatedly change from the latent state to the infectious cycle.  
For EBV up to nine different proteins are synthesized during latent infection, six of which 
are necessary for establishing and maintaining of the non-productive cycle in B-cells in 
vitro and the immortalisation of the cells (EBNA1, EBNA2, EBNA3A and EBNA3C, 
EBNA-LP (leader protein) and LMP1 (latent membrane protein 1). In tissue culture 
EBNA3B and LMP2A/B are not essential for the immortalisation of B-cells (reviewed in 
Robertson, 2005). 
 
EBNA2 
EBNA2 (Epstein-Barr-Virus nuclear antigen 2) is the major viral interaction partner of 
RBP-Jκ and is responsible for the immortalisation of B-cells upon infection with Epstein-
Barr-Virus. It was characterized after reintroduction of a lost DNA fragment spanning 
EBNA2 and EBNA-LP (Bornkamm et al., 1982; Dambaugh et al., 1984; Dillner et al., 
1986; Hennessy and Kieff, 1985; Mueller-Lantzsch et al., 1985) into the transformation 
defective Epstein-Barr virus strain P3HR1 (Hinuma et al., 1967; Miller et al., 1974), 
leading to a restoration of the transformation activity (Cohen et al., 1989; Hammerschmidt 
and Sugden, 1989). 
EBNA-LP induces the switch of resting B-cells from G0 to G1 as well as synthesis of 
EBNA2. The presence of both proteins is sufficient to immortalize these cells through 
expression activation of cyclin D2, which causes continuous cell division. EBNA-LP also 
binds to the tumour suppressor proteins RB and p53, but this does not influence their 
regulatory function (Modrow, 2003).  
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EBNA2 is essential not only for establishing latency and immortality (Cohen et al., 1989; 
Hammerschmidt and Sugden, 1989) but also for maintenance of B cell immortalization 
(Kempkes et al., 1995).  
Two subtypes of EBV are known: Whereas type 1 has a high transformation rate, induction 
of transformation in B-lymphocytes by type 2 is reduced. Since both subtypes are found in 
ex vivo established cell lines from B-cell lymphomas a different potential to create tumours 
is unlikely. In type 1 the sequence of EBNA2 is 491 aa long, whereas that of type 2 has 
443 aa. Major differences are found in a relatively hydrophobic domain in the centre of the 
protein. In contrast, both proteins contain a proline-rich region and repeats of Arg/Lys-Gly 
(for an overview of the primary structure of EBNA2 see Figure 1.4). Both proteins are 
phosphorylated, have a molecular mass of 75 to 88 kDa, and accumulate in the nucleus in 
the form of oligomeric complexes. EBNA2 does not bind DNA directly but acts as 
transactivator by binding to RBP-Jκ (Grossman et al., 1994; Henkel et al., 1994; Waltzer et 
al., 1994; Zimber-Strobl et al., 1994) and Pu-1 (Laux et al., 1994). It is likely to act as the 
viral equivalent of the constitutively active cellular Notch receptor (for a comparative 
reaction scheme see Figure 1.7) (Johannsen et al., 1995; Sakai et al., 1998). Binding to 
RBP-Jκ was mapped to the region between aa 252 and 425 which contains the conserved 
regions CR5, CR6 and CR7 (Ling et al., 1993), where CR6 holds an important function 
since a double mutation of tryptophans 323 and 324 abolishes the ability of EBNA2 to 
interact with RBP-Jκ (Ling et al., 1993).  
Figure 1.4: Primary structure and functional units of EBNA2 (after (Kempkes, 2002)). The conserved 
regions are depicted as boxes, in the case of CR5 and CR6 the interaction partners are also indicated. 
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EBNA2 induces the C-promoter, which regulates the expression of EBNA proteins as well 
as the promoters of the latent membrane proteins LMP1, LMP2A- and LMP2B (Fahraeus 
et al., 1990; Sung et al., 1991; Woisetschlaeger et al., 1990; Zimber-Strobl et al., 1991). In 
addition, it enhances the synthesis of the cellular proteins CD21 and CD23 (Calender et al., 
1987; Cordier et al., 1990; Wang et al., 1987) as well as of the proto-oncogene c-fgr 
(Knutson, 1990). CD23 is a weak IgE binding receptor expressed on EBV-transformed B-
cells and primary B-lymphocytes stimulated by antigens. A secreted isoform of CD23 acts 
as B-cell growth factor and contributes to the activation and proliferation of B-lymphocytes 
in the course of EBV infection. EBNA2 possesses a strong transactivation domain through 
which it is able to interact with constituents of the RNA-polymerase transcription initiation 
complex. It is also known to interact with human SKIP protein, being involved in e.g. 
chromatin remodelling or splicing (for a recent review on viral interactions with 
components of the Notch pathway see Hayward, 2004). 
 
EBNA3A, EBNA3B and EBNA3C 
The three proteins belonging to the EBNA3 family of Epstein-Barr virus proteins consist of 
944 (EBNA3A), 938 (EBNA3B) and 992 aa (EBNA3C), respectively. EBNA3A and 
EBNA3B are distantly homologous to EBNA3C. The genes encoding the three proteins are 
tandemly organized in the EBV genome indicating that they evolved from a common 
ancestor by gene duplication (reviewed in Robertson, 2005). 
EBNA3C can transactivate some EBNA2-regulated genes (Allday and Farrell, 1994; 
Murray et al., 1988; Wang et al., 1990), was shown to associate with RBP-Jκ in human 
lymphoblasts (Robertson et al., 1995) and can block EBNA2 transactivation of the LMP1 
and LMP2 promoters in transient transfection assays (Le Roux et al., 1994; Marshall and 
Sample, 1995; Robertson et al., 1995). The protein possesses a glutamine- and proline-rich 
domain which can functionally substitute for the EBNA2 acidic domain in transcriptional 
activation (Cohen and Kieff, 1991; Marshall and Sample, 1995). 
Like EBNA3C, EBNA3A and EBNA3B can specifically block EBNA2 activation of the 
LMP2 promoter in transient transfection assays (Le Roux et al., 1994), indicating 
competition for a similar binding site on RBP-Jκ. In GST-pull-down assays all three 
proteins bind GST-RBP-Jκ, although this assay shows the affinity of EBNA3A for GST-
RBP-Jκ to be only slightly above background (Robertson et al., 1995). The source of the 
respective protein may play an important role, since in vivo expressed EBNA3A was later 
shown to have a similar affinity for RBP-Jκ as the other two proteins, whereas the in vitro-
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translated EBNA3A interacts only weakly (Robertson et al., 1995). The binding region 
within the EBNA3 proteins could be narrowed to the amino terminal domain (Robertson et 
al., 1995; Zhao et al., 1996). By binding to RBP-Jκ all three proteins alter the ability of 
RBP-Jκ to recognize its cognate DNA sequence, thus altering its transactivation activity. 
All three proteins compete with EBNA2 as well as Notch-IC, but most probably do not 
bind to the same region. The interaction site of EBNA3C on RBP-Jκ was mapped to the 
region encompassing aa 144 to 178 (Zhao et al., 1996). 
 
1.3 Interaction of RBP-Jκ with Notch1 and EBNA2: structural aspects 
1.3.1 Structure of RBP-Jκ 
The crystal structure of the RBP-Jκ homologue in C. elegans, Lag-1, was solved at 2.85 Å 
resolution (Kovall and Hendrickson, 2004) yielding the model in Figure 1.5. Alignment of 
CSL-proteins of different organisms revealed that a portion of about 425 aa is conserved 
throughout all organisms. The structural genomics approach which was used and which 
included RBP-Jκ homologues from different organisms revealed only the structure of the C. 
elegans homologue of RBP-Jκ bound to a 13 bp double-strand DNA, derived from the 
mammalian HES-1 promoter.  
The structure of Lag-1 includes three distinct domains, displaying considerable similarity 
to already known structures: Lag-1 contains two domains resembling those of members of 
the Rel transcription factor family, the N-terminal domain (NTD) and the C-terminal 
domain (CTD), corresponding to Rel-homology regions RHR-N and RHR-C (Nam et al., 
2003). In contrast with the situation in Rel-proteins they are, however, separated by a 
modified β-trefoil domain (BTD), which is inserted where the junction between the two 
domains of a Rel transcription factor would be. The protein does not form a beads-on-a-
string system but parts of the domains are structurally integrated into others. DNA-binding 
occurs via the NTD and the BTD, whereas the CTD does not contribute to the binding. 
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Figure 1.5: Ribbon structure of C. elegans Lag-1 (PDB-code 1TTU). The domain organisation is depicted in 
blue for the N-terminal domain (NTD), yellow for the C-terminal domain (CTD) and green for the β-trefoil 
domain (BTD). The β-strand bridging BTD and CTD is coloured magenta. The sequence of the DNA with 
the framed core binding sequence and 5’-single-strand double base overhangs is depicted at the bottom of the 
figure. The DNA sequence was derived from the mammalian HES-1 promoter. 
 
1.3.2 Structural information about Notch1 
The domain organization of Notch1 is shown in Figure 1.1. Structural details are only 
known for the ankyrin domain (ANK), consisting of seven ankyrin repeats (Ehebauer et al., 
2005; Zweifel et al., 2003), and the extracellular ligand binding region (Zweifel et al., 
2005). 
Various analyses have been carried out to map the exact interaction site of Notch-IC with 
RBP-Jκ. The amino acids involved in the interaction with Notch-Ram are highlighted in 
Figure 1.9 below (section 1.3.4).  
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In the case of the Ram domain the crucial amino acids participating in the interaction with 
RBP-Jκ could be mapped. Peptide arrays with Ram fragments containing between five and 
twenty five amino acids revealed that a stretch of five amino acids around a conserved 
tryptophan is sufficient to mediate the interaction with RBP-Jκ (B. Kempkes, unpublished 
data). Extensive analysis of the differential binding of RBP-Jκ point mutations (Fuchs et al., 
2001; Tani et al., 2001) further narrowed the number of amino acids involved in binding to 
amino acids Lys456, Leu 457, Val458, Ala465, Asp440, Asn441 and Phe 442. According 
to the Lag-1 crystal structure amino acids Lys456 to Val458 and Ala465 form a 
hydrophobic pocket suitable for hydrophobic interactions. This study could, however, not 
define the role of the different amino acids, i. e. whether they are directly involved in the 
interaction or if their mutation causes a conformational change, which abolishes the 
interaction. 
Since an interaction or at least a role of the ankyrin repeats had been described, it was also 
tried to map that interaction (Tani et al., 2001). On the side of the ankyrin repeats a 
mutation in the fourth repeat resulted in loss of transactivation activity. Mutational analysis 
suggested that Arg397, Lys391, Arg472, Phe498, Glu499 and Glu433 contribute to the 
interaction with RBP-Jκ. 
1.3.3 EBNA2  
So far no structural information is available for EBNA2. A secondary structure prediction 
(Figure 1.6) obtained using the program PHD (Rost, 1996) shows why it may be difficult 
to approach this problem.  
The protein is predicted to contain long stretches of low complexity regions, depicted as 
loops (L), without defined secondary structure. This might make it difficult to crystallize 
even a truncated form containing the binding region because this region does not contain 
any detectable secondary structure element. 
As in the case of the initially unfolded Ram domain of Notch-IC, folding may occur upon 
binding to RBP-Jκ or other protein interaction partners. The RBP-Jκ binding motif of 
EBNA2 was mapped to two crucial tryptophans in CR6. When aligned with Notch-Ram 
(Figure 1.7) this motif has a detectable similarity with the region crucial for Ram-RBP-Jκ 
interaction. This similarity in the binding motif does not necessarily contradict the 
assumption of slightly different binding sites of Notch-Ram and EBNA2 on RBP-Jκ. The 
low number of conserved amino acids comprises mostly hydrophobic residues, so that a 
Introduction
 
 16
coincidence could also be due to a similar binding mode involving hydrophobic 
interactions. 
 
 
 
Figure 1.6: Secondary structure prediction based on the EBNA2 sequence with the program PHD. Low 
complexity regions, i. e. loop structures are highlighted in light grey, α-helices in turquoise and β-sheets in 
yellow. The score gives the likelihood of the prediction; letters below the score indicate predicted secondary 
structure elements; E= β-strand, H=α-helix, L=loop region. 
 
 
 
Figure 1.7: Manual alignment of the primary structures of the regions of Notch-Ram and EBNA2 interacting 
with RBP-Jκ. The conserved binding motif is highlighted by a box, conserved amino acids within in 
turquoise. Identical amino acids in the surrounding region are indicated by a yellow background.  
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1.3.4 Common and distinct features of Notch and EBNA2 
Both EBNA2 and Notch-IC abolish RBP-Jκ repression and activate transcription of 
responsive promoters through a combination of abolition of repression and the positive 
effect of an endogenous activation domain. 
In contrast to Notch1, which needs a ligand to be activated by the sequential cleavage 
steps, which set free its intracellular (IC) domain, EBNA2 is already constitutively active 
after expression. Similarities can be found in the mode of action of activated (constitutively 
active) Notch (Notch-IC), occurring in aberrant chromosomal translocations, and EBNA2. 
Chromosomal translocations that cause expression of a truncated from of Notch are found 
in a subset of acute T-cell lymphoblastic lymphoma as well as EBNA2 expression is found 
in immunoblastic B-cell lymphomas. The two proteins have no obvious sequence 
homology apart from two conserved amino acids (ΦWΦP) in the main RBP-Jκ interacting 
domain Ram (Notch-IC) and CR6 (EBNA2) (Nam et al., 2003). Whereas Notch-IC is 
predicted to contain a high percentage of secondary structure elements, EBNA2 is mainly 
composed of low complexity regions with long proline-rich sequences. The polyproline 
stretches should, in particular, result in a high flexibility of EBNA2. Their function is 
essentially still unknown. 
 
 
Figure 1.8: Analogous action of Notch1 and EBNA2 in the displacement of corepressor complexes from 
RBP-Jκ on the example of the SMRT corepressor complex (figure based on Zhou et al., 2000). 
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The set of proteins interacting with Notch-IC and EBNA2 is remarkably similar in function: 
Both proteins interact with a number of others belonging to the basal transcription 
machinery. EBNA2 binds to TFIIH, TATA box binding protein (TBP) associated factor 
TAF40, TFIIB and the co-activator p100, which interacts with TFIIE (Tong et al., 1995a; 
Tong et al., 1995b). The EBNA2 transactivation domain interacts with histone 
acetyltransferases (HATs) p300/CBP and PCAF, whereas besides p300/CBP Notch-IC 
binds to PCAF and GCN5. Both proteins bind to SKIP, a transcriptional coactivator 
involved in various other cellular processes (see section 1.3.2). The similarity between the 
action of Notch-IC and EBNA2 on RBP-Jκ is illustrated in Figure 1.8 on the example of 
the displacement of the SMRT corepressor complex from RBP-Jκ to activate transcription. 
Notch-IC activates target genes involved in developmental processes, like the hairy 
enhancer of split complex E(spl) related genes Hes1 and Hes5 (Lecourtois and 
Schweisguth, 1995), Hey1, Hey2 and HeyL (Maier and Gessler, 2000), ERBB-2 (Chen et 
al., 1997), NFκB (Oswald et al., 1998) and hairy-related transcription factor (HRT) 
(Nakagawa et al., 2000). Recently, strong hints for the activation of c-myc by Notch-IC 
were also found (Gordadze et al., 2001). EBNA2 responsive elements can be found within 
the viral Cp (Sung et al., 1991; Woisetschlaeger et al., 1990), LMP1 and LMP2A 
promoters (Fahraeus et al., 1990; Zimber-Strobl et al., 1991). Both Notch-IC and EBNA2 
activate the expression of cellular CD21 and CD23 (Gordadze et al., 2001; Hofelmayr et al., 
2001). All these responsive elements contain at least one RBP-Jκ binding site with varying 
sequences resulting in more or less tight binding of RBP-Jκ to DNA as well as of Notch-IC 
and EBNA2 to RBP-Jκ.  The two overlapping sets of target genes activated by Notch and 
EBNA2, are presently being characterized in more detail using micro-arrays (Maier et al., 
submitted). 
Figure 1.9 displays amino acids of RBP-Jκ known to interact with Notch-Ram and EBNA2. 
Apart from the conserved ΦWΦP motif, which is present in both proteins, the interaction 
sites appear to be sufficiently different to imply that despite similarities in the binding 
mode, different mechanisms may be involved in the differential activation of the specific 
target genes of Notch-Ram and EBNA2.  
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Figure 1.9: Amino acids crucial for the binding of Notch-Ram (Lys456, Leu457, Val458, Ala465, Asp440, 
Asn441 and Phe442; red) and EBNA2 (Phe425, Leu510 and Gln517; blue) mapped onto the crystal structure 
of Lag-1 bound to DNA. The views are rotated by 90º. The Figure was created using Pymol 
(http://www.pymol.org). 
 
1.4 Open questions 
The question regarding the interchangeability of Notch-Ram and EBNA2 is still not 
satisfactorily answered. The obvious differences in the binding mode resulting from 
various mutation analyses should be studied in more detail. This may also lead to 
predictions about the transactivation mechanism, which in addition to a common set of 
activated or repressed genes enables the differentiated regulation of certain target genes. 
Examination of the functionally similar development of regulatory proteins in cells and 
viruses is an important issue towards the understanding of physical interactions of proteins 
in the context of transcriptional regulation. 
Controversial results have been obtained concerning the role of the ankyrin repeats in the 
interaction of Notch-IC with RBP-Jκ. A direct approach to examine the interaction would 
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answer this question more clearly than the indirect reporter assay methods and EMSAs 
(electrophoretic mobility shift assay) with protein mixtures, which have hitherto been used. 
Some structural questions have been answered by the publication of the crystal structure of 
the RBP-Jκ homologue of C. elegans, Lag-1, bound to DNA (Kovall and Hendrickson, 
2004). The two proteins have a high sequence identity, which speaks for a similar overall 
structure. In the present work, differences have, however, been found, which cannot be 
explained yet. The crystal structure of a quaternary complex including C. elegans Lag-1 
bound to DNA, Notch-RamANK and Mastermind (Nam et al., 2006; Wilson and Kovall, 
2006), which was published soon after the completion of the present work, provides insight 
into the interplay between different activators on RBP-Jκ, but does not clarify whether 
ANK is able to bind RBP-Jκ by itself or only in the presence of coactivators such as 
Mastermind. 
 
1.5 Scope of this thesis 
The aim of this work was to characterise the physical interactions between RBP-Jκ and its 
protein and DNA interaction partners and, if possible, determine the high resolution crystal 
structure of the protein in complex with different interaction partners.   
The low resolution models of RBP-Jκ in complex with DNA or Notch comprising the Ram 
and ANK domain in solution obtained by small angle X-ray scattering represent a first 
important step towards the structural characterization of RBP-Jκ and its complexes.  The 
question as to whether the Notch ankyrin repeats participate in the interaction with RBP-Jκ 
could be unambiguously answered using ITC (isothermal titration calorimetry) and EMSA 
(electrophoretic mobility shift assay) data. 
Crystallographic studies were aimed at gaining insight into structural aspects of the 
protein-nucleic acid interactions as well as understanding the protein-protein interactions of 
RBP-Jκ with Notch-Ram. The conditions where RBP-Jκ is likely to crystallize could be 
narrowed down for both a binary complex of DNA-RBP-Jκ and a ternary complex of 
DNA-RBP-Jκ-Ram. No adequate crystals of either of the complexes could, however, be 
obtained so far but this can at least partly be understood in the light of the small angle 
scattering results. 
During the work it became apparent that the properties of RBP-Jκ expressed in procaryotic 
(E. coli) and eucaryotic expression systems (recombinant baculovirus in insect cells) 
differed. This provided the opportunity to compare the properties and activity of both 
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purified proteins by various biochemical and biophysical assays, such as circular dichroism 
(CD) spectroscopy, EMSA and ITC. 
Truncation mutants were designed, expressed in two different expression systems and 
characterized biochemically and biophysically to study the domain structure of RBP-Jκ in 
relation to that of Lag-1. Different binding properties of protein fragments derived from the 
full-length interaction partners were determined using ITC and EMSA. 
Although the viral protein EBNA2 and cellular Notch-IC protein are known to fulfil 
similar functions in the cell it was found, rather surprisingly, that EBNA2 has a much 
higher binding affinity to RBP-Jκ than Notch-IC. 
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2 Materials and Methods 
2.1 Materials 
2.1.1 Bacterial Strains 
Strains used for plasmid amplification 
 
Strain       Genotype 
E. coli DH5a  F-, lacI-, recA1, endA1, hsdR17, Δ(lacZYA-argF),   
U169, F80dlacZΔM15, supE44, thi-1, gyrA96, relA1 
available at  the EMBL 
E. coli DH10 Bac   F-, mcrA, Δ(mrr-hsdRMS-mcrBC), Φ80lacZΔM15, 
ΔlacX74, deoR, recA1, endA1, araD139, 
Δ(ara,leu)7697, galU, galK, λ, rpsL, nupG, 
/bMON14272/pMON7124 
 
Strains used for protein expression 
 
Strain     Genotype 
E. coli BL21(DE3)RIL     F-, argU, ileY ,  leuW (Cam) 
E. coli BL21(DE3)PlysS    B, F-, dcm, ompT, hsdS(rB-mB-), gal, λ(DE3), pLysS 
Cam 
E. coli Rosetta(DE3)PlysS    F-, ompT, hsdSB(rB-mB-), gal, dcm, (DE3), argU, 
argW, ileX, glyT, leuW, proL, metT, thrT, tyrU, 
thrU (Cam) 
 
2.1.2 Cell lines 
2.1.2.1 Mammalian cell lines 
DG 75    EBV negative Burkitt’s lymphoma cell line (Ben-
Bassat et al., 1977) 
SM261 RBP-Jκ-/- cell line derived from DG75 (Maier et al., 
2003) 
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2.1.2.2 Insect cell lines 
High Five™ (H5) cell line derived from Trichoplusia ni egg cell homogenates, 
(Invitrogen, Carlsbad, CA, USA) 
SF21 cell line isolated from Spodoptera frugiperda (Fall Armyworm) 
ovarian insect cells 
expresSF+ (SFplus) derived from Sf9, (Protein Sciences Corporation, Meriden, CT, 
USA) 
 
2.1.3 Plasmids 
Plasmids provided for this work 
pEBNA2 EBNA2 aa 259 to aa 435, comprises CR5 to CR7; K. Fuchs, 
GSF Munich 
PSV180 EBNA2 aa 291 to aa 355, comprises CR5 to CR6; S. Valencia, 
GSF Munich 
pVK60 human RBP-Jκ  full-length in pETM11; V. Kapetaniou, GSF Munich 
pVK91 human RBP-Jκ full-length in pETM30; V. Kapetaniou, GSF Munich 
 
Plasmids produced for this work 
pKH1 human RBP-Jκ RBP-Jκ aa 157 to 333 in pETM11 
pKH2 human RBP-Jκ RBP-Jκ aa 100 to 188 in pETM11 
pKH3 human RBP-Jκ RBP-Jκ aa 165 to 348 in pETM11 
pKH4 human RBP-Jκ RBP-Jκ aa 100 to 333 in pETM11 
pKH5 human RBP-Jκ RBP-Jκ aa 63 to 487 in pETM11 
pKH6 human RBP-Jκ RBP-Jκ aa 74 to 487 in pETM11 
pKH11-7 human RBP-Jκ RBP-Jκ aa 32 to 333 in pETM11 
pKH11-8 human RBP-Jκ RBP-Jκ aa 32 to 435 in pETM11 
pKH11-9 human RBP-Jκ RBP-Jκ aa 157 to 435 in pETM11 
pKH11-10 human RBP-Jκ RBP-Jκ aa 12 to 431 in pETM11 
pKH11-11 human RBP-Jκ RBP-Jκ aa 12 to 435 in pETM11 
pKH11-12 human RBP-Jκ RBP-Jκ aa 12 to 452 in pETM11 
pKH11-13 human RBP-Jκ RBP-Jκ aa 28 to 431 in pETM11 
pKH11-14 human RBP-Jκ RBP-Jκ aa 28 to 435 in pETM11 
pKH11-15 human RBP-Jκ RBP-Jκ aa 28 to 452 in pETM11 
pKH11-16 human RBP-Jκ RBP-Jκ aa 63 to 431 in pETM11 
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pKH11-17 human RBP-Jκ RBP-J aa 63 to 435 in pETM11 
pKH11-18 human RBP-Jκ RBP-J aa 63 to 452 in pETM11 
pKH11-19 human RBP-Jκ RBP-J aa 74 to 431 in pETM11 
pKH11-20 human RBP-Jκ RBP-J aa 74 to 435 in pETM11 
pKH11-21 human RBP-Jκ RBP-J aa 74 to 452 in pETM11 
pKH11-22 human Notch-Ram Notch1 aa 1768 to 1861 in pETM11 
pKH11-23 human Notch-RamANK Notch1 aa 1768 to 2122 in pETM11 
pKH24.1 human RBP-Jκ RBP-J aa 28 to 432 in pFastBac-HTa 
pKH25.1 human RBP-Jκ full-length in pFastBac-HTa 
pKH30-5 human RBP-Jκ RBP-J aa 63 to 487 in pETM30 
pKH30-6 human RBP-Jκ RBP-J aa 74 to 487 in pETM30 
pKH30-7 human RBP-Jκ RBP-J aa 32 to 333 in pETM30 
pKH30-8 human RBP-Jκ RBP-J aa 32 to 435 in pETM30 
pKH30-9 human RBP-Jκ RBP-J aa 157 to 435 in pETM30 
 
2.1.4 Oligonucleotides 
Oligonucleotides used for cloning 
 
Primers used to generate PCR products for the cloning of RBP-Jκ constructs  
Numbers in the name of the primer correspond to the first amino acid for forward primers (_f) 
or the last one for reverse primers (_r) in the corresponding construct; enzyme names indicate 
the restriction site introduced 
 
RBP_1_Nco_f ATG AGC CAT GGC GCC TGT TGT GAC 
RBP_487_Kpn_r ATT CGG TAC CTT AGG ATA CCA CTG TGG CTG TA 
oRBP_12_Nco_f GAG CCA TGG ATC GGC CTC CAC CTA AAC GAC T 
oRBP_17_Nco_f GAG ATT CCA TGG ATC GAC TTA CTA GGG AAG CTA TG 
oRBP_28_Nco_f GAG CCA TGG ATA AAG AGC GAG GGG ATC AAA CA 
oRBP_32_Nco_f GAG CCA TGG ATC AAA CAG TAC TTA TTC TTC ATG CA 
oRBP_63_Nco_f GAG CCA TGG GCA GTG GAT GGA AGA AAA AAA AAG AAC A 
oRBP_74_Nco_f GAG CCA TGG AAC GCG ATG GTT GTT CTG AAC AAG AGT CT 
oRBP_100_Nco_f GAG CCA TGG TGC AGC AGC TAA ACT TGG AAG GAA AGA ACT 
ATT GCA CA 
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oRBP_157_Nco_f GAG CCA TGG TGA AGA AGC AGT CAT TGA AAA ATG CTG ACT 
TAT GCA TTG CCT 
oRBP_165_Nco_f GAG CCA TGG TGG ACT TAT GCA TTG CCT CAG GAA CAA AGG 
TGG CTC T 
oRBP_188_Kpn_r GGA ATT CGG TAC CTT ATC TGG TAC TAA CTG TCT GGG ATC 
GTA GTC GAT TAA ACA 
oRBP_333_Kpn_r GGA ATT CGG TAC CTT AAG GGC CCA TTC CCT CAT 
oRBP_348_Kpn_r GGA ATT CGG TAC CTT ACT GAA CGGC TCT CTA CCA CAG GCA 
CAG GAG TGA CT 
oRBP_431_Kpn_r GGA ATT CGG TAC CTT AGT AGG TAA AGG TAA GGC TGG TG 
oRBP_433_Kpn_r GGA ATT CGG TAC CTT ATG GTG TGT AGG TAA AGG TAA GG 
oRBP_435_Kpn_r GGA ATT CGG TAC CTT ATG GTT CTG GTG TGT AGG TAA AGG 
oRBP_452_Kpn_r GGA ATT CGG TAC CTT ATG AAT TGG CTC GAA GGA TTG CT 
oRBP_487_Kpn_r GGA ATT CGG TAC CTT AGG ATA CCA CTG TGG CTG TAG ATG 
ATG TGA CAC TGG T 
 
Primers used to generate PCR products for the cloning of Notch constructs  
Numbers in the name of the primer correspond to the first amino acid for forward primers (_f) 
or the last one for reverse primers (_r) in the corresponding construct; enzyme names indicate 
the restriction site introduced 
 
Notch_1768_Pci_f CAT GAC ATG TCC CGC AAG CGC CGG C 
Ram_1861_Kpn_r ATT CGG TAC CTT AAT CCA GGT GCT GCT GAG TCC 
RamANK_2075_Kpn_r ATT CGG TAC CTT AGT AGC TGC CCT CCC GGG 
RamANK_2122_Kpn_r ATT CGG TAC CTT AGC TGC GCA CCA GGT TGT ACT 
Notch_2075_Pci_f ATG AGA CAT GTT TAG CTA CGA GAC CGC CAA G 
Notch_2508_Kpn_r GAA TTC GGT ACC TTA GTG CTC AGG CAC CTG TAG 
 
 
Oligonucleotides used to form binary complexes with RBP-Jκ 
The core RBP-Jκ binding sequence is underlined in each oligonucleotide. 
Oligonucleotides derived from the C-promoter; without single-stranded overhangs 
Cp_f GAT CTG GTG TAA ACA CGC CGT GGG AAA AAA TTT ATG 
Cp-r GAT CCA TAA ATT TTT TCC CAC GGC GTG TTT ACA CCA 
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RI_f GAT CTG GTG TAA ACA CGC CGT GGG AAA AAA TTT ATG GAT C 
RI_r GAT CCA TAA ATT TTT TCC CAC GGC GTG TTT ACA CCA GAT C 
RI_30_f TGT AAA CAC GCC GTG GGA AAA AAT TTA TGG 
RI_30_r CCA TAA ATT TTT TCC CAC GGC GTG TTT ACA 
RI_26_f TAA ACA CGC CGT GGG AAA AAA TTT AT 
RI_26_r ATA AAT TTT TTC CCA CGG CGT GTT TA 
RI_22_f AAC ACG CCG TGG GAA AAA ATT T 
RI_22_r AAA TTT TTT CCC ACG GCG TGT T 
RI_20_f ACA CGC CGT GGG AAA AAA TT 
RI_20_r AAT TTT TTC CCA CGG CGT GT 
RI_18_f CAC GCC GTG GGA AAA AAT 
RI_18_r ATT TTT TCC CAC GGC GTG 
RI_16_f ACG CCG TGG GAA AAA A 
RI_16_r TTT TTT CCC ACG GCG T 
RI_14_f CGC CGT GGG AAA AA 
RI_14_r TTT TTC CCA CGG CG 
RI_12_f GCC GTG GGA AAA 
RI_12_r TTT TCC CAC GGC 
RI_10_f CCG TGG GAA A 
RI_10_r TTT CCC ACG G 
 
Oligonucleotides derived from the C-promoter; with single base single-stranded overhangs 
RI_26_f_A A TAA ACA CGC CGT GGG AAA AAA TTT AT 
RI_26_r_T T ATA AAT TTT TTC CCA CGG CGT GTT TA 
RI_25_f_A A TAA ACA CGC CGT GGG AAA AAA TTT A 
RI_25_r_T T TAA ATT TTT TCC CAC GGC GTG TTT A 
RI_24_f_A A AAA CAC GCC GTG GGA AAA AAT TTA 
RI_24_r_T T TAA ATT TTT TCC CAC GGC GTG TTT 
RI_23_f_A A AAC ACG CCG TGG GAA AAA ATT TA 
RI_23_r_T T TAA ATT TTT TCC CAC GGC GTG TT 
RI_22_f_A A AAC ACG CCG TGG GAA AAA ATT T 
RI_22_r_T T AAA TTT TTT CCC ACG GCG TGT T 
RI_21_f_A A ACA CGC CGT GGG AAA AAA TTT 
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RI_21_r_T T AAA TTT TTT CCC ACG GCG TGT 
RI_20_f_A A ACA CGC CGT GGG AAA AAA TT 
RI_20_r_T T AAT TTT TTC CCA CGG CGT GT 
RI_17_f_T T CAC GCC GTG GGA AAA AA 
RI_17_r_A A TTT TTT CCC ACG GCG TG 
RI_16_f_T T ACG CCG TGG GAA AAA A 
RI_16_r_A A TTT TTT CCC ACG GCG T 
RI_15_f_T T ACG CCG TGG GAA AAA 
RI_15_r_A A TTT TTC CCA CGG CGT 
RI_14_f_T T CGC CGT GGG AAA AA 
RI_14_r_A A TTT TTC CCA CGG CG 
 
Oligonucleotides derived from the C-promoter; with double base single-stranded overhangs 
RI_23_f_AA AA AAC ACG CCG TGG GAA AAA ATT TA 
RI_23_r_TT TT TAA ATT TTT TCC CAC GGC GTG TT 
RI_22_f_AA AA AAC ACG CCG TGG GAA AAA ATT T 
RI_22_r_TT TT AAA TTT TTT CCC ACG GCG TGT T 
RI_21_f_AA AA AAC ACG CCG TGG GAA AAA ATT 
RI_21_r_TT TT AAT TTT TTC CCA CGG CGT GTT 
RI_20_f_AA AA ACA CGC CGT GGG AAA AAA TT 
RI_20_r_TT TT AAT TTT TTC CCA CGG CGT GT 
RI_19_f_AA AA ACA CGC CGT GGG AAA AAA T 
RI_19_r_TT TT ATT TTT TCC CAC GGC GTG T 
RI_18_f_AA AA CAC GCC GTG GGA AAA AAT 
RI_18_r_TT TT ATT TTT TCC CAC GGC GTG 
RI_17_f_AA AA CAC GCC GTG GGA AAA AA 
RI_17_r_TT TT TTT TTT CCC ACG GCG TG 
RI_13_f_AA AA CGC CGT GGG AAA A 
RI_13_r_TT TT TTT TCC CAC GGC G 
RI_13_f_TT TT GCC GTG GGA AAA A 
RI_13_r_AA AA TTT TTC CCA CGG C 
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Oligonucleotides derived from the LMP1 promoter 
SM615-LMP1wt GGT CCC CGG GGG GCA AGC TGT GGG AAT GCG GTG GCC 
SM615-LMP1wt-as GGC CAC CGC ATT CCC ACA GCT TGC CCC CCG GGG ACC 
 
Oligonucleotides derived from the LMP2A promoter 
O54-sense CTC GCG ACT CGT GGG AAA ATG GGC GGA AGG GCA CCG 
O54-anti CCT GGA ACT ATT TTC CCA CGG TGC CCT TCC GCC CAT 
 
Oligonucleotides derived from the mammalian HES-1 promoter 
Cele_13_f_TT TT ACT GTG GGA AAG A 
Cele_13_r_AA AA TCT TTC CCA CAG T 
 
DNA-oligonucleotides to test unspecific binding of RBP-Jκ 
Un_f CCA TGA ATC CTA CAG TAC 
Un_r GTA CTG TAG GAT TCA TGG 
 
2.1.5 Antibodies 
Primary antibodies (provided by E. Kremmer, GSF Munich) 
 Species isotype 
α-EBNA2, WWP-K 6C8   Rat  IgG 2a 
α-GST 2C8    Mouse  IgG 1 
α-RBP-Jκ 7A11 (Western blotting)   Rat  IgG 2b 
α-RBJκ 6E7 (immunoprecipitation)   Rat  IgG 2b 
α-Ram, ICN 5B5    Rat  IgG 2b 
 
Conjugated antibodies 
species target conjugate Manufacturer 
Goat      α-rat      IgG-HRP    Santa Cruz Biotechnology,  Santa Cruz, CA, USA 
Goat      α-mouse    IgG-HRP   GE Healthcare (Amersham Biosc.), Munich, DE 
2.1.6 Enzymes 
Alkaline shrimp phosphatase     Boehringer, Mannheim, DE 
Klenow fragment    Roche, Mannheim, DE 
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Kod polymerase    Invitrogen, Carlsbad, CA, USA 
Proteinase K    Roche, Mannheim, DE 
Restriction enzymes   New England Biolabs, Ipswich, MA, USA
Subtilisin Roche, Mannheim, DE 
Taq polymerase Peqlab Biotech. GmbH, Erlangen, DE 
TEV protease    G. Stier, EMBL 
Trypsin     Roche, Mannheim, DE 
  
2.1.7 Peptides 
Peptide    derived from
QLWFP  Notch-Ram 
RQHGQLWFPEGE Notch-Ram 
PSGPPWWPPI    EBNA2 
RPSGPPWWPPIE    EBNA2 
 
2.1.8 Chemicals 
Acetic Acid Roth, Karlsruhe, DE 
Agarose Invitrogen, Carlsbad, CA, USA 
Amphotericine B Sigma Aldrich, Taufkirchen, DE 
Ampicillin Roth, Karlsruhe, DE 
Arabinose Sigma Aldrich, Taufkirchen, DE 
Arginine Sigma Aldrich, Taufkirchen, DE 
β-Mercaptoethanol Sigma Aldrich, Taufkirchen, DE 
Bacto agar Invitrogen, Carlsbad, CA, USA 
Bovine serum albumine New England Biolabs, Ipswich, MA, 
USA 
Bradford Reagent Biorad, Hercules, CA, USA 
Chloramphenicol Sigma Aldrich, Taufkirchen, DE 
  
Complete protease inhibitor cocktail, 
EDTA-free 
Roche, Mannheim, DE 
Dithiothreitol Roth, Karlsruhe, DE 
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DNA markers Fermentas, St Leon-Rot, DE 
DNTP Roche, Mannheim, DE 
EDTA Roth, Karlsruhe, DE 
Ethidium bromide Sigma Aldrich, Taufkirchen, DE 
Fetal calf serum PAA Laboratories, Cölbe, DE 
Glycerol Roth, Karlsruhe, DE 
Glycine Sigma Aldrich, Taufkirchen, DE 
Guanidinium Hydrochloride Roth, Karlsruhe, DE 
HEPES Roth, Karlsruhe, DE 
Hydrochloric Acid Roth, Karlsruhe, DE 
Imidazole Roth, Karlsruhe, DE 
IPTG Roth, Karlsruhe, DE 
Kanamycin Roth, Karlsruhe, DE 
LB broth (Lennox) Roth, Karlsruhe, DE 
Lipofectin Invitrogen, Carlsbad, CA, USA 
Nickel sulfate Sigma Aldrich, Taufkirchen, DE 
Magnesium Cloride Sigma Aldrich, Taufkirchen, DE 
Magnesium Formate Hampton Res., Aliso Viejo, CA, USA 
MES Roth, Karlsruhe, DE 
Pefabloc Pentapharma, Basel, CH 
Penicillin/Streptomycine Invitrogen/Gibco, Carlsbad, CA, USA 
Polyethyleneglycol  Sigma Aldrich (Fluka), Taufkirchen, DE  
Polyethyleneglycol 3350 Sigma Aldrich (Fluka), Taufkirchen, DE  
Polyethyleneglycol 4000 Sigma Aldrich (Fluka), Taufkirchen, DE 
Polyethyleneglycol 5000 MME Sigma Aldrich (Fluka), Taufkirchen, DE  
Polyethyleneglycol 8000 Sigma Aldrich (Fluka), Taufkirchen, DE  
Polyethyleneglycol  Sigma Aldrich (Fluka), Taufkirchen, DE  
Potassium Chloride Sigma Aldrich, Taufkirchen, DE 
Protein Standard for size  
exclusion chromatography 
Biorad, Hercules, CA, Hercules, CA, 
USA 
SDS  Sigma Aldrich (Fluka), Munich,DE 
SF900 medium Invitrogen, Carlsbad, CA, USA 
Silicon grease Dow Corning, Wiesbaden, DE 
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Sodium Chloride Roth, Karlsruhe, DE 
Sodium Hydroxide Roth, Karlsruhe, DE 
TCEP Sigma Aldrich, Taufkirchen, DE 
TNM medium Sigma Aldrich, Taufkirchen, DE 
Tris-hydroxymethyl-aminomethane Omni Lifesciences, Vista, CA, USA 
XTRA Blue Xgal solution Qbiogene, Morgan Irvine, CA 
 
2.1.9 Crystallisation screens 
All crystallisation screens used (Additive Screen 2; Crystal Screen 1 and 2; Grid Screens 
Ammonium Sulfate, MPD, PEG 6000 and Na-Malonate; Natrix Screen; PEG/Ion Screen) 
were purchased from Hampton Research, Aliso Viejo, CA, USA 
 
2.1.10  Laboratory equipment 
Air Fuge   Beckman Coulter, Krefeld, DE 
Äkta Explorer   GEHC*  (Amersham Pharmacia), Munich, DE 
Äkta Prime               GEHC (Amersham Pharmacia), Munich, DE 
Äkta Purifier   GEHC (Amersham Pharmacia), Munich, DE 
Bacteria shaker Multitron Infors, Bottmingen, CH 
CD spectrometer   Jasco GmbH, Gross-Umstadt, DE 
Flow hood work bench          Heraeus Instruments, Langenselbold, DE 
Gel documentation system 
ChemiDoc   
Biorad, Hercules, CA, USA 
Gel electrophoresis units (DNA)  
Mini-Sub cell GT      
Biorad, Hercules, CA, USA 
Gel electrophoresis units (protein) 
X Cell Sure Lock    
Invitrogen, Carlsbad, CA, USA 
Centrifuge 5810 R   Eppendorf AG, Hamburg, DE 
Centrifuge 5415 R   Eppendorf AG, Hamburg, DE 
Centrifuge 5415 D   Eppendorf AG, Hamburg, DE 
Centrifuge Allegra   Eppendorf AG, Hamburg, DE 
Centrifuge Avanti J-20 XP  Beckman Coulter, Krefeld, DE 
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Centrifuge RC 26 Plus  Sorvall, Langenselbold, DE 
Counter QC 4000 XER  Bioscan, Washington DC, USA 
Incubator for bacteria cultures Heraeus Instruments, Langenselbold, DE 
Insect cell incubator Multitron Infors, Bottmingen, CH 
Mammalian cell incubator Heraeus Instruments, Langenselbold, DE 
Rotors GSA, SA300, SS34  Sorvall, Langenselbold, DE 
Rotor JLA 8.1000   Beckman Coulter, Krefeld, DE 
Rotor JA 25.50   Beckman Coulter, Krefeld, DE 
PCR machine Mastercycler 
Gradient 
Eppendorf AG, Hamburg, DE 
PH-Meter Seven Easy  Mettler Toledo, Giessen, DE 
Spectrophotometer BioPhotometer Eppendorf AG, Hamburg, DE 
Thermomixer Comfort  Eppendorf AG, Hamburg, DE 
Ultrasonic Cell Disrupter  
Sonoplus HD 2200 
Bandelin electronic, Berlin, DE 
UV transilluminator Angewandte Gentechnologische Systeme 
GmbH, Heidelberg, DE 
Water purification system Millipore GmbH, Schwalbach, DE 
X-ray film developer  GEHC (Amersham Biosc.), Munich, DE 
 
*GEHC: GE Healthcare 
2.1.11  Synchrotron radiation sources 
Source Instrument Technique 
BESSY Berlin  X-ray crystallography 
CLRC Daresbury 12.1 Circular Dichroism 
EMBL Hamburg at DESY X33 SAXS 
EMBL Hamburg at DESY BW7B X-ray crystallography 
 
2.1.12  Software 
BLAST http://blast2srs.embl.de 
Clone Manager Sci Ed Central, www.scied.com 
ClustalW www.ebi.ac.uk/clustalw/ 
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Entrez Pubmed www.ncbi.nlm.nih.gov/entrez/query.fcgi 
FoldIt http://iubio.bio.indiana.edu:7780/archive/00000038/  
MODELLER http://salilab.org/modeller/ 
PestFind http://bioweb.pasteur.fr/seqanal/interfaces/pestfind.html 
Pfam www.sanger.ac.uk/Software/Pfam/ 
PHD www.embl-heidelberg.de/predictprotein/predictprotein.html 
PDB Protein Data Bank www.pdb.org 
Protein parameter tool www.expasy.org/tools/protparam.html 
Pymol www.pymol.org 
Rasmol www.umass.edu/microbio/rasmol/ 
 
2.1.13  Kits, columns and other material 
ECL Western Blotting detection 
reagent    
GEHC* Amersham Biosc., Munich, DE 
HiTrap Chelating 1 ml                  GEHC Amersham Biosc., Munich, DE 
HiTrap Chelating 5 ml GEHC Amersham Biosc., Munich, DE 
Hybond N+ nylon membrane Millipore GmbH, Krefeld, DE 
QIAquick Gel Extraction Kit                  Qiagen, Hilden, DE 
QIAquick PCR purification Kit Qiagen, Hilden, DE 
QIAquick Spin Mini Kit                        Qiagen, Hilden, DE 
Superdex 75 10/30, size excl. column GEHC Amersham Biosc., Munich, DE 
Superdex 75 16/60, size excl. column GEHC Amersham Biosc., Munich, DE 
Superdex 200 10/30, size excl. column   GEHCAmersham Biosc. Munich, DE 
Superdex 200 16/60, size excl. column   GEHCAmersham Biosc., Munich, DE 
Whatman paper  Biometra, Goettingen, DE 
X-ray film  Eastman Kodak Co., USA 
 
Plastic laboratory-ware were purchased from Greiner GmbH, Frickenhausen, DE, NUNC GmbH, Wiesbaden, 
DE, Eppendorf AG, Hamburg, DE. 
*GEHC: GE Healthcare 
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2.2 Methods 
2.2.1 Bacterial cell culture 
Maintenance and propagation of bacteria 
Bacteria were cultured at 37 °C on LB-agar plates in an incubator or in liquid LB-medium in a 
shaker. Transformed bacteria were selected by adding the appropriate antibiotics to agar or 
LB-medium (kanamycin 50 µg/ml, chloramphenicol 34 µg/ml, ampicillin 50 µg/ml). For 
liquid cultures 100 to 1000 ml LB-medium were inoculated with a single bacterial colony 
picked from an agar plate. 
Glycerol stocks for long-term storage were only prepared for plasmids transformed into DH5a 
to be able to regrow cultures quickly for DNA preparation. Aliquots of 700 µl of culture 
(OD600 = 0.6) were mixed with 300 µl glycerol and stored at -80 °C. 
 
LB-medium: 1% (w/v) Bacto-Tryptone; 0.5% (w/v) Bacto-yeast extract; 0.5% (w/v) NaCl 
LB-agar: LB-medium; 1.5% (w/v) Bacto-agar 
Preparation of competent bacteria 
A sample from a frozen bacterial stock was spread out onto an LB-agar plate and grown 
overnight. A single colony was used to inoculate 5 ml of LB-medium overnight at 37 °C. 200 
ml LB-medium containing 20 mM MgSO4 and 10 mM KCl were inoculated with 1 ml of the 
overnight culture in a 1 l flask. The cells were fermented at 37 °C up to an OD600 of 0.6-0.7. 
Bacteria were kept on ice for 10 minutes and pelleted at 3500 rpm (rotor GSA, Sorvall, 
Langenselbold, DE) for 10 minutes at 4 °C. The medium was discarded and the pellet 
resuspended in 20 ml of ice-cold 0.1 M CaCl2. The bacteria were then pelleted at 3500 rpm for 
20 minutes at 4 °C and resuspended in 4 ml of ice-cold 0.1 M CaCl2. After another 
centrifugation step (as above) the cells were resuspended in 2 ml cold 10 % glycerol. Aliquots 
of 100 µl bacteria suspension were flash-frozen in liquid nitrogen and stored at -80 °C. 
Heat shock transformation 
100 μl of competent cells stored at -80 °C were thawed on ice. 10 to 100 ng of plasmid DNA 
or 10 µl of ligation mix were added and the bacteria-DNA mix incubated on ice for 30 
minutes. Following a 45 sec heat shock at 42 °C the mix was incubated on ice for 2 minutes. 
500 µl LB-medium were added and the cells were incubated at 37 °C in a shaker for one hour.  
If a ligation product was transformed the cells were centrifuged at 2000 rpm (centrifuge 5810 
R, Eppendorf AG, Hamburg, DE) for 1 minute, the supernatant discarded until 50 µl were left 
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and spread onto an agar plate containing the appropriate antibiotics. The LB-agar plates were 
incubated at 37 °C for 16 to 18 hours. 
For the transformation of pre-existing plasmids an aliquot of the culture of transformed 
bacteria was plated out onto an agar plate containing the appropriate antibiotics. 
Heat shock transformation of recombinant baculo-virus vectors 
A recombinant Bacmid (rBacmid) is produced when, after ligation of the gene of interest into 
a baculo-virus pFASTBAC vector and transformation of the ligation product into DH10Bac E. 
coli cells the gene of interest including possible tags recombines into a baculo-viral genome 
present in DH10Bac cells. The new recombinant artificial baculo-virus genome is called 
rBacmid (for a scheme of rBacmid production see Figure 2.1). 
Transformation of a recombinant baculo-virus vector into DH10Bac follows a modified 
version of the protocol described before. An aliquot of competent DH10Bac cells stored at –
80 °C was thawed on ice. 1 ng of baculo-virus vector was mixed with 25 μl competent cells 
and incubated on ice for 30 min. Following a 45 sec heat shock at 42 °C the mix was 
incubated on ice for 2 minutes. 200 µl LB-medium were added and the cells were incubated at 
37 °C in a shaker for four hours.  20 μl of the culture were plated on agar containing 50 μg/ml 
kanamycin, 10 μg/ml gentamicin, 40 μg/ml tetracycline, 40 μg/ml IPTG and 1 mg/ml Bluogal 
and incubated at 37 °C for 48 to 72 hours until blue and white colonies could be distinguished. 
Isolation of plasmid DNA 
Single colonies obtained from transformation of bacteria with ligation reactions or plasmid 
DNA were used to inoculate 5 ml of LB-medium with the appropriate antibiotics. The culture 
was grown overnight at 37 °C and harvested by centrifugation at 4000 rpm (Allegra centrifuge, 
Eppendorf) for 10 minutes. The QIAquick Spin Mini Kit (QIAGEN) was used according to 
the manufacturer’s instructions. 
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Figure 2.1: Scheme for the production of a recombinant Bacmid (rBacmid). The gene of interest is ligated into 
an appropriate baculo-virus transfer vector. The recombinant vector is transformed into competent DH10Bac E. 
coli cells containing one copy of a baculo-virus genome and helper plasmids expressing a recombinase. The 
recombination sites flanking the gene of interest in the vector enable it to recombine into the viral genome to 
form a recombinant Bacmid. Clones containing the rBacmid are visualized by blue-white selection, since 
successful recombination destroys the β-galactosidase gene expressed to metabolise a chromogenic substrate 
such as BluoGal™ contained in the agar into a blue substance colouring the bacteria. The insertion of a gene 
destroys the reading frame of β-galactosidase resulting in white bacteria. 
Isolation of rBacmid-DNA  
As described in Figure 2.1 successful recombination of the gene of interest into the baculo-
virus genome results in the destruction of the reading frame of the β -galactosidase gene. 
Bacterial clones containing a recombinant Bacmid are therefore incapable of converting a 
chromogneic substrate such as BluoGal™ into a blue substance and thus remain white. 
To amplify and isolate rBacmid-DNA two white DH10Bac colonies were picked and 
inoculated into 2 ml of medium and grown overnight at 37 °C in a shaker. Cell lysis and 
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separation of rBacmid-DNA from proteins and cell debris was carried out using buffers P1, P2 
and N3 supplied with the QIAquick Spin Mini kit (QIAGEN) according to the manufacturer’s 
instructions. Since the desired rBacmid is very large (16 kbp), miniprep columns are not 
suitable for DNA purification. A clear lysate containing rBacmid-DNA was obtained by a 
centrifugation step. The rBacmid-DNA was precipitated by addition of 3 volumes of 100% 
ethanol and by centrifugation at 16100 g and 4 °C for 30 minutes. The DNA pellet was 
washed with 500 µl of 70% ethanol, dried under a sterile bench and dissolved in 50 µl of 
MilliQ water. 
 
P1: 50 mM Tris-HCl, pH 8.0, 10 mM EDTA, 100 µg/ml RNase A 
P2: 200 mM NaOH, 1% SDS (w/v) 
N3: 3.0 M potassium acetate, pH 5.5 
 
2.2.2 Eucaryotic cell culture 
Mammalian cell culture 
Cultivation of cells in suspension 
DG75 cells were grown in suspension culture in RPMI containing 10% (v/v) FCS, 2mM L-
glutamine and 100 U/ml penicillin/streptomycine. They were kept at 37 °C in a 5% CO2, 
water saturated atmosphere.  
Cells were counted in a Neubauer chamber in a 1:1 solution in trypan blue to exclude dead 
cells. As soon as the culture had reached a density of 1x106/ml they were split 1:4 to 1:6. 
Insect cell culture 
Cultivation of suspension and adherent cells 
Adherent cells 
High Five™ cells, SF21 and SFplus cells were grown in monolayer cultures with TNM media 
+ 10% FCS. Cells were grown in 5, 10 or 25 ml cell culture bottles, where they grow as 
monolayer with a duplication time of 12 hours. When confluent, the cells were split according 
to the desired confluence level and incubated until 70 to 80% confluency for infection or up to 
100 % for propagation. 
 
Materials and Methods 
 
 38
TNM medium: 51 g TNM-FH powder (Sigma) per litre medium were dissolved in deionised 
H2O, supplemented with 0.35 g/l NaHCO3, adjusted to pH 6.2 and filtered through a sterile 
filter into a sterile bottle. 
 
Suspension cultures 
SFplus cells were grown in suspension in flasks holding 300 ml of SF900 medium 
supplemented with 1.25 µg/ml amphotericin and 100 U/ml penicillin/streptomycin. After 
reaching a density of 2x106 cells/ml they were split 1:2 or infected with the appropriate 
recombinant baculo-virus. 
 
SF900 medium: 38.4 g SF900 powder (Sigma) per litre medium were dissolved in deionised 
H2O, supplemented with 0.8 ml insect cell supplement (Invitrogen) and 0.35 g/l NaHCO3, 
adjusted to pH 6.2 and filtered through a sterile filter into a sterile bottle. 
 
Production of a recombinant baculo-virus 
rBacmid transfection 
SF21 cells in 6-well plates holding 9x105 cells/well were used for transfection. The cells were 
washed twice with 2 ml TNM medium without any supplements. The medium was then 
discarded and replaced by a mix of 6 µl Cellfectin and 5 µl rBacmid-DNA (200 ng) in 200 µl 
TNM only. After 45 min 800 µl TNM only were added and the mix was incubated for five 
hours at 27 °C. The mix was replaced by 2 ml of TNM + FCS. The supernatant, which 
contains the primary virus (P1), was collected after 72 hours. 
 
Virus production 
To produce a larger amount of virus, SF21 cells were grown in TNM+FCS media to 60-70% 
confluence in 25 ml plates and infected with 600 µl of P1 virus. Depending on the appearance 
of the cells after infection the supernatant containing the secondary virus (P2) was taken 48-72 
hours after infection. 
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2.2.3 DNA manipulation and analysis 
Cloning of recombinant plasmids 
Constructs for protein expression in bacteria 
Primers for any DNA fragment of interest were designed with an NcoI- or, if this site was 
present in the fragment, a PciI-restriction site at the 5’-end of the forward primer and a KpnI-
restriction site at the 5’-end of the reverse primer. The DNA fragment was amplified by PCR 
and digested with the appropriate restriction enzymes (NEB) according to the manufacturer’s 
instructions. It was ligated into a linearized pETM11 vector (G. Stier, EMBL Heidelberg) with 
flanking sites for NcoI and KpnI. Chemically competent E. coli DH5α bacteria were 
transformed with the ligation product and spread onto an agar plate containing the appropriate 
antibiotic.  
Constructs for protein expression in insect cells 
The DNA fragments encoding the protein of interest amplified by PCR were ligated into the 
baculo-virus shuttle vector pFastBac-Hta, containing a 6xHis-Tag. The multiple cloning site 
included the commonly used NcoI and KpnI sites, which were used to cut both vector and 
fragment. Competent DH10Bac cells were transformed according to the protocol in section 
2.2.1. After 48 to 72 hours the colonies are visible and can be distinguished on the basis their 
blue and white colour. After isolation of Bacmid-DNA the presence of the insert was verified 
by restriction digestion with NcoI and KpnI. 
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Figure 2.2: Map of the baculovirus vector pFastBac-HT A indicating features important for cloning and 
replication. The vector contains an N-terminal 6xHis tag separated from the gene of interest by a TEV cleavage 
site. Within the multi-cloning site both full-length RBP-Jκ and a truncated fragment containing      aa 28 to 432 
were ligated between NcoI and KpnI restriction sites. 
Polymerase chain reaction 
To check the presence of an insert Taq polymerase (Roche, Mannheim, DE) was used 
according to the manufacturer’s instructions. 
Kod polymerase (Invitrogen, Carlsbad, CA, USA) was used to amplify DNA fragments 
intended for cloning. The kit delivered with the polymerase was used according to the 
manufacturer’s instructions. 
Annealing of single-stranded oligonucleotides 
Equal molar ratios of single-stranded complementary oligonucleotide were mixed in 10 mM 
Tris, pH 8.0 and 1 mM MgCl2. The solution was heated to 95 ºC for 10 minutes in a heat 
block and then left to gradually cool down to room temperature by switching the heat block 
off. The final concentration of annealed oligonucleotides was 0.5 nM/µl in each case. 
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Radioactive labelling of DNA 
End-labelling with γ-32P-ATP using T4 polynucleotide kinase 
End-labelling was used for oligonucleotides derived from the C-promoter containing an RBP-
Jκ binding site, which were shortened to lengths of 14 to 24 bp. Before labelling the 
oligonucleotide pairs were annealed. 
20 pMol of oligonucleotide ends were incubated with 2 µl of 10x buffer for T4- 
polynucleotide kinase (Roche, Mannheim, DE) and 1 µl kinase (Roche, Mannheim, DE). The 
reaction mixture was made up to 15 µl with H2O and 5 µl γ-32P-ATP added to make a final 
volume of 20 µl. It was then incubated at 37 °C for 30 min and separated from free γ-32P-ATP 
using Nick™ columns (GE Healthcare, Amersham Pharmacia, Munich, DE) for 
oligonucleotides longer than 20 bp or Nap™ columns (GE Healthcare, Amersham Pharmacia, 
Munich, DE) for oligonucleotides shorter than 21 bp according to the manufacturer’s 
instructions. 100 µl fractions were collected and the three most strongly labelled fractions as 
determined with a QC4000 XER counter (Bioscan, Washington DC, USA) were used further.  
 
Fill-in with radioactive dCTP using Klenow fragment 
The oligonucleotides derived from the Epstein-Barr viral Cp, LMP1P and LMP2AP were 
annealed and treated with Klenow-polymerase to fill up the overhangs with cold 
dATP/dTTP/dGTP and radioactive dCTP. 
6.6 pM of double-strand oligonucleotide were added to 2 µl of 10x buffer 2 (restriction buffer 
2, NEB), 2 µl dATP, dGTP, dTTP (0.5 mM each) and 2 µl Klenow polymerase (Roche, 
Mannheim, DE). The reaction mixture was made up to 15 µl with H2O. 5 µl of dCTP were 
added to make the reaction volume 20 µl. It was then incubated for 1 h at 37 °C. To separate 
free radioactive nucleotides the labelled oligonucleotide was purified using Nick™ 
purification columns (GE Healthcare, Amersham Pharmacia, Munich, DE) according to the 
manufacturer’s instructions. 100 µl fractions were collected and the three most strongly 
labelled fractions as determined with a QC4000 XER counter (Bioscan, Washington DC, USA) 
were used for experiments.  
 
NEB2: 10 mM Tris-HCl, pH 7.9, 50 mM NaCl, 10 mM MgCl2, 1 mM DTT 
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2.2.4 Methods for the analysis of proteins and DNA/protein interactions 
Protein quantification 
Purified proteins 
5 µl of protein solution were mixed with 95 µl UV cocktail. The absorption of the mixture 
was measured at 280 nm after defining a blank with 5 µl of the corresponding buffer. The 
protein concentration was calculated according to Lambert-Beer’s Law: 
lcE ⋅⋅= ε  
with E being the extinction at 280 nm, ε the calculated molar extinction coefficient and l the 
pathlength of the cuvette. 
UV cocktail: 50 mM Na3PO4, pH 8.0; 6 M guanidinium hydrochloride 
 
Protein mixtures 
10 µl of the protein solution were mixed with 990 µl Bradford reagent (Biorad, Hercules, CA). 
The absorption of the solution was determined at 600 nm. For calibration, a BSA stock 
solution was diluted to concentrations of 0.1, 0.2, 0.5, 0.8, 1.0 and 1.2 mg/ml. 10 µl of each 
dilution were added to 990 µl of Bradford reagent and the absorption measured at 600 nm. 
SDS-polyacrylamide gel electrophoresis (SDS-PAGE) 
SDS-PAGE separates proteins according to their molecular mass on a polyacrylamide gel. The 
individual charge of each protein is neutralized by addition of sodium dodecylsulfate (SDS) to 
the protein sample. The negatively charged SDS molecules denature and coat each protein 
molecule producing a layer of negative charges resulting in the migration of coated proteins 
towards the cathode in an electric field applied to the polyacrylamide gel. 
Samples were mixed with 4x LDS sample buffer (Invitrogen, Carlsbad, CA, USA) and 
applied to polyacrylamide gels (12% or 5 to 20% gradient gels) cast with Tris-Tricine buffer. 
The gel was run at 12.5 V/cm for 90 minutes.  
 
LDS sample buffer: 10%Glycerol, 141 mM Tris Base, 106 mM Tris HCl, pH 8.5, 2% 
lithiumdodecylsulfate (LDS), 0.51 mM EDTA, 0.22 mM SERVA® Blue G250, 0.175 mM 
Phenol Red 
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Native polyacrylamide gel electrophoresis 
Electrophoretic mobility shift assay (EMSA) using radioactive isotopes 
The following reaction was set up to form binary DNA-protein or ternary protein-protein-
DNA complexes: 5 µl binding buffer were mixed with 2 µl poly-dIdC and 2 µl BSA to 
produce the binding mix. This was made up, with the desired amount of protein (0.01 to 250 
ng) and H2O, to 18 µl and incubated for 5 minutes at room temperature, followed by addition 
of 2 µl 32P labelled oligonucleotide (radioactivity calculated for and diluted to 3x104 
counts/(µl·s)). The final mixture was incubated for 30 minutes at room temperature and loaded 
onto a 4% polyacrylamide gel in TBE buffer. The gel was run at 6.5 V/cm for 3 hours, dried 
and exposed to an X-ray film. 
 
Buffer 4x BB: 40 mM Hepes, pH 7.9, 4 mM EDTA, 800 mM KCl; 16% Ficoll 
poly dIdC: 1mg/ml poly dIdC in TE buffer and 100 mM NaCl 
BSA: 1 mg/ml in H2O 
Electrophoretic mobility shift assay with non-radioactive detection 
Check for the presence of binary protein-DNA and ternary protein-protein-DNA 
complexes 
Oligonucleotides were incubated with 10 µg of the respective protein for 30 minutes at room 
temperature in buffer N. The complexes were loaded onto an 8% polyacrylamide gel in TBE 
buffer (Invitrogen, Carlsbad, CA, USA) and run for 75 minutes at 10 V/cm. The gels were 
stained with ethidium bromide to visualise the DNA and Coomassie Brilliant blue for protein 
bands. 
 
Buffer N: 20 mM Tris-HCl, pH 8.0; 100 mM NaCl; 1 mM DTT; 1 mM MgCl2 
Coomassie Brilliant Blue staining solution: 30 % ethanol, 10 % acetic acid, 0.1 % 
Coomassie Briliant Blue R (Sigma) 
 
Estimation of the binding affinity of proteins to DNA, other proteins and peptides 
5 µg of protein were incubated with the appropriate amount of DNA, other protein and/or 
peptide with 5µl buffer BB and 2 µl BSA in a total volume of 20 µl for 30 minutes at room 
temperature. The samples were applied to an 8% polyacrylamide gel in TBE buffer and run 
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for 6 hours at 6.5 V/cm. The gels were stained with ethidium bromide to visualise the DNA 
and Coomassie Brilliant blue or Safe Stain for protein bands. 
 
Buffer 4x BB: 40 mM Hepes, pH 7.9, 4 mM EDTA, 800 mM KCl; 16% Ficoll 
BSA: 1 mg/ml in H2O 
 
Western blotting and immunodetection of proteins 
Proteins separated by SDS-PAGE were transferred to a PVDF membrane in a transfer unit 
(TE 22 Mini Tank Transfer Unit, Hoefer, San Francisco, CA, USA) filled with transfer buffer. 
The blotting sandwich consisted of the gel placed on top of two pieces of Whatman 3MM 
filter paper and a sponge and overlaid with the PVDF membrane, pre-washed in methanol and 
equilibrated in transfer buffer. An additional layer of filter paper and a sponge placed on top 
of the membrane completed the blotting sandwich. The transfer was carried out at 400 mA for 
1 hour.  
Following transfer the membrane was incubated in blocking buffer to block all non-specific 
binding sites. The primary antibody (cell supernatant) was diluted to its correct working 
concentration (1:5) in blocking buffer and applied to the membrane for one hour at room 
temperature. The membrane was then washed three times for 10 minutes with PBS-T, before 
applying the peroxidase-conjugated secondary antibody for 1 hour at room temperature. This 
antibody is specific for the isotype of the primary antibody used. It was diluted according to 
the manufacturer’s instructions in PBS-T. The membrane was washed three times for 10 
minutes with 50 ml PBS-T and the blot was developed using ECL reagents A and B (GE 
Healthcare, Amersham Pharmacia, Munich, DE) according to the manufacturer’s instructions. 
An X-ray film was exposed to the blot to detect protein antibody complexes by the appearance 
of bands of the appropriate molecular mass. 
 
Transfer buffer: 25% methanol; 25 mM Tris, pH; 0.2 M glycine; 0,1% SDS 
Blocking buffer: 1x PBS; 0.05% Tween-20; 5% fat-free milk powder 
PBS-T: 1x PBS; 0.05% Tween-20 
 
Immunoprecipitation of recombinant proteins 
500 ng of recombinant protein in 300 µl equilibration buffer were incubated with 50 µl of 
antibody for 1 h on ice. 20 µl of preequilibrated protein G-beads were added and the mixture 
left rocking for 1 h. The beads were sedimented at 800 g and washed 3 times with 
Materials and Methods 
 
 45
equilibration buffer. SDS sample buffer was added to elute the bound protein from the beads 
and to separate recombinant protein and antibody and the mixture was boiled for 10 minutes 
in a thermomixer. 
The results were analysed by SDS-PAGE, Western Blotting and immunodetection (see above). 
 
Limited proteolysis 
10 µg of pure protein in cleavage buffer CB were incubated with 0.1 µg trypsin between 30 
seconds and 2 hours at room temperature. The reaction was stopped with SDS sample loading 
buffer containing 10 mM ß-mercaptoethanol and boiled for 10 min. Samples were analysed by 
SDS-PAGE. 
CB: 50 mM Tris, pH 8.0, 150 mM NaCl, 1 mM EDTA and 2 mM ß-mercaptoethanol 
 
Dynamic light scattering 
Monodispersity is a measure of the homogeneity of a molecular species, and therefore of the 
sample quality. High monodispersity is correlated with the likelihood of a sample 
crystallizing. Dynamic light scattering allows one to estimate the size of macromolecules in 
solution (their hydrodynamic radius) and their monodispersity. 
A sample of 25 μl protein solution with the desired concentration, which could be recovered 
after the measurements, was pipetted into a quartz cuvette put into a Temperature Controlled 
Microsampler (Wyatt Technology Corp., Santa Barbara, CA, USA) and the DLS measured at 
4 ºC with a Dyna Pro 99 (Wyatt Technology Corp., Santa Barbara, CA, USA). At least 15 
data points were taken in each case. 
2.2.5 Expression and purification of proteins 
Proteins expressed in bacteria 
Expression test 
A 1 ml overnight culture grown from a single colony of freshly transformed bacteria on an 
agar plate was used to inoculate 50 ml of LB-medium supplemented with the appropriate 
antibiotics. The 50 ml culture was grown at 37 °C until an OD600 of 0.6 was reached. After 
induction with 2 mM IPTG the culture was incubated at 37 °C for 3 hours. Aliquots of 0.5 ml 
culture suspension were taken before and after induction, pelleted by centrifugation, lysed and 
analysed by SDS-PAGE. 
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Overexpression of recombinant proteins 
A 10 ml overnight culture grown from a single colony of freshly transformed bacteria on an 
agar plate was used to inoculate 1 l of LB-medium supplemented with the appropriate 
antibiotics. The 1 l culture was grown at 37 °C until an OD600 of 0.6 was reached and 
subsequently induced with 0.5 mM IPTG or 1% arabinose. After induction the culture was 
grown at 20 °C for 13 to 15 hours.  The cells were harvested by centrifugation at 5000 rpm 
(rotor JLA 8.1000, Beckman Coulter, Krefeld, DE) for 15 minutes. After washing the pellet 
with cold PBS and another centrifugation step (as above) the pellets were frozen at -20 °C and 
stored until needed. 
 
Optimisation of expression conditions to promote soluble expression 
Expression conditions for different proteins can be optimised in order to promote the 
solubility of the overexpressed recombinant protein by changing one or more variables, e.g. 
expression temperature, expression host, additives in the medium or expression time. Table 
2.1 lists variables having been changed alone or pair wise to promote soluble expression of 
proteins expressed into inclusion bodies under standard expression conditions. 
The coexpression of chaperones as achieved in the bacterial strains listed in table 2.2 together 
with the protein of interest may promote proper folding of the protein. These strains were 
therefore used to test whether the solubility of the protein of interest could be increased. 
 
Temperature 
(°C) 
before Induction 
→ after induction 
Additives  IPTG 
(mM) 
Expression 
time 
(hrs) 
Expression host 
37 50 mM Tris-HCl pH 7.4 1 20 BL21(DE3)PlysS 
37→30 0.5 -5 % Glucose 0.5 2 BL21(DE3)RIL 
37→25 5 mM MgCl2 0.1 4 BL21(DE3) 
37→20 5% ethanol  6 RosettaRIL 
37→18   10 RosettaPLysS 
 
Table 2.1: Variables in protein expression changed to promote soluble expression; single changes or a 
combination of changes were applied  
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Strain Chaperones expressed 
BL21(DE3)cc1 DnaK, DnaJ, GrpE 
BL21(DE3)cc2 DnaK, DnaJ, GrpE, ClpB 
BL21(DE3)cc3 GroESL 
BL21(DE3)cc4 DnaK, DnaJ, GrpE, GroESL (large amounts) 
BL21(DE3)cc5 DnaK, DnaJ, GrpE, GroESL (small amounts) 
 
Table 2.2: E. coli strains used to improve solubility of RBP-Jκ. The five strains are stably transformed with 
different combinations of genes coding for bacterial chaperones known to promote protein folding (kind gift of 
Prof. B. Bukau, University of Heidelberg, Germany). 
 
Solubility screens to solubilise proteins under non-denaturing conditions 
Depending on the properties of the overexpressed protein certain components in the lysis 
buffer may promote its solubility. The screen summarized in table 2.3 was used to check the 
solubility of otherwise insoluble proteins.  
After lysis (200 μl/ml cell culture) and sonication the suspension was centrifuged at 20 krpm 
(rotor SA300) at 4 °C for 45 minutes. The remaining pellet was solubilized in the same 
volume 6 M guanidinium hydrochloride. Both fractions were analysed by SDS-PAGE to 
estimate the percentage of protein in the soluble and insoluble fraction. 
 
pH 
50 mM NaCl 
5 mM EDTA 
1mg/ml lysozyme 
50 mM 
Salt 
50mM Tris, pH 
7.5 
5 mM EDTA 
1 mg/ml lysozyme 
Urea 
50mM Tris, pH 7.5 
50mM NaCl 
5mM EDTA 
1 mg/ml lysozyme 
up to 3 M urea 
Detergent 
20 mM Tris, pH 7.5 
50 mM NaCl 
1 mg/ml lysozyme 
Stabiliser 
20 mMTris, 
pH7.5 
50 mM NaCl 
1 mg/ml lysozyme 
Na-Acetate, pH 5 0.1 M NaCl 0.5 M urea 0.2 % NP40 10 % glycerol 
MES, pH 6 0.5 M NaCl 1-6 M urea in steps 
of 1 M 
0.2 % Triton X-100 50 % glycerol 
Tris-HCl, pH 7 1 M NaCl  0.2 % Tween20  
Tris-HCl, pH 8 0.1 M KCl  0.2 % dodecylmaltoside  
Tris-HCl, pH 9 1 M KCl    
 
Table 2.3: Screen to check the solubility of a protein in different buffer conditions designed by J. Perry (UCLA, 
CA, USA); different parameters are subsequently changed. The first row lists the basic components of the buffer; 
each column lists the extent of the changed parameter.  
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Purification of proteins under native conditions 
His-tagged proteins 
Pellets were thawed on ice and resuspended in 40 ml buffer LBB per 1 l of cell culture (6-8 g 
wet cell weight). The cell walls were disrupted by sonication on ice (probe TT34 of the 
HD2200 generator (Bandelin electronic, Berlin, DE) for 3 x 4 minutes with 30% total 
sonication time and 50% maximum energy output). The lysate was clarified by centrifugation 
at 20 krpm (rotor SS34, Sorvall, Langenselbold, DE) for 40 minutes at 4 °C, passed through a 
45 µm sterile filter and applied to 3.5 ml of Ni-NTA beads equilibrated with buffer LBB, 
followed by gentle mixing at 4 °C for one hour. The mix of lysate and Ni-NTA beads was 
applied to an empty Biorad column (Hercules, CA, USA), where the lysate flowed through 
whereas the Ni-beads were assembled to form a column. The beads were washed with 5 
column volumes of buffer LIB (low imidazole wash), 5 column volumes of buffer HSB (high 
salt wash) and another 5 column volumes of buffer LIB. The protein bound to the Ni-NTA 
beads was eluted with buffer EB. 2 ml fractions were collected and analysed on an SDS-
PAGE. The fractions containing the desired protein were pooled and TCEP was added to a 
final concentration of 2 mM to quantitatively reduce random disulfide bridges. The protein 
concentration was determined and the sample flash frozen in liquid nitrogen before storage at 
-80°C. 
Buffer LBB: 50 mM Tris-HCl, pH 8.0; 150 mM NaCl; 800 mM urea, 1 µg/ml DNase, 
Complete mini EDTA free protease inhibitor cocktail according to manufacturer’s instructions 
Buffer LIB: Buffer LBB + 5 mM imidazole 
Buffer HSB: Buffer LBB + 500 mM NaCl 
Buffer EB: Buffer LBB + 400 mM imidazole 
 
GST-tagged proteins 
Pellets were thawed on ice and resuspended in 40 ml buffer LBB per 1 l of cell culture (6-8 g 
wet cell weight). The cell walls were disrupted by sonication on ice (probe TT34 of the 
HD2200 generator (Bandelin electronic, Berlin, DE) for 3 x 4 minutes with 30% total 
sonication time and 50% maximum energy output). The lysate was clarified by centrifugation 
at 20 krpm (rotor SS34, Sorvall, Langenselbold, DE) for 40 minutes at 4 °C, passed through a 
45 µm sterile filter and applied to 3 ml of GST-beads equilibrated with buffer LBB, followed 
by gentle mixing at 4 °C for one hour. The mix of lysate and GST-beads was centrifuged at 
300g for 10 minutes to sediment the beads. The beads were washed 3 times with 5 column 
volumes of buffer LBB containing 300 mM NaCl. The protein bound to the GST-beads was 
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eluted with 2x 3ml buffer GEB. The elution fractions were analysed on an SDS-PAGE. The 
fractions containing the desired protein were pooled and TCEP was added to a final 
concentration of 2 mM to quantitatively reduce random disulfide bridges. The protein 
concentration was determined and the sample flash frozen in liquid nitrogen before storage at 
-80°C. 
 
Buffer GEB: Buffer LBB + 30 mM reduced glutathione 
 
Purification of proteins from inclusion bodies under denaturing conditions followed by 
refolding 
Pellets from 2l of bacterial culture were resuspended in buffer LBR, sonicated with probe 
TT34 of the HD2200 generator (Bandelin electronic, Berlin, DE) for 3 x 4 minutes with 30% 
total sonication time and 50% maximum energy output and centrifuged at 4 °C for 40 minutes 
at 20 krpm (rotor SS34, Sorvall, Langenselbold, DE). The supernatant was discarded and the 
pellet containing the inclusion bodies resuspended in buffer RR and incubated for at least 30 
minutes at room temperature. The solution with the solubilized inclusion bodies was clarified 
by centrifugation at 4 °C for 40 minutes at 20 krpm and filtered through a 45 µm sterile filter. 
After application to 5 ml Ni-NTA beads pre-equilibrated with buffer RR the beads were 
washed with 10 column volumes of buffer RW. The sample was eluted using the minimum 
amount (5-10 ml) of buffer RE.  
Since the standard refolding protocol depicted in Figure 2.3 (a) did not result in soluble and 
functional protein the refolding screen listed in table 2.3 was applied. It consists of 16 
conditions varying in the content of guanidinium hydrochloride, sodium chloride, arginine and 
glycine.  
The highest ratio of soluble:insoluble protein combined with the lowest possible content of 
denaturing agents defined condition 13 as optimal for refolding in all cases (changed protocol 
shown in Figure 2.3 (b)). 
The purified protein solution resulting from the affinity purification was rapidly diluted in 
refolding buffer 13 in 1:20 ratio. The solution was stirred slowly overnight at 4 °C and frozen 
at -80 °C.  
 
Buffer LBR: 50 mM Tris, pH 8.0; 150 mM NaCl ; 1 µg/ml DNase, Complete mini EDTA 
free protease inhibitor cocktail according to manufacturer’s instructions 
Buffer RR: 40 mM Tris, pH 8.0; 500 mM KCl; 6 M guanidinium hydrochloride 
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Buffer RW: 40 mM Tris, pH 8.0; 40 mM KCl; 5.7 M guanidinium hydrochloride; 30 mM 
imidazole 
Buffer RE: 40 mM Tris, pH 8.0; 40 mM KCl ; 4.7 M guanidinium hydrochloride; 300 mM 
imidazole 
Refolding buffer 13: 50 mM Tris, pH 9.0; 1 M arginine; 150 mM NaCl; 1% glycine 
 
Purification of binary DNA-protein complexes and ternary protein-protein-DNA 
complexes using size exclusion chromatography 
Size exclusion chromatography was carried out on an Äkta Explorer (Amersham Pharmacia). 
One or two proteins and DNA were mixed in appropriate ratio. Depending on the size of the 
column the solution was concentrated to 1 ml (Superdex 16/60) or 200 µl (Superdex 10/30) 
and applied to the column, which was equilibrated in GF buffer. Fractions of 1 ml or 200 µl, 
respectively, were collected and analysed by SDS-PAGE. 
 
GF buffer: 50 mM Tris-HCl, pH 8.0; 100 mM NaCl; 2 mM DTT 
 
Materials and Methods 
 
 51 
 
 
    Figure 2.3: Flow charts of refolding procedures based on rapid dilution. (a) Standard refolding protocol and (b) adapted refolding protocol.
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 1 2 3 4 
Tris-HCl, 
pH 7.5 
50 mM Tris 50 mM Tris 
250 mM Gd-HCl 
250 mM L-Arginine 
150 mM NaCl 
0.5% Glycine 
50 mM Tris 
500 mM Gd-HCl 
500 mM L-Arginine 
200 mM NaCl 
1% Glycine 
50 mM Tris 
1 M Gd-HCl 
1 M L-Arginine 
300 mM NaCl 
2% Glycine 
 5 6 7 8 
Tris-HCl, 
pH 8.0 
50 mM Tris 
0 mM Gd-HCl 
250 mM L-Arginine 
200 mM NaCl 
2% Glycine 
50 mM Tris 
250 mM Gd-HCl 
0 mM L-Arginine 
300 mM NaCl 
1% Glycine 
50 mM Tris 
500 mM Gd-HCl 
1000 mM L-Arginine 
0 mM NaCl 
0.5% Glycine 
50 mM Tris 
1000 mM Gd-HCl 
500 mM L-Arginine 
150 mM NaCl 
0% Glycine 
 9 10 11 12 
Tris-HCl, 
pH 8.5 
50 mM Tris 
0 mM Gd-HCl 
500 mM L-Arginine 
300 mM NaCl 
0.5% Glycine 
50 mM Tris 
250 mM Gd-HCl 
1000 mM L-Arginine 
200 mM NaCl 
5% Glycine 
50 mM Tris 
500 mM Gd-HCl 
0 mM L-Arginine 
150 mM NaCl 
2% Glycine 
50 mM Tris 
1000 mM Gd-HCl 
250 mM L-Arginine 
0 mM NaCl 
1% Glycine 
 13 14 15 16 
Tris-HCl, 
pH 9.0 
50 mM Tris 
0 mM Gd-HCl 
1000 mM L-Arginine 
150 mM NaCl 
1% Glycine 
50 mM Tris 
250 mM Gd-HCl 
500 mM L-Arginine 
0 mM NaCl 
2% Glycine 
50 mM Tris 
500 mM Gd-HCl 
250 mM L-Arginine 
300 mM NaCl 
0% Glycine 
50 mM Tris 
1000 mM Gd-HCl 
0 mM L-Arginine 
200 mM NaCl 
0.5% Glycine 
 
Table 2.4: Refolding screen consisting of 16 conditions. Conditions differ by the concentration of guanidine-
HCl, NaCl, L-arginine and glycine. The most suitable condition for refolding combines the lowest 
concentration of denaturing agents with the best soluble:insoluble protein ratio. 
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Proteins expressed in insect cells 
Overexpression of proteins 
SFplus cells grown in suspension were cultivated until their density reached 2x106 cells/ml. 
4 ml of P2 virus supernatant were added to infect the cells. Depending on their appearance 
the cells were harvested 48 to 72 hours after infection. After centrifugation at 1000 g at 4 
ºC for 15 minutes the pellet was washed with ice-cold PBS and centrifuged again. It was 
frozen and stored at -20 ºC until needed. 
 
Purification of overexpressed proteins 
A cell pellet from 300 ml of cell culture was thawed on ice. After resuspension in LBI 
buffer the solution was sonicated with probe TT34 of the generator HD2200 (Bandelin 
electronic, Berlin, DE) for 2 minutes with 30% total sonication time and 50% maximum 
energy output until no more intact cells were visible under the microscope and centrifuged 
at 20 krpm (rotor SS34, Sorvall, Langenselbold, DE) for 40 minutes at 4 ºC. The 
supernatant was passed through a 45 µm filter and applied to 3.5 ml Ni-NTA beads pre-
equilibrated with LBI buffer. The mixture of lysate and beads were gently mixed at 4 ºC 
for 1 hour and then applied to an empty Biorad column (Hercules, CA), where the lysate 
flowed through whereas the Ni-beads were assembled to form a column. The beads were 
washed with 5 column volumes of LII buffer (low imidazole wash), 5 column volumes of 
buffer HSI (high salt wash) and another 5 column volumes of LII buffer. The protein 
bound to the Ni-NTA beads was eluted with EI buffer. 2 ml fractions were collected and 
analysed by SDS-PAGE. The fractions containing the desired protein were pooled, TCEP 
added to a final concentration of 2 mM, the protein concentration determined and the 
sample flash frozen in liquid nitrogen before storage at -80°C. 
 
Buffer LBI: 50 mM Tris-HCl,pH 8.0; 300 mM NaCl; 5 % glycerol; 2.5 mM MgCl2; 1mM 
ß-Mercaptoethanol; 1 µg/ml DNase, Complete mini EDTA free protease inhibitor cocktail 
according to manufacturer’s instructions 
Buffer LII: Buffer LBI + 5 mM imidazole 
Buffer HSI: Buffer LBI + 500 mM NaCl 
Buffer EI: Buffer LBI + 400 mM imidazole 
 
Materials and Methods 
 
 54
Preparation of nuclear extracts 
50 ml of DG75 cell culture were centrifuged at 300g at 4 ºC and washed with 5 ml cold 
PBS. After another centrifugation step as above the cells were resuspended in 3-4 pellet 
volumes (usually about 300 µl) of buffer A and kept on ice for 60 minutes to make the 
cells swell. The mixture was subsequently homogenized using a DOUNCE-homogenizer 
(Wheaton). The suspension was centrifuged for 10 seconds at 16100 g and the pellet was 
washed with 300 µl buffer A without resuspending it, followed by resuspension in 300 µl 
buffer B. The mix was kept on ice for 30 minutes, vortexed and centrifuged at 4 ºC for 20 
minutes at 16100 g. The protein concentration of the supernatant and of the nuclear extract 
was determined and aliquots were shock frozen in liquid nitrogen. 
 
Buffer A: 10 mM HEPES, pH 7.9; 10 mM KCl; 1.5 mM MgCl2, prior to use add 5 mM 
DTT and 5mM Pefabloc (Pentapharma, Basel, CH) 
Buffer B: 20 mM HEPES, pH 7,9; 25% glycerol; 420 mM NaCl, 1.5 mM MgCl2; 0.8 mM 
EDTA; prior to use add 5 mM DTT and 5 mM Pefabloc (Pentapharma, Basel, CH). 
 
2.2.6 Isothermal titration calorimetry (ITC) 
Introduction 
Isothermal titration calorimetry is used to study interactions between molecules (reviewed 
in (Pierce et al., 1999)). These can be protein-ligand (e.g. peptides or DNA) interactions as 
well as protein-protein interactions. Not only can the overall binding of two molecules 
easily be detected, but the stoichiometry n, the binding affinity (Ka) and the enthalpy (ΔH) 
and entropy (ΔS) changes of a given reaction can also be determined in a straightforward 
manner. The total concentration of all but one of the reactants remains constant throughout 
the experiment. Non-linear least square fitting of the calorimetric data from a single 
experiment, where heat is the only dependent variable, allows an estimation of the 
thermodynamic parameters. The method has many advantages, when compared to others 
such as surface plasmon resonance (SPR) or analytical ultracentrifugation. For SPR the 
protein must be attached to a surface, which depending on the binding site on the protein 
could potentially interfere with the binding of the ligand or interacting protein.  In the case 
of ultracentrifugation pressure may interfere with the equilibrium. 
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Whereas other methods only give mostly qualitative evidence of binding, ITC allows one 
to separate the enthalpic and entropic contributions to the binding affinity. 
The ITC device consists of two identical cells located inside an adiabatic jacket. The 
reference cell is kept at constant temperature (Figure 2.4). During the measurement the 
temperature difference between the two cells is measured and a cell feedback (CFB) or 
differential power is applied to maintain them at the same temperature. An endothermic 
reaction causes a positive feedback, because heat must be supplied to the sample cell to 
keep its initial temperature, whereas an exothermic reaction results in a negative feedback, 
because heat must be extracted to lower the temperature to its initial value. 
 
Figure 2.4: Schematic view of the VP-ITC device (Microcal, USA) taken from the VP-ITC manual. 
 
The feedback system is usually based on a Peltier element, where the heat Q, which is 
absorbed or dissipated during a time t, depending on the direction of the current is 
proportional to the current (I): 
tIPQ ⋅⋅=  
where P is the Peltier factor, which depends on the materials used in the element. Unlike 
the Joule effect, which is proportional to the square of the current 
tIRQ ⋅⋅= 2  
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(R: resistance), the Peltier effect is proportional to the current and changes sign (-/+) when 
the current changes direction. 
During the ITC measurement small volumes of the ligand are injected into a large volume 
of the protein solution at time intervals allowing the solution to reach equilibrium.  
The entropy of the reaction (ΔS) and the Gibbs free energy (ΔG) can be calculated using 
Gibbs equation: 
∆G = -RT lnK = ∆H -T∆S 
 
As the reaction is done a constant pressure ∆H = Q, where Q is the total heat absorbed or 
dissipated during the reaction. 
In addition it is possible to determine the heat capacity of binding at constant pressure (∆Cp) 
from two ITC measurements carried out at different temperatures: 
 
12
12
TT
HH
C TTp −
Δ−Δ=Δ  
with  T1 < T2. 
This parameter is a good indicator of changes in hydrophobic interactions. The value is 
negative if hydrophobic contacts are formed and positive if they are broken. 
Beside hydrophobic interactions, protonation plays a role in molecular interactions. It can 
be characterized to some extent by carrying out the experiment with buffers having 
different enthalpies of ionisation. A less exothermic ∆H in a buffer displaying a higher heat 
of ionisation than in a buffer with a lower heat of ionisation indicates that protons are taken 
up as sample and ligand interact.  
ITC is used to measure the heat evolved or absorbed when e.g. a protein and a ligand are 
mixed. In general, the ligand, which has about ten-fold higher concentration than the 
protein is titrated in small volumes into a large volume of protein solution. The method is 
non-destructive so that the protein and the ligand can be recovered after the measurement. 
The time integral of the measured CFB is a direct measurement of the heat absorbed or 
dissipated which is directly proportional to the extent of binding. 
The binding reaction corresponds to an equilibrium:   
  
M1 +M2                 M1M2 
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where M1 and M2 represent the macromolecule and its ligand. The strength of the 
interaction is described by the association (Ka) or dissociation constant (Kd): 
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where [M1] and [M2] are the concentrations of each molecule and [M1M2] that of the 
complex. These constants are related to the Gibbs free energy of association ∆Ga and 
dissociation ∆Gd (=-∆Ga), respectively. They can be expressed in terms of the 
corresponding change of enthalpy (∆H) and entropy (∆S) during the reaction: 
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where R is the gas constant (1.9872 kcalK-1Mol-1) and T the absolute temperature. 
The sequence of injections is continued until the heat change is zero or remains constant at 
a very low level, which may be due to dilution effects. This means that the protein 
molecule is saturated with ligand and the concentration of complex has reached its 
maximum. 
Prerequisites 
ITC experiments require large amounts and volumes of sample. The MicroCal VP-ITC 
device (MicroCal LLC, Northampton, MA, USA) requires 1.6 ml of protein solution with a 
concentration of 10-100 µM and 300 µl ligand solution with a concentration of 100 to 1000 
µM. Both concentrations must be exactly known. All solutions should be degassed and 
made with identical buffers as differences in buffer composition and pH may give large 
heat changes and lead to spurious results. 
 
Controls 
To test the sensitivity and accuracy of the VP-ITC device two kinds of control runs were 
carried out: 
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Methanol run to test sensitivity  
The cell is filled with degassed water, the syringe with a 2.5% methanol/water solution. 
The experimental parameters of the run are provided by the manufacturer and stored in the 
computer. The only detectable signal should be the heat dissipated when methanol is 
diluted into water. Since the concentration of methanol in the cell increases with every 
injection, this heat should decrease after each injection. Typical results obtained in 
methanol runs are shown in Figure 2.5. 
 
Figure 2.5: Exemplary data set of a methanol run. 
 
Rnase-2’CMP Experiment 
2’CMP solution (ca. 2.0 – 2.2 mM): 10 mg 2’CMP were dissolved in 5.5 ml 50 mM 
potassium acetate solution, followed by addition of another 5.5 ml potassium acetate buffer, 
pH 5.5. The pH was adjusted to 5.5 with 50 mM acetic acid. The concentration of 2’CMP 
was determined by absorption at 260 nm after 20-fold dilution of the solution in 0.2 M 
Tris-HCL, pH 7.0, using an extinction coefficient of 7400 cm-1 M-1 (c=A/(7400 x l)). 
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Figure 2.6: Exemplary data set of an RNase-2’CMP run 
 
RNase solution (ca. 0.06 mM): 20 mg RNase A were dissolved in 20 ml potassium acetate 
buffer, pH 5.5. The solution was dialyzed against two changes of 500 ml potassium acetate 
buffer at 4 ˚C for three hours per change (dialysis tubing: Spectra/Por, cut-off 6-8000, 
Sigma). The concentration is determined spectrophotometrically using an extinction 
coefficient of 9800 cm-1 M-1 at 280 nm (c=A/(9800 x l); c: concentration, A: absorbance at 
280 nm; l: pathlength in cm). 
The experimental parameters are provided by the manufacturer and stored in the computer. 
Figure 2.6 displays the results obtained with the RNase-2’CMP run. The sigmoidal binding 
curve derived from the set of ligand injections indicates the saturation of the available 
binding sites upon addition of more ligand. The binding constant can be calculated from 
the slope of the curve combined with the concentrations of the components. 
Experiment 
RBP-Jκ protein in complex with DNA (16 to 20 bp) was concentrated to about 22 to 35 
µM. Protein solution (1.8 ml) was filled into the sample cell, which had been cleaned and 
flushed with the appropriate buffer. The ligand solution, which had a concentration 
between 250 µM and 0.5 mM, was filled into the syringe according to the manufacturer’s 
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instructions. The syringe was assembled into the sample cell. The experimental conditions 
(temperature of the cell: 15 to 30 °C, desired number of injections, stirring speed: 290 rpm, 
injection parameters: filter period 2 s, duration 2.4 s and equilibration options: Fast 
Equilibration, Auto) were set on the user interface provided by the manufacturer. A 
sequence of 50 to 70 injections of 3 to 6 µl separated by 300-second intervals to allow 
equilibration was used to determine the binding curve. Figure 2.7 displays exemplary 
datasets of experiments carried out with an nRBPfull-length-J-DNA binary complex and 
NotchRam (a) and NotchRamANK (b) as ligand. 
The ability of the components to form complexes was tested with non-radioactive EMSA 
before and after the experiment. 
Evaluation 
The recorded data was evaluated using the program ORIGIN, adjusted to the needs of 
microcalorimetry and provided by the manufacturer. ORIGIN uses the measured 
concentrations of protein and ligand to calculate the binding constants, the enthalpy and 
entropy changes and the stoichiometry of the reaction. The results are visualised on a graph 
depicting the reaction curve and a table displaying the calculated values. 
The differential power or heat flow, which had to be applied to or extracted from the 
sample cell during each injection, compared to the power applied to the reference cell is 
measured and displayed in μcal/s. Given the information on the concentration of both 
reactants and the injection volume, the ORIGIN program calculates the enthalpy ΔH from 
the changes in the differential power after each injection and displays it as kcal/M of 
injectant in a graph containing the integrated data from all injections. 
The heat measured is determined by integrating the current in the Peltier element over time 
∫
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The heat associated with the change of state after each injection (qi) is proportional to the 
increment in the concentration of the complex after injection in the calorimetric cell, which 
has a volume V, [M1M2] is the concentration of complex and ∆H the enthalpy of binding: 
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A general model of binding including multiple, noninteracting binding sites quantifies 
cumulative heat of binding with: 
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with V0 being the volume of the cell, ∆Hi the enthalpy change at each injection and [M]t is 
the total macromolecule concentration including bound and free fractions, Ka is the binding 
constant and [L] is the free ligand concentration. 
Before normalizing the heat of binding to the ligand concentration, a volume correction is 
made to account for dilution of the macromolecule at each injection. The baseline is 
subtracted and the area under the peak is integrated. 
To determine n, Ka and ∆Hb as the enthalpy of binding per mole of ligand the above 
equation is represented in terms of the binding constant and total ligand concentration [L]t 
to obtain the quadratic 
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The n, Ka and ∆Hb parameters are then optimised with the routines provided in the 
ORIGIN software. 
As the reaction takes place at constant pressure and temperature the entropy change in the 
system can be calculated from the enthalpy change 
 
T
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Figure 2.7: Exemplary datasets of unprocessed  (top) and processed data (bottom) of experiments carried out with an RBP-Jκ-DNA binary complex 
and NotchRam (left panel) and NotchRamANK (right panel) as ligand. 
Materials and Methods 
 
 63
2.2.7 Small angle X-ray scattering (SAXS) 
Introduction 
Small angle X-ray scattering experiments allow one to obtain low resolution (1-100 nm) 
structural information on proteins and their complexes in solution, as well as on 
microemulsions or polymers. For monodisperse solutions the method can provide 
information on the shape and size of macromolecules or oligomers. 
Experimental setup 
The basic experimental setup is illustrated in Figure 2.8. An X-ray beam generated by a 
generator or a synchrotron source is diffracted by a monochromator to select an appropriate 
wavelength band and may be focussed on the detector using mirrors.  The sample is usually 
contained in a cell with mica windows or in a capillary. The small angle scattering 
(scattering angle 2θ < 10 degrees) is transmitted through a vacuum flight path to a detector. 
The distance between sample and detector can be varied depending on the required angular 
range. 
 
 
 
Figure 2.8: Basic layout of a small angle X-ray scattering (SAXS) instrument. The detector used in our 
measurements was an imaging plate (IP). 
 
The scattering process 
The incident X-rays, which are characterised by the wave-vector k0 and the wavelength, 
0
2
k
πλ =  hit the sample and are scattered at angles 2θ corresponding to a wave-vector k. 
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The momentum transfer S (often also referred to as Q, in the literature) is defined by the 
difference of the wave vectors: 
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The differential scattering cross-section dσ/dΩ of the sample in a given direction is the 
ratio between the energy scattered per unit solid angle dΩ and unit time and the intensity 
(energy per unit area and time) of the incident radiation.  
The experiment results in a plot of the differential scattering cross-section as a function of 
momentum transfer S or scattering angle 2θ.  
 Monodisperse solutions of proteins are composed of isolated particles with a volume Vp 
which can be represented by an assembly of atoms (or scattering centres) at distances ir
v    
from the origin. Waves with a mean amplitude bi originate from the scattering centres and 
interfere. Depending on the phase difference, irS
v⋅→  , constructive or destructive 
interference occurs.  The detector records the intensity, which is related to the differential 
scattering cross-section: 
 
)()(2
2
SSFSPKNebN
d
d
P
i
rSi
iP ⋅⋅=⋅⋅=⎟⎠
⎞⎜⎝
⎛
Ω ∑
vrσ  
 
where NP is the number density of molecules in the sample, K the contrast factor 
corresponding to the difference between the average electron density of the solute and of 
the solvent. P(S) is the formfactor of the molecules and SF(S) the structure factor of the 
solution, which reflects the arrangement of the molecules relative to each other. For ideal 
monodisperse solutions (i.e. with negligible intermolecular interactions) this function is 
uniformly equal to one. 
Fourier transformation of the intensity yields the distance distribution function p(r), 
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To extract the shape of the molecules from the measured differential scattering cross-
section indirect methods have to be used because of the spherical averaging in solution and 
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the loss of phase information due to the fact that only intensities rather than amplitudes and 
phases are measured.  
For monodisperse solutions the molecular mass and radius of gyration can easily be 
obtained from a plot of the logarithm of the intensity vs S2. Indeed, as shown by Guinier 
(see e.g. (Guinier, 1939)) the scattering at small angles can be approximated by: 
 
I(s) = I(0)exp(-Rg2S2/3) 
 
By linear extrapolation to zero angle a plot of I(S) vs S2 will thus yield I(0), the forward 
scattering which is proportional to the molecular mass of the solute, and its slope gives the 
radius of gyration Rg, which is a measure for the extension of a molecule. It is defined by: 
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Experiment 
After purification, the sample was concentrated, centrifuged in an Airfuge (Beckman 
Coulter, Krefeld, DE) at about 30 krpm for 20 minutes and the concentration was 
determined spectrophotometrically. 70 μl of sample, needed for each measurement, were 
carefully filled into a cell with mica windows to avoid air bubbles. Each measurement of a 
protein sample was bracketed by two buffer measurements. The data were recorded on the 
double focusing beamline X33 using an imaging plate scanner (mar345 Image Plate 
Detector; Marresearch GmbH, Norderstedt, DE). Each sample was exposed to X-rays for 
three minutes in the 64-bunch mode of the DORIS III storage ring.  
Evaluation 
Data processing 
Recorded data were normalised to incident beam intensity, corrected for detector response, 
buffer background subtracted, scaled to protein concentration and extrapolated to infinite 
dilution following standard procedures implemented in the program PRIMUS (Konarev et 
al., 2003).  
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Porod analysis (Porod, 1982) was used to estimate the excluded particle volume and the 
radius of gyration R
g of the solute was evaluated using the Guinier approximation (see e.g. 
(Koch et al., 2003)) and the indirect transform program GNOM (Svergun, 1992). 
 
Model building 
Low-resolution models of the binary RBP-Jκ-DNA and the ternary RBP-Jκ-DNA-
NotchRamANK complex were built ab initio from the X-ray scattering data using the program 
DAMMIN (Svergun, 1999). This program initially represents the protein-DNA or protein-
protein-DNA complex as a collection of dummy atoms (DA) and builds a chain-compatible 
spatial distribution of these DAs into the search volume, by simulated annealing. When the 
number of residues is known, DAMMIN can fit the scattering data to 10 to 15Å resolution.  
 
Model evaluation 
A model for the DNA-RBP-Jκ binary complex was created starting from the Lag-1-DNA 
binary complex structure. The program BUNCH (Petoukhov and Svergun, 2005) was used 
to preliminarily check whether addition of the missing portions at the N- and the C-
terminus of the protein, compared to the Lag-1 structure, led to a theoretical scattering 
curve, which could be fitted to the experimental scattering curve.  
After confirmation five bodies were created, corresponding to the binary complex, the two 
segments added at the N- and the C-terminus, the NotchRam domain and the Notch-ANK 
domain. The body corresponding to ANK was built with a merged PDB-file created from 
the recently solved structure of the six ankyrin repeats of hNotch1 (Ehebauer et al., 2005) 
extended with another repeat to create the seven repeats contained in Notch_IC. For the 
body corresponding to NotchRam a dummy molecule of the same size as the Ram domain 
with preferably α-helical structure was taken.  
Of the two models taken into account one assumed a participation of the ankyrin repeats in 
the binding, the other did not. Both, however, included the available information about the 
interaction of RBP-Jκ with Ram. 
The program SASREF (Petoukhov and Svergun, 2005) combined the bodies to obtain a 
model of the binary and ternary complexes whose theoretical scattering curves fitted the 
experimental data for both complexes, with any given restraint, e.g. the necessity for 
certain amino acids to interact. The chi-value, calculated for each dataset, serves as 
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indicator of the quality of the fit and represents the level of confidence with which two data 
sets are correlated. It is calculated as: 
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where Iexp is the experimental intensity specified at n points sj, j=1, …n, σ(sj) is the 
corresponding standard deviation, and c is a scaling coefficient. 
 
2.2.8 Circular dichroism (CD) 
Introduction 
Circular dichroism is based on the interaction of optically active substances with circularly 
polarized light, whereby the refractive index and absorption coefficients depend on the 
polarization (left or right).  
Optical activity results from structural asymmetry (enantiomorphism) in molecules 
resulting in different molar extinction coefficients for left and right circularly polarized 
light. The measurement yields the difference between the two: 
 
RL εεε −=Δ  
 
displayed as ellipticity θ 
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where d is the thickness of the cuvette and c the sample concentration. The CD spectrum 
thus represents the ellipticity θ as a function of the wavelength λ.  
CD spectroscopy can be used to determine whether a protein is folded and if so which 
secondary structure elements are present. Good CD measurements give ratios of secondary 
structure elements, which are 95% reliable.  
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The useful range for conventional CD measurements extends from 190 to 250 nm (far UV 
range). Within this range the peptide bonds in a protein act as chromophores, where 
*π→n  and the *ππ → transitions take place and a signal can be detected if there is a 
regular, folded environment. The region below 190 nm to about 160 nm (vacuum UV 
range) provides further information but the requirements regarding sample buffer and 
concentration and intensity of the light source are considerably higher and the 
measurements can only be performed on a synchrotron radiation source.  
Figure 2.9: Characteristic spectra of secondary structure elements  (taken from www. AP 
lab.com/circular_dichroism.htm) 
 
Spectra of proteins or peptides consisting of a single type of secondary structure element 
(α-helix, β-sheet, random coil) are displayed in Figure 2.9. To evaluate the secondary 
structure of a protein a linear combination of spectra of the three structural elements is 
fitted to its CD spectrum, which yields the ratio of the contributions of the different 
secondary structure elements. 
Experiment 
Conventional CD experiments were carried out on a J-810 spectropolarimeter (Jasco 
GmbH, Gross-Umstadt, DE). Samples were dialysed overnight against 10 mM Tris, pH 8 
and concentrated to 22 µM for protein complexes and 50 µM for NotchRamANK. Spectra 
were recorded between 160 and 230 nm at 4 ºC in 0.5 nm steps with 1 second integration 
time in a 1 mm quartz cuvette. After subtraction of the buffer background and the DNA 
signal the data were scaled to molar ellipticity using the equation: 
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with [θ] = mean residue ellipticity in deg cm² dmol-1 
signal = unprocessed output in mdeg 
C = protein concentration in mM 
n = number of amino acids 
l = cell pathlength in cm 
 
Secondary structure content and ratios were calculated using the software of the 
spectropolarimeter. 
SRCD spectra were recorded at beamline CD12 of the CLRC Daresbury Laboratory’s 
Synchrotron Radiation Source (Clarke and Jones, 2004). Prior to measuring protein spectra, 
a (+)-10-camphosulphonic acid (CSA) spectrum was measured for ellipticity calibration 
(Woody, 1995). CSA was used at 1mg/ml in a 0.1mm quartz cuvette (Hellma, Müllheim, 
DE).  
Before the measurement RBP-Jκ was dialysed against 10 mM Tris, pH 8 and 300 mM 
NaBr, which gives a lower absorption signal than NaCl. RBP-Jκ in complex with DNA 
was dialysed against 10 mM Tris, pH 8. Both samples were concentrated to the maximum 
possible. About 30μl of sample were needed to fill a 0.1 mm path-length quartz cuvette. 
For samples with lower concentrations a 0.2 mm cuvette was used. Spectra were measured 
over the range of 170 nm to 250 nm, with 1 nm and 0.5 nm intervals, respectively, and 1 
second integration time. No radiation damage due to the high photon flux at the beamline 
could be detected after several measurements with the same sample. The spectra were 
corrected for buffer background and DNA signal and scaled against the CSA ellipticity 
calibration and converted to molar ellipticity (in deg cm2
 
dmol-1).  
Data analysis 
A modified version of the program SELCON (Sreerama & Woody, 1993; Clarke & Jones, 
1999) was used to determine the secondary structure content using the data range from 180 
to 230 nm. SELCON uses a singular value decomposition algorithm to assign secondary 
structure by comparison with a basis set of spectra from proteins of known structure, 
repeated iteratively to self-consistency.  
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The original version of the other program used, CONTIN, implemented the ridge 
regression algorithm of Provencher & Glockner, 1981 (Provencher and Glockner, 1981). 
The latest version incorporates the locally linearised model (Van Stokkum et al., 1990) in 
selecting basis set proteins from the reference database. 
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3 Results 
3.1 Expression and purification of human RBP-Jκ, Notch1 and EBNA2 
constructs 
3.1.1 Expression and purification of full-length human RBP-Jκ and RBP-Jκ 
fragments 
3.1.1.1 E. coli as expression host for RBP-Jκ and truncation constructs 
E. coli is presently the most frequently used expression host because it is easy to handle 
and yields high amounts of protein. One major drawback is, however, that the 
overexpressed recombinant proteins are often insoluble or non-functional. Since such 
difficulties are not predictable and can in many cases be overcome E. coli remains the 
expression system of first choice. 
Individual proteins require different expression conditions. Whereas some can be 
expressed in E. coli in soluble and functional form using a standard protocol others require 
different conditions, subcloning to different expression vectors or expression in a different 
expression host than E. coli. 
In this work the priority was to express full-length functional RBP-Jκ in E. coli with  
sufficient yield to carry out crystallization studies.  
Expression in soluble form can be promoted by changing expression conditions, e. g. 
parameters such as temperature, concentration of inducing agent, buffer added to the LB 
medium (for a more detailed overview see table 2.1). When this fails one can try to express 
a truncated form of the protein and optimize the conditions as above. If necessary, one may 
try to solubilize the expressed protein in different buffers. 
 
3.1.1.2 Purification of full-length RBP-Jκ 
The plasmids pVK60 and pVK91 (section 2.1.3), comprising full-length RBP-Jκ cloned 
into pETM11 (N-terminal 6xHis-tag) and pETM30 (N-terminal 6xHis-tag and GST-tag) 
were kindly provided by Bettina Kempkes at GSF in Munich. Initial expression of the 
VK60 and VK91 proteins was carried out as described in section 2.2.5. Figure 3.1 
illustrates the generally high levels of expression obtained with His-and GST-tagged full-
length RBP-Jκ. Besides facilitating purification an N-terminal GST-tag fused to the protein 
of interest, as the case in VK91, promotes its solubility.  The solubility of both VK60 and 
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VK91 could neither be increased by changing expression parameters (tables 2.1 and table 
2.2) nor by using different buffers during the biological pulping of the bacterial cells (table 
2.3), so that different approaches such as refolding or expression of truncated RBP-Jκ 
proteins were used to obtain sufficient amounts of functional protein. Unless indicated 
otherwise, further efforts to promote soluble expression or solubility studies concentrated 
on VK60, since both the His-tagged and the His-GST-tagged proteins were expressed as 
inclusion bodies and were thus insoluble.  
Figure 3.1: Analysis of the induction of full-length RBP-Jκ fused to a 6xHis-tag (VK60) and a GST-tag 
(VK91). The expression pattern before induction (lanes 1 and 4) is compared to that 2 hrs after induction with 
1 mM IPTG (lanes 2 and 5). Lane 3: Protein marker (Biorad). 
 
Purification of soluble VK60 
Independently of the expression host and growing conditions, both RBP-Jκ fused to a His-
tag and to a GST-tag and all deletion mutants listed in table 3.1 expressed into inclusion 
bodies. Despite extensive solubility studies the yield never exceeded 5% of the total 
amount of overexpressed recombinant protein.  A small amount of protein could finally be 
purified using a lysis buffer containing 1.6 M urea and 20 % sucrose. Urea at 
concentrations of 1.6 M does not completely denature proteins but promotes solubilization, 
whereas sucrose stabilises the solubilized protein. The small amount of protein recovered 
after affinity purification did not suffice, however, for crystallization trials nor DNA 
binding studies. It was used to form a binary complex to compare its DNA-binding 
properties to those of RBP-Jκ expressed in insect cells. Since no substantial differences 
were observed during the purification process of His-tagged and GST-tagged RBP-Jκ 
further effort was focused on the His-tagged protein (VK60) and its truncated versions. 
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Purification of VK60 under denaturing conditions followed by refolding 
To find a suitable refolding buffer a refolding screen was used as shown in Figure 2.3(b). 
The full-length His-tagged protein was affinity-purified before refolding. Following the 
procedure described in Materials and Methods (section 2.2.4) large amounts of pure protein 
could be obtained as illustrated in Figure 3.2. Using the E. coli strain BL21(DE3)PlysS as 
expression host up to 120 mg of protein could be extracted from 1 l of cell culture. 
The refolding screen consisted of the 16 conditions listed in table 2.4 in section 2.2.4 , 
which differ by their concentrations in guanidinium hydrochloride, salt, arginine and 
glycine. The aim was to find conditions where most of the protein would remain soluble 
after addition to the respective buffer and stirring overnight (app. 10 hrs) at 4 °C. The 
amount of guanidinium hydrochloride also had to be adjusted so that no or close to no 
denaturant was left in the final refolding solution.  
Figure 3.2: SDS PAGE analysis of the elution fraction of Ni-affinity purified VK60 (7.7 μg, lane 1), which 
was subsequently subjected to refolding. Lane 2: Protein marker (Biorad)  
 
The samples corresponding to each of the different conditions were centrifuged after rapid 
dilution of the protein solution in the refolding buffer and overnight stirring. The pellets 
were resuspended in the same volume of 8 M urea as the original sample. Samples of the 
resuspended pellets and the supernatants were analysed by SDS-PAGE to estimate the ratio 
of soluble and insoluble protein after refolding. Figure 3.3 shows the results for the pellet 
fraction (right lane) and the supernatant (left lane) for each condition. Condition 13 (1M 
arginine, 150 mM NaCl and 1% glycine in Tris-HCl, pH 9.0) yielded the highest ratio of 
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soluble to insoluble protein for VK60 and all other insoluble RBP-Jκ truncations and at the 
same time corresponds like condition 1 to zero concentration of denaturant. Condition 13 
was therefore used for all subsequent purifications of VK60 and insoluble RBP-Jκ 
truncations (refolded VK60 will from here on be referred to as rRBPfull-length). 
 
Figure 3.3: SDS PAGE analysis of the refolding screen consisting of 16 conditions with full-length RBP-Jκ 
(VK60) to find the optimal refolding condition by comparison of the highest soluble:insoluble protein ratio. 
In each case 15 μl of the soluble fraction and the pellet dissolved in the same volume as the soluble fraction 
were applied to allow comparison. The labels refer to the refolding conditions for the pellets (P) and the 
supernatants (S) preceded by the number of the corresponding condition. Of all suitable conditions, i. e.  
those containing the smallest amount of denaturing agents, condition 13 (50 mM Tris-HCl, pH 9.5, 1 M 
arginine, 150 mM NaCl, 1% glycine) gave the highest soluble:insoluble protein ratio for VK60.  
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The refolded protein could be shock frozen in liquid nitrogen and indefinitely stored at -80 
degrees. 
3.1.1.3 Truncation constructs 
Truncation constructs were designed to promote solubility of the protein, based on the 
knowledge available at the time. The amount of soluble full-length protein obtained from 
natively purified RBP-Jκ did not suffice to carry out binding studies nor crystallisation 
trials. Table 3.1 lists all designed truncation constructs including their size and domains. 
 
Truncation constructs comprising one or more known functional domains of RBP-Jκ 
The constructs belonging to group 1 in table 3.1 (a) were based on the results of mutational 
analyses of RBP-Jκ (Chung et al., 1994) where the DNA binding ability of point mutants 
of the protein was analysed using electrophoretic mobility shift assays (EMSA). As a result 
of this study these constructs were no longer considered useful, because they did not 
include the complete DNA-binding domain.  
 
Truncation constructs according to putative laternative starting points RBP-Jκ for 
translation 
Additional methionines within the amino acid sequence may indicate the presence of 
alternative starting points for translation of the protein. Two such methionines were found 
in RBP-Jκ at positions 89 and 99. Truncated proteins expressed with these amino acids as 
starting points should still be able to bind DNA and NotchRam (Chung et al., 1994; Fuchs et 
al., 2001; Sakai et al., 1998). Figure 3.4 illustrates an initial solubility screen with both 
proteins showing their presence in the insoluble fraction.   
Figure 3.4: Analysis of the solubility of truncated RBP-Jκ proteins RBP63-487 (KH5, lanes 1 and 2) and 
RBP74-487 (KH6, lanes 3 and 4). Bacterial pellets of 1 ml of culture were lysed in 1 ml buffer and the 
solution was centrifuged. The resulting pellet was dissolved in 1 ml 8 M urea. 10 µl of the supernatant (lanes 
1 and 3) and 10 µl of the dissolved insoluble portion (lanes 2 and 4) were analysed by SDS-PAGE.  The 
arrow indicates differences in the soluble and insoluble fractions. 
75 kDa
50 kDa
37 kDa
Lane    1     2   3    4   5      
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(a) Group 1 
Protein Molecular 
mass (kDa) 
Number of 
amino acids 
Amino acid 
range 
Theoretical pI Domains included 
VK60 58 513 1-487 8.29 All 
KH1 20 202 157-333 4.8 Ram binding 
DNA binding 
KH2 10 114 100-188 9.9 SAB domain 
KH3 20 209 165-348 4.7 Ram binding 
DNA binding 
KH4 26 259 100-333 6.3 Ram binding 
DNA binding 
SAB domain 
(b) Group 2 
Protein Molecular 
mass (kDa) 
Number of 
amino acids 
Range Theoretical pI Domains included 
KH5 46 450 63-487 5.6 Ram binding 
DNA binding 
SAB domain 
KH6 47 439 74-487 6.0 Ram binding 
DNA binding 
SAB domain 
(c) Group 3 
Protein Molecular 
mass (kDa) 
Number of 
amino acids 
Range Theoretical 
pI 
Domains included 
KH7 37 327 32-333 7.6 N-RHR 
linker 
KH8 49 430 32-435 6.4 N-RHR  
linker 
C-RHR 
KH9 35 304 157-435 5.5 C-RHR 
(d) Group 4 
Protein Molecular 
mass (kDa) 
Number of 
amino acids 
Range Theoretical pI Domains included 
KH12 50 466 12-452 8.3 All 
KH13 46 429 28-431 6.7 All 
KH14 46 433 28-435 6.4 All 
KH15 48 450 28-452 7.1 All 
 
Table 3.1: Truncated proteins designed based on information available at the time; the number of amino 
acids include 26 aa for the 6xHis-tag and a linker with a TEV cleavage site. (a) Designs according to 
mutational analysis; SAB: strong ANK binding (b) Constructs designed from putative alternative starting 
points of hRBP-Jκ translation starting at aa 64 and 74, respectively; (c) Designs assuming that RBP-Jκ 
belongs to the Rel familiy of transcription factors, which contain two domains (N-RHR and C-RHR) 
separated by an unusually long linker in the case of RBP-Jκ; (d) Constructs based on the alignment of 
primary structures of RBP-Jκ homologues from different species (see Figure 3.5); constructs which did not 
express in E. coli or did not bind DNA are not listed. 
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Neither of the constructs described as group 2 in table 3.1 formed binary complexes with 
oligonucleotides derived from Cp (for an example see Figure 3.8, lanes 6 and 7). 
 
Truncation constructs designed assuming that RBP-Jκ is a member of the familiy of Rel-
transcription factors 
Using bioinformatical methods (a combination of sequence alignment with CLUSTALW 
and secondary structure prediction with PHD with the fold recognition program 3D-PSSM 
(Fischer et al., 1999; Kelley et al., 2000) it was discovered that RBP-Jκ belongs to the 
family of Rel transcription factors (Nam et al., 2003). These proteins consist of two 
domains called N-RHR (Rel Homology Region) and C-RHR, which are connected by a 
short linker. In the case of RBP-Jκ the linker consists of 125 aa and is thus unusually long. 
The design of the three truncations of group 3 in table 3.1(c) was based on this information. 
None of the three truncations fused to a His-tag resulted in soluble expression. An SDS-
PAGE analysing the induction of the generally well expressed but insoluble proteins is 
shown in Figure 3.5. 
Figure 3.5: Analysis of the induction of RBP-Jκ truncation mutants belonging to group 3 in table 3.1. All 
fragments are fused to a 6xHis-tag. The expression pattern before induction (lanes 1, 3 and 5) of RBP32-333 
(KH7), RBP32-435 (KH8) and RBP157-435 (KH9) is compared to that 2 hrs after induction with 1 mM IPTG 
(lanes 2, 4 and 6). Induction bands of the corresponding proteins are indicated by arrows. Lane 7: Protein 
marker (Biorad). 
 
Truncation constructs designed based on alignments with homologues of the protein family 
from other species  
The structure of C. elegans Lag-1 has been recently solved (Kovall and Hendrickson, 2004) 
and is described in the introduction. The corresponding PDB file (PDB-code 1TTU) does 
not contain all amino acids in the construct used. Three amino acids are not visible at the 
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N- terminus and another three cannot be found at the C-terminus. In total, the construct is 
63 aa shorter than full-length human RBP-Jκ, but includes the conserved part. Figure 3.6 
shows an alignment of human RBP-Jκ with C. elegans Lag-1 highlighting the borders 
chosen for the deletion according to the visible amino acids in the Lag-1 structure.  
The approach applied to solve the structure of C. elegans Lag-1 is based on a sequence 
alignment of RBP-Jκ homologues of different organisms shown in Figure 3.6. This 
alignment served as template for the design of RBP-Jκ truncations, which are more likely 
to crystallise. The truncation constructs based on sequence alignment are listed as group 4 
in table 3.1(d). They differ from each other by only a few amino acids, but a great variety 
was designed to enhance the chances for crystallisation, since many cases are known, 
where a difference of a few amino acids determines success in crystallisation.  
 
Figure 3.6: Alignment of  homologs of the CSL family (C. elegans, Halocynthia, human, D. melanogaster, 
and Xenopus laevis) showing the most conserved region of the proteins (from (Kovall and Hendrickson, 
2004)). These regions were cloned and expressed and the crystal structure of the protein derived from C. 
elegans was solved at 2.85 Å resolution (Kovall and Hendrickson, 2004). The boundaries of the three distinct 
domains are coloured in blue for the N-terminal domain, green for the β-trefoil domain and orange for the C-
terminal domain. Residues belonging to the bridging βC4 strand are coloured in magenta. Blue brackets 
indicate the borders of the truncation construct expressed in insect cells (nRBP28-432), which ist described in 
section 3.1.1.4 below. 
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Activity test of purified protein: DNA binding 
RBP-Jκ is a transcription factor, which specifically binds to an 8-base pair core sequence, 
which is conserved among many species. To establish the DNA-binding activity of any 
RBP-Jκ construct purified in this work and especially to judge its successful refolding a   
40 bp double-strand DNA oligonucleotide derived from Cp was used. After determining 
the protein concentration by measuring absorption at 280 nm an equimolar amount of DNA 
was added to the solution and a non-radioactive EMSA was run after incubation for 10 
minutes at room temperature. DNA binding was detected by staining the gels with 
ethidium bromide and Coomassie Brilliant Blue. The theoretical pI of full-length RBP-Jκ is 
8.29 so that RBP-Jκ without DNA should not enter the native gel run at pH 8.0. None of 
the constructs used could be visualized on a native gel without DNA. In contrast full-length 
RBP-Jκ and truncated proteins bound to DNA enter the native gel and result in a band, 
which can be stained with both ethidium bromide and Coomassie Brilliant blue, therefore 
proving the formation of a binary complex. Figure 3.7 shows a native gel with a binary 
rRBPfull-length-DNA complex subsequently stained with ethidium bromide and Coomassie 
Brilliant blue.  
 
Figure 3.7: Analysis of the DNA binding activity of rRBPfull-length by non-radioactive EMSA. The gel 
containing the binary complex formed with 1.5 μg rRBPfull-length obtained after Ni-affinity purification and an 
equimolar amount of oli-Cp40 was successively stained with ethidium bromide (lane 1) and Coomassie 
Brilliant Blue (lane 2). 
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Figure 3.8: (a) Analysis of the DNA-binding activity of truncated RBP-Jκ proteins (5 ng each) listed in table 
3.1(d) by radioactive EMSA. All proteins were expressed in E. coli and refolded in condition 13. Arrows on 
the left side indicate the binary complexes of RBP-Jκ and DNA. Lane 1:  rRBPfull-length; lane 2: rRBP12-452 
(KH11-12); lane 3: rRBP28-431(KH11-13); lane 4: rRBP28-435 (KH11-14); lane 5: rRBP28-452 (KH11-15); lanes 
6 and 7: negative controls, truncated variants of RBP-Jκ with putative alternative starting points, which do 
not bind DNA (rRBP64-487 and rRBP 74-487, see table 3.1(b)). (b) Western blot analysis of 5 ng of the truncated 
proteins belonging to group 4 after refolding (table 3.1): rRBP12-452 (lane 1), rRBP28-432 (lane 2), rRBP28-435 
(lane 3), rRBP28-452 (lane 4). 
 
All of the truncation constructs in table 3.1(d) expressed as inclusion bodies and the 
refolding protocol described for full-length RBP-Jκ thus had to be applied in all cases. The 
result of the DNA-binding activity tested in an EMSA with radioactively labelled 
oligonucleotides derived from Cp, is depicted in Figure 3.8. Full-length refolded RBP-Jκ 
was taken as positive control (lane 1) and constructs corresponding to truncated RBP-Jκ 
variants with putative alternative starting points, which do not bind DNA, as negative 
control (lanes 6 and 7). Although all refolded truncation constructs bind DNA they offer no 
advantage as they all expressed as inclusion bodies. 
 
Activity test of purified rRBPfull-length: Ternary complex formation 
It was attempted to form ternary complexes with DNA and proteins derived from hNotch1 
as described in section 2.2.5. No ternary complex was detected by size exclusion 
chromatography of the mixture of the two proteins and DNA in the case of rRBPfull-length.  
Binding conditions including a range of pH (5.5 to 9) and salt concentrations (50 to 300 
mM) were tried out – without success - to promote ternary complex formation. No shift of 
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the binary RBP-Jκ-DNA complex was observed on non-radioactive EMSA gels in the 
presence of NotchRam or NotchRamANK protein suggesting that the refolded RBP-Jκ 
expressed in E. coli either is only partially refolded or lacks crucial posttranslational 
modifications. 
3.1.1.4 Baculovirus-infected insect cells as alternative expression system 
Insect cells process translated proteins in a similar way to mammalian cells. Although in 
some cases posttranslational modifications are applied differently, the system provides 
many advantages for overexpression of soluble recombinant proteins with the help of 
recombinant baculoviruses. Since only insufficient soluble expression could be obtained 
with E. coli as expression host and some of the refolded proteins did bind DNA but not 
protein interaction partners derived from hNotch (see below), the expression system was 
changed to obtain fully active RBP-Jκ. 
 
Constructs and viruses  
A construct coding for full-length RBP-Jκ (pKH25.1) as well as a final truncation construct 
comprising aa 28 to 432 of human RBP-Jκ (pKH24.1), designed according to the 
alignment shown in Figure 3.6 and the residues visible in the electron density map of C. 
elegans Lag-1 were cloned into the baculovirus vector pFastBac-HTa, displayed in Figure 
2.2. These constructs were transformed into competent DH10 bacteria containing the 
Baculovirus genome as episome. The gene of interest, fused with a 6xHis-tag, recombined 
within the virus genome. The isolated viral DNA was then transfected to SF21 cells. The 
primary virus (P1) could be harvested in the cell medium after five days. Taking the 
truncation construct pKH24.1, coding for nRBP28-432, (see section 2.1.3) as an example, the 
control PCR in Figure 3.9 shows the presence of the gene of interest in the Bacmid-DNA, 
the primary virus.  
Purification 
After infection with a baculovirus encoding either KH25.1 or the truncation mutant 
pKH24.1 SFplus cells express the protein within two days. Harvest took place after 48 
hours depending on the appearance of the cells.  
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Figure 3.9: Control PCR proving the presence of the KH24 PCR fragment in the Bacmid DNA and in the 
primary baculovirus; lanes 1 and 2: two clones of the Bacmid DNA (pKH24.1 and pKH24.2), lanes 3 and 4: 
primary virus derived from clones in lanes 1 and 2 (P1-24.1 and P1-24.2), lane 5: Gene Ruler™ 1 kb DNA 
ladder (Fermentas), lane 6: positive control (pVK60). 
 
Figure 3.10: Final purification of a binary complex of nRBP28-432 bound to a 22 bp oligonucleotide derived 
from Cp with double A and T overhangs at each 5´end. Size exclusion chromatography was carried out using 
a Superdex 200 16/60 column (Amersham Pharmacia). Peak fractions were pooled, concentrated and 
analysed by non-radioactive EMSA. The 1st peak corresponds to the void volume of the column and 
presumably contains aggregated protein, the 2nd  peak contains the binary nRBP-DNA complex, and the 3rd  
one is free excess DNA. Blue curve: absorption at 280 nm, red curve: absorption at 254 nm. Non-radioactive 
EMSA stained with ethidium bromide: Lane 1: 1st peak; lane 2: 2nd peak containing the binary complex; lane 
3: 3rd peak. Red curve: absorption at 260 nm; blue curve: absorption at 280 nm. 
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Both KH25.1 and KH24.1 were completely soluble and were purified following the 
procedure described in Section 2.5.2. From here on both proteins will be referred to as 
nRBPfull-length for KH25.1 and nRBP28-432 for KH24.1. After the first purification step using 
Ni-NTA the proteins were about 80% pure. After complexation with DNA they were 
further purified using size exclusion chromatography. TEV protease was applied to the 
complex before this last step depending on further use. An exemplary size exclusion 
chromatogram for   nRBP28-432 bound to DNA is shown in Figure 3.10.  
Depending on the time after infection and the cell density, 5 to 9 mg of pure protein could 
be obtained from 300 ml of cell culture. 
 
3.1.2 Expression and purification of NotchRam and NotchRamANK 
Two truncations comprising the Notch-Ram and –RamANK domains have been designed 
for the present work. An overview of their arrangement within Notch is illustrated in 
Figure 3.11. 
Figure 3.11: Overview of the arrangement and location of the truncated proteins designed for the present 
work. Notch-IC was not used, but is mentionned here because it represents the part of Notch which binds 
RBP-Jκ in vivo. 
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NotchRam 
The expression construct and its properties 
The human NotchRam domain (aa 1768-1861) comprises about 100 amino acids. The 
EXPASY protein parameter tool (Gasteiger et al., 2005) predicts a molecular mass of 11.3 
kDa and a theoretical pI of 5.62. The PHD secondary structure prediction tool (Rost, 
1996)reveals that it does not contain any secondary structure element with an average 
reliability of 0.9.  This was confirmed previously (Nam et al., 2003) and in our study by 
CD spectroscopy (see below). 
 
Expression and purification 
Transformed into the expression host BL21(DE3)PlysS the protein expressed in high levels 
and could be purified in the native state. The procedure followed a standard protocol using 
a two-step purification. After application to Ni-NTA, low imidazole and high salt washing 
steps, the protein could be eluted in large amounts. SDS-PAGE analysis showed it to be 
about 80% pure. After overnight TEV cleavage size exclusion chromatography with a 
Superdex 75 16/60 column (Amersham Pharmacia) was used to purify the protein to about 
>95% purity. Figure 3.12 displays the SDS-PAGE analysis of the size exclusion 
chromatography peak showing pure and homogenous NotchRam protein. The pure protein 
was used for binding experiments with Isothermal Titration Calorimetry, electrophoretic 
mobility shift assays and for crystallization trials. 
Figure 3.12: Final purification of NotchRam using size exclusion chromatography; the chromatogram shows a 
run with a Superdex 75 16/60 column. Four fractions of the major peak were analysed by SDS-PAGE: lane 1: 
elution fraction from Ni-NTA resin; lane 2: fraction after overnight TEV cleavage at 4 °C; lane 3: protein 
marker (Biorad); lanes 4 to 7: fractions C7 to C10 from size exclusion chromatography as indicated by black 
dashes. 
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NotchRamANK 
The expression construct and its properties 
Cloning of the RamANK domain of Notch1 was unsuccessful until alternative cleavage 
sites (Acc651 and PciI) were used to clone it into pETM11. The C-terminal end of the Ram 
domain is followed by seven ankyrin repeats (further referred to as ANK) which were 
reported to be involved in the binding of the Notch-IC domain to RBP-Jκ (Tani et al., 
2001). On average each of the ANK repeats consist of about 25 to 30 aa which fold up to a 
tightly packed helical structure involved in signal transduction processes. The NotchRamANK 
construct cloned from the human Notch1 receptor possesses 364 aa and has a theoretical 
molecular mass of 40.3 kDa. The ExPASy protein parameter tool predicts a theoretical pI 
of 4.87 for the protein. 
 
Expression and purification 
Transformed into BL21 (DE3)PlysS the protein could be expressed in high amounts and 
purified in the native state using the same protocol as for the NotchRam protein. After 
purification using Ni-NTA the protein was about 70% pure and was further processed in 
the same manner as the NotchRam protein.  
3.1.3 Expression and purification of EBNA2 proteins 
EBNA2 constructs EBNA2259-435 (KF214), comprising CR5 to CR7, and EBNA2291-355 
(SV180), including CR5 and CR6 (for a graphical overview of the constructs designed and 
cloned by S. Valencia, GSF Munich, see Figure 3.13) were overexpressed in E. coli 
BL21(DE3)PLysS as expression host. Purification followed the protocol described in 
section 2.2.4. As illustrated in Figure 3.14 both proteins were highly soluble and >90 % 
pure after the GST-affinity step. 
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Figure 3.13: Sequence of full-length EBNA2 with the truncated constructs EBNA2259-435 (KF214), 
highlighted in blue and EBNA2291-355 (SV180), underlined, used in the present work. The conserved regions 
(CR) included in the different constructs are framed. 
 
 
Figure 3.14: SDS-PAGE analysis of the one-step purification of proteins derived from EBNA2; lane 1: 
protein marker (Fermentas), lane 2: EBNA2259-435 (0.5 μg), lane 3: EBNA2291-335 (1 μg). 
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3.2 Biochemical and biophysical characterization of the interaction of RBP-Jκ 
with NotchRam or NotchRamANK or EBNA2 
3.2.1  Binary complexes of RBP-Jκ with DNA and comparison of recombinant RBP-
Jκ proteins expressed in E. coli and insect cells 
Influence of reducing agents on the quality of purified RBP-Jκ 
Full-length human RBP-Jκ contains 13 cysteines, which are unlikely to form disulphide 
bridges in the reducing environment of the nucleus, but may well form random intra- or 
intermolecular disulphide bridges in solution, which may lead to unspecific aggregation, 
especially at higher concentrations. Furthermore, because of the susceptibility of the SH-
group to oxidation exposure to oxygen may change the properties of the protein.  
For these reasons and to guarantee a uniform and monodisperse protein solution it is 
essential to add sufficient amounts of reducing agents. 
Dithiothreitol (DTT, see Figure 3.15(a)) is a commonly used reducing agent during and 
after the protein purification process. DTT is, however, easily oxidized when exposed to 
oxygen, and the reaction is reversible, i. e. reduced thiols can be re-oxidized.  
Since all attempts at producing a homogenous protein solution using common working 
concentrations of DTT (1-10 mM) failed, a less commonly used reducing agent, Tris(2-
carboxyethyl)phosphine (TCEP, see Figure 3.15(b) (Burns et al., 1991)), which 
stoichiometrically and irreversibly reduces disulphide bridges according to the reaction in 
Figure 3.16(a) was tried out as alternative. Figure 3.16 compares the reaction mechanisms 
of both substances. 
(a)                                                  (b) 
Figure 3.15: Chemical formula of the reducing agents (a) dithiothreitol (DTT); (b) Tris(2-
carboxyethyl)phosphine (TCEP). 
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Figure 3.16: (a) Irreversible reaction of TCEP with thiols; (b) reversible reaction of DTT with thiols. 
 
 
Figure 3.17: Comparison of the reducing abilities of dithiothreitol (DTT) and Tris(2-carboxyethyl)phosphine 
(TCEP) on a complex of nRBPfull-length with a oli-Cp20 by non-radioactive EMSA. Left panel: Increasing 
concentrations (1 to 20 mM) of DTT added to the preformed binary complex; right panel: increasing 
concentrations (1 to 20 mM) of TCEP added to the preformed binary complex. 
 
Whereas with DTT a second band of a binary nRBJfull-length-DNA complex located above 
the band of the monomeric 1:1 complex on a non-radioactive EMSA gel was always 
obtained (see Figure 3.17), addition of 2 mM TCEP resulted in a single band corresponding 
to the native 1:1 nRBP-DNA complex. 
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Since monodispersity is an essential prerequisite for crystallization and X-ray small angle 
scattering as well as reliable binding studies using non-radioactive EMSA or isothermal 
titration calorimetry and virtually any biophysical characterisation technique (e.g. CD 
spectroscopy), DTT was replaced by TCEP during and after purification of RBP-Jκ 
proteins. 
A surprising observation, which has apparently not been described before and remains 
unexplained, was made when binary and ternary complexes with RBP-Jκ were purified on 
a size exclusion column in a buffer containing 5 mM TCEP. Whereas the usual elution 
volume of the binary complex is at about 70 ml in a Superdex 200 16/60 size exclusion 
column, binary complexes formed with two different oligonucleotides eluted after nearly 
one column volume (about 120 ml), when TCEP was present in the buffer (Figure 3.18(a) 
and (b)), which could be shown with non-radioactive EMSA (Figure 3.18(c). The same 
result was obtained when a molecular mass standard (Biorad) containing five proteins of 
different molecular masses was run on the same column in the same buffer (Figure 3.18(d).  
 
Following page: 
Figure 3.18: Changed elution profiles of binary DNA-nRBPfull-length complexes in the presence of 2 mM 
TCEP in the gel filtration buffer. (a) Elution profile of a size exclusion run of nRBPfull-length bound to oli-Cp14 
on a S200 10/30 size exclusion column (Amersham). Absorption was measured at an elution volume where 
normally peptides elute. (b) Elution profile of a size exclusion run of nRBPfull-length bound to oli-Cp15 on a 
S200 10/30 size exclusion column (Amersham). The elution profile resembles the one in (a). (c) Analysis of 
the peaks obtained in (a) and (b) by non-radioactive EMSA. The pure and functional binary complex could be 
detected in both cases. In the figure nRBPfull-length is abbreviated nRBP. (d) Verification of the altered elution 
profile of the column depending on the presence of 5 mM TCEP in the gel filtration buffer by a size 
exclusion run with standard proteins on the same column. Under normal circumstances the void volume of a 
S200 10/30 column is about 7.5 ml, corresponding to the elution of the first component of the protein 
standard with a molecular mass of 680 kDa. In the present case the elution profile is shifted by about 6 ml, so 
that the peak according to protein with the highest molecular mass (680 kDa) appears only at an elution 
volume of about 13 ml.  
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The difference in activity of RBP-Jκ expressed in E. coli or insect cells is not related 
to properties measurable with CD spectroscopy, EMSA or mass spectrometry 
Post translational modification occurs differently in bacteria and insect cells or mammals. 
Differences may influence the ability of the overexpressed and purified protein to 
crystallize. The different properties regarding the binding of other proteins and peptides 
mentioned above suggest major differences between RBP-Jκ expressed in E. coli and in 
insect cells. Besides incomplete refolding of the protein expressed in bacteria, 
posttranslational modifications may be the cause for the different binding properties.  
Mass spectrometry provides a means of comparing the total mass of both proteins with 
their theoretical mass.  
The molecular mass of His-tagged full-length RBP-Jκ calculated with the Expasy protein 
parameter tool (Gasteiger et al., 2005) is 57.423 kDa. The molecular mass of nRBPfull-length 
expressed in insect cells obtained by mass spectrometry is 57.419 kDa. The small 
difference (4 Da) does not correspond to any of the common posttranslational 
modifications and is most probably not significant. This suggests that the yield of fully 
functional RBP-Jκ proteins depends on other factors than posttranslational modifications, 
such as e. g. correct folding. 
 
DNA-binding ability 
The ability of RBP-Jκ to bind specifically to an eight base pair double-strand DNA 
sequence was used to compare the binding mode of rRBPfull-length and nRBPfull-length. 
Oligonucleotides with 14 to 22 base pairs, derived from Cp, were used to determine the 
DNA-binding ability of rRBPfull-length and of full-length and deleted RBP-Jκ expressed in 
insect cells (nRBPfull-length and nRBP28-432). The binding affinity of       nRBPfull-length and 
nRBP28-432 purified from insect cells is compared with that of rRBPfull-length purified from E. 
coli in Figure 3.19. The results clearly illustrate that the two proteins purified from insect 
cells bind to oligonucleotides shorter than 16 bp, whereas the corresponding bands are 
barely detectable in the case of the refolded protein purified from E. coli.  
Compared to EMSAs with radiolabelled DNA much higher amounts of protein and DNA 
are required for native gels, which have to be stained with ethidium bromide and 
Coomassie Brilliant blue. Figure 3.20 displays an EMSA using radiolabelled DNA for 
rRBPfull-length and nRBPfull-length expressed in insect cells for comparison. In contrast to the 
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Figure 3.19: Comparison of ability of nRBP28-432, nRBPfull-length and rRBPfull-length to bind DNA of different 
length using non-radioactive EMSA. Left panel: 10 μg rRBPfull-length, right panel: 2 μg nRBP28-432 and 10 μg 
nRBPfull-length bound to oligonucleotides derived from Cp (oli-Cp14, oli-Cp15, oli-Cp16, oli-Cp17 and oli-Cp20).  
 
Figure 3.20: Comparison of the ability of nRBPfull-length and rRBPfull-length to bind DNA of different length 
using radioactive EMSA. The oligonucleotides are derived from Cp (oli-Cp40, prepared with Klenow-fill-in; 
oli-Cp22, oli-Cp20, oli-Cp18, oli-Cp16 and oli-Cp14, all prepared by end-labelling); left panel: nRBPfull-length (1 
ng); Right panel: rRBPfull-length (2 ng).  
 
result obtained with the non-radioactive EMSA gel stained with ethidium bromide the 
protein no longer binds to the shorter oligonucleotides: 14 bp in case of nRBPfull-length and 
14 and 16 bp for rRBPfull-length.  
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Both types of assay, the EMSA with radiolabelled oligonucleotides and the one without 
any label stained with ethidium bromide and Coomassie Brilliant Blue are essentially the 
same and differ only in the amounts of protein and DNA added. The differences in DNA-
binding are clearly seen in the shifts carried out with radiolabelled DNA, where only 
nanogram amounts of protein and DNA are added. As the binding affinities for the shorter 
oligonucleotides are lower the equilibrium  
 
RBP-Jκ + DNA                      RBP-Jκ-DNA 
 
is shifted towards the left side, which results in amounts of complex too low to detect as is 
happening in the radioactive EMSA in Figure 3.20. 
 
Biological activity of purified RBP-Jκ on binding sites found in the viral promoters Cp, 
LMP1P and LMP2AP 
Cp has a strong binding site for RBP-Jκ (Ling et al., 1994) so that 1 ng of refolded RBP-Jκ 
can easily be detected using radioactive EMSA. To compare the binding affinities of 
proteins expressed in insect cells and rRBPfull-length from E. coli an EMSA with 
radiolabelled oli-Cp40 oligonucleotide was made. Figure 3.21(a) displays the results with 
both nRBP28-432 and nRBPfull-length and with rRBPfull-length as positive control. All three 
proteins were run on the same gel. The binding affinity of the two proteins purified from 
insect cells is up to an order of magnitude higher than that of rRBPfull-length purified from E. 
coli.  
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Figure 3.21: Comparison of the affinity of RBP-Jκ expressed in different hosts (nRBP28-432, nRBPfull-length 
and rRBPfull-length) to oligonucleotides derived from different viral promoters using radioactive EMSAs on 4% 
TBE polyacrylamide gels. (a) Cp: 0.5-10 ng of nRBP28-432 and nRBPfull-length and 2 ng of rRBPfull-length were 
incubated with equal amounts of oli-Cp40. (b) LMP1P: 1-20 ng nRBP28-432 and nRBPfull-length and 10 ng 
rRBPfull-length were incubated with equal amounts of a oli-LMP1P36. (c) LMP2AP: 0.05-10 ng nRBP28-432 and 
nRBPfull-length and 5-10 ng of rRBPfull-length were incubated with equal amounts of oli-LMP2AP54. 
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rRBPfull-length was shown to bind an oligonucleotide derived from LMP1P (oli-LMP1P36) 
much less tightly than those derived from Cp. Therefore the experiment was carried out 
using higher amounts of protein than for the corresponding experiment with oli-Cp40. 
Figure 3.21(b) displays the results of the binding assay with radiolabelled oli-LMP1P36. As 
in the case of Cp, the binding affinity of both nRBP28-432 and nRBPfull-length is about 10 times 
higher than that of rRBPfull-length. 
LMP2AP contains two separate binding sites for RBP-Jκ, which are successively occupied 
upon addition of increasing amounts of protein. The affinities of both sites are compared in 
Figure 3.21(c). As shown previously for oligonucleotides derived from LMP1P and Cp the 
affinity of proteins purified from insect cells for LMP2AP is higher than that of rRBPfull-
length, the ratio is about an order of magnitude. Moreover, in case of nRBP28-432 and nRBPfull-
length the second binding site on LMP2AP is occupied at much lower concentrations than in 
case of rRBPfull-length. 
 
 
Comparison of the secondary structure of rRBPfull-length and native nRBPfull-length 
The EMSA results and the many unsuccessful trials to form ternary complexes of rRBPfull-
length with DNA and Notch proteins suggested that incomplete refolding may be the cause 
for the lack of binding of rRBPfull-length to Notch proteins. CD spectroscopy was therefore 
used to investigate the secondary structure of rRBPfull-length and nRBPfull-length alone and in 
binary complexes with DNA.   
For the complexes the contribution of DNA to the spectra must be subtracted prior to data 
evaluation. In other words, it is assumed that binding does not alter the contribution of 
DNA.  
The spectra of rRBPfull-length and nRBPfull-length alone and bound to DNA, after subtraction of 
the contribution of DNA, are displayed in Figure 3.22(a) and (b). For unbound RBP-Jκ the 
curves match quite well in the range 220-260 nm, but significant differences are observed 
in the range 185-215 nm..  
Similar results are obtained with RBP-Jκ bound to DNA. In the wavelength range from 185 
to 215 nm the maxima are inverted and the general shape of the curves differs. As 
illustrated in Tables 3.2 and 3.3 by the result of the CONTIN evaluation, none of the 
programs detects more than 5% difference in any of the classes of secondary structure 
element considered (helix, sheet, turn, random coil). 
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As the structure of the C. elegans homologue Lag-1 mostly consists of β-sheets, one would 
expect nRBPfull-length to have a higher contribution of β-sheets than refolded rRBPfull-length. 
The results in Table 3.2 and 3.3 confirm that the beta-sheet content of nRBPfull-length is 
about 5% higher than that of refolded rRBPfull-length, both in the free and bound states, and 
that this increase occurs mainly at the expense of random coils and to a lesser extent α-
helices and turns. 
The interpretation of CD results requires some caution and it should be noted that none of 
the programs predicted the content of β-sheets in nRBPfull-length in the range, found in the 
crystal structure of Lag-1. All programs gave satisfactory results, however, concerning the 
proportion of secondary structure elements for the reference data collected with lysozyme. 
The results of the programs sometimes differ considerably from the judgement of human 
experts, who more easily recognize considerable changes in secondary structure. The 
computer programs use singular value decomposition to fit the experimental data by linear 
combinations of sets of curves representing proteins containing only one secondary 
structure element. Experience shows that the error range is quite large, so that usually a 
combination of personal judgement and computer analysis are combined to come to a 
conclusion. In the present case one would definitely conclude that there are major 
differences in secondary structure between the native and the refolded RBP-Jκ. 
 
Taken together the assays carried out point to differences in the properties of rRBPfull-length 
and nRBPfull-length without, however, revealing any obvious cause.  
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Figure 3.22: CD spectra of (a) rRBPfull-length and nRBPfull-length and (b) rRBPfull-length and nRBPfull-length 
bound to DNA; after subtraction of the DNA signal the data was converted from difference ellipticity ΔΦ to 
mean residue ellipticity, which is concentration independent. 
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rRBPfull-length α-helix β-sheet Turns Random coil 
Reference set 3 13.4 % 29.3 % 24.8 % 32.6 % 
Reference set 4 12.5 % 28.6 % 24.5 % 34.3 % 
Reference set 6 9.2 % 24.0 % 19.2 % 47.6 % 
Reference set 7 11.2 % 22.7 % 18.3 % 47.8 % 
Average 11.6 % 26.2 % 21.7 % 40.5 % 
 
nRBPfull-length α-helix β-sheet Turns Random coil 
Reference set 3 9.9 % 34.6 % 23.4 % 32.0 % 
Reference set 4 10.1 % 34.0 % 22.8 % 33.0 % 
Reference set 6 7.3 % 30.8 % 19.0 % 43.0 % 
Reference set 7 9.1 % 29.2 % 17.9 % 43.8 % 
Average 9.1 % 32.2 % 20.8 % 37.9 % 
Table 3.2: Calculation of secondary structure elements for refolded and native RBP-Jκ with CONTIN. 
Protein reference sets 3, 4, 6 and 7 were chosen because they are optimized for measurements in the range of 
190 to 260 nm. 
 
rRBPfull-length-
DNA 
α-helix β-sheet Turns Random coil 
Reference set 3 9.8 % 32.9 % 24.2 % 33.8 % 
Reference set 4 9.9 % 33.0 % 23.3 % 33.0 % 
Reference set 6 7.5 % 27.7 % 17.9 % 46.9 % 
Reference set 7 8.7 % 27.7 % 17.8 % 45.7 % 
Average 9.0 % 27.8 % 20.8 % 39.9 % 
 
nRBPfull-length-
DNA 
α-helix β-sheet Turns Random coil 
Reference set 3 9.1 % 35.5 % 22.9 % 31.5 % 
Reference set 4 8.0 % 35.7 % 22.8 % 33.5 % 
Reference set 6 5.0 % 31.7 % 18.4 % 44.9 % 
Reference set 7 6.0 % 30.8 % 16.7 % 46.5 % 
Average 7.0 % 33.4 % 20.2 % 39.1 % 
Table 3.3: Calculation of secondary structure elements for rRBPfull-length and nRBPfull-length bound to DNA 
with CONTIN.  
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3.2.2 Formation of ternary complexes with RBP-Jκ, DNA and NotchRam or 
NotchRamANK 
Both nRBPfull-length and nRBP28-432 were expressed in insect cells because although the 
corresponding proteins expressed in E. coli and refolded (rRBPfull-length and rRBP28-432) bind 
DNA they did not bind NotchRam or NotchRamANK (see section 3.2.3), nor peptides derived 
from NotchRam. Exemplary ITC data sets collected with nRBPfull-length and the ligands 
mentionned above are shown in Figure 2.7 in section 2.2.6. Interestingly, this difficulty did 
not occur with the proteins derived from EBNA2, for which binding to rRBPfull-length can be 
detected on radioactive EMSAs (data not shown). 
 
Figure 3.23: Analysis of the ability of nRBP28-432 and nRBPfull-length to form binary and ternary complexes 
with DNA and proteins derived from human Notch1 (Ram and RamAMK) by non-radioactive EMSA. 
Analysis was carried out with 2 μg nRBPfull-length or nRBP28-432 and the corresponding amount of oli-Cp23 
and NotchRam expressed in E. coli to form 1:1:1 complexes. (a): Comparison of the ability of nRBP28-432 and 
nRBPfull-length to form ternary complexes with DNA and NotchRam. Lane1: DNA-nRBP28-432; lane 2: DNA-
nRBP28-432-NotchRam; lane 3: DNA-nRBPfull-length; lane 4: DNA-nRBPfull-length-NotchRam; (b): Non-
radioactive EMSA gel comparing the binary DNA-nRBPfull-length complex (lane 1) with the ternary DNA-
nRBPfull-length-NotchRam and DNA-nRBPfull-length-NotchRamANK complexes (lanes 2 and 3). 
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Ternary complexes were formed with nRBP28-432 and nRBPfull-length as described in section 
2.2.5. Prior to the effort to further purify the complex the ability of the components to form 
complexes was tested by non-radioactive EMSA. Figure 3.23 shows the first trials to form 
ternary complexes with NotchRam and NotchRamANK. Figure 3.23(a) shows a non-radioactive 
EMSA with both proteins forming complexes with DNA and NotchRam proving full activity 
for both of them in this assay. The binding to NotchRamANK is displayed in Figure 3.23(b). 
Size exclusion chromatography and analysis with non-radioactive EMSA showed the 
presence of ternary complexes after addition of NotchRam or NotchRamANK proteins 
(examples are illustrated in Figure 3.24). An exemplary chromatogram is displayed in 3.11 
showing the peak of the complex eluting just after the void volume of the column (40 ml). 
As in the case of the complex formed by nRBP and DNA the elongated DNA molecule 
causes the complex to elute at a higher volume than expected from its size. To confirm the 
activity of the ternary complex and exclude aggregation, the peak was analysed with non-
radioactive EMSA and subsequently stained with ethidium bromide and Coomassie 
Brilliant Blue.  
 
Following page: 
Figure 3.24: Final purification of ternary complexes formed with nRBP28-432, oli-Cp19 and protein derived 
from human Notch1 (Ram and RamANK) using size exclusion chromatography. Blue curves: Absorption at 
280 nm; red curves: Absorption at 260 nm. The fractions of the peaks obtained were pooled, concentrated 
and analysed by SDS PAGE and non-radioactive EMSA. (a) Purification of DNA-nRBP28-432-NotchRam on a 
S75 16/60 size exclusion column (Amersham); the SDS PAGE gel, where a 10 μl sample was applied, shows 
the presence of both protein components, the non-radioactive EMSA gel shows the supershift caused by 
binding of NotchRam to the binary DNA-nRBP28-432 complex (10 μl sample obtained from size exclusion 
chromatography) in comparison to a binary DNA- nRBP28-432 complex (1 μg), which was formed prior to the 
ternary complex. (b) Purification of DNA-nRBP28-432-NotchRamANK on a S200 16/60 size exclusion column 
(Amersham); the SDS PAGE gel shows the presence of both protein components in the first two peaks (lanes 
1 and 2) and the separated TEV protease applied to cleave of the 6xHis-tag from both protein components 
(lanes 3 and 4); the non-radioactive EMSA gel shows, however, that only the 2nd peak (lane 2) contains DNA 
and thus corresponds to a ternary complex. 
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Evidence for the folding of NotchRam upon binding to nRBPfull-length 
The Ram domain of Notch1 has previously been reported to be unfolded (Nam et al., 2003). 
The hypothesis that upon binding to nRBPfull-length Ram folds into a unit consisting of the 
usual secondary structure elements was verified by CD spectroscopy. For this study the 
ternary complex of NotchRam with nRBPfull-length and DNA (oli-Cp16)was examined. To 
calculate the contribution of NotchRam to the spectrum of the ternary complex the 
contribution of the binary complex between nRBPfull-length and DNA was subtracted before 
converting the data into mean residue ellipticity. The spectra obtained are depicted in 
Figure 3.25, and the results obtained with CONTIN are listed in table 3.4.  
 
Figure 3.25: CD spectra of free NotchRam and NotchRam bound to nRBPfull-length-DNA; after subtraction of the 
contribution of nRBPfull-length-DNA to the ternary complex the data was converted from difference ellipticity 
ΔΦ to mean residue ellipticity. 
 
If turns are considered as fairly unstructured patches the unfolded part of free NotchRam 
adds up to about 60 % of the protein. Two thirds of the remaining part (~27 %) correspond 
to β-sheets and one third (~13 %) to α-helices. Major changes are detected after binding of 
NotchRam to nRBPfull-length: the contribution of β-sheets drastically diminishes and that of 
turns also moderately decreases whereas that of α-helices and the percentage of random 
coils slightly increases. The calculated increase in the proportion of α-helices indicates a 
major change in the secondary structure of NotchRam upon binding nRBPfull-length. Although, 
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as already mentioned, one has to be very cautious in the interpretation of secondary 
structure calculation from CD data, in the present case the changes before and after Ram 
binding, which are obvious for the human eye are also detected by the programs. Usually 
one considers a difference of 5 %, in this case between bound and unbound Ram, as 
significant.   
 
NotchRam 
unbound 
α-helix β-sheet Turns Random coil 
Reference set 3 19.2 % 28.2 % 23.2 % 29.4 % 
Reference set 4 13.5 % 29.3 % 23.6 % 32.7 % 
Reference set 6 10.8 % 24.5 % 17.8 % 47.0 % 
Reference set 7 12.2 % 24.1 % 16.6 % 47.1 % 
Average 13.9 % 26.6 % 20.4 % 39.1 % 
 
NotchRam 
bound 
α-helix β-sheet Turns Random coil 
Reference set 3 39.1 % 8.0 % 17.8 % 35.1 % 
Reference set 4 35.9 % 8.0 % 22.9 % 33.1 % 
Reference set 6 32.4 % 6.2 % 7.7 % 52.7 % 
Reference set 7 33.8 % 6.5 % 16.2 % 43.5 % 
Average 35.3 % 7.2 % 16.2 % 41.1 % 
Table 3.4: Calculation of secondary structure elements for free NotchRam and NotchRam bound to       
nRBPfull-length-DNA with the program CONTIN. Reference sets 3, 4, 6 and 7 were chosen, because they are 
optimized for measurement in the range of 190 to 260 nm. The average content of secondary structure 
elements is calculated from the values obtained with all reference sets. 
3.2.3 Contribution of the ANK domain to RBP-Jκ binding 
RBP-Jκ purified from insect cells binds to NotchRam or NotchRamANK only at high 
concentrations 
EMSAs with radiolabelled DNA were used to show binding of a binary complex of 
nRBPfull-length and DNA to the Notch constructs. Figure 3.26 shows a representative EMSA 
with nRBPfull-length bound to oli-Cp40. Increasing amounts of NotchRam or NotchRamANK were 
added, but only with a 1250-fold excess of NotchRamANK could a supershift be observed, 
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which given the large excess of ternary complex partner can no longer be considered to be 
specific. No supershift was observed with the NotchRam protein. Since EMSAs with 
radiolabelled oligonucleotides are very sensitive, this indicates that no binding occurred, 
contradicting the results obtained with non-radioactive EMSA (see e.g. Figure 3.23), size 
exclusion chromatography (Figure 3.24) and ITC (tables 3.5 and 3.6 below).  
 
Figure 3.26: Representative EMSA to analyse the ability of nRBPfull-length to form ternary complexes with 
NotchRam or NotchRamANK . The assay was carried out using radiolabelled oli-Cp40 to form a 1:1 complex with 
1.7 pMol nRBPfull-length; amounts of ternary complex partner added are indicated at the top of the respective 
lane. Lanes 1 to 7: attempt to form a ternary complex with nRBPfull-length-DNA and increasing amounts of 
NotchRam; lanes 8 to 14: ternary complex formation with nRBPfull-length-DNA and increasing amounts of 
NotchRamANK; lanes 1 and 8: binary complex, following lanes. nRBPfull-length:Notch-protein ratios: 1:2.5; 1:5; 
1:10; 1:50; 1:500; 1:1250 
 
Protein-protein complexes sometimes only form in a narrow range of conditions. Therefore 
the experiment was repeated with amounts of protein comparable to those used in the non-
radioactive EMSA before (µg instead of ng) on a 4 % TBE gel. The radiolabelled 
oligonucleotide was replaced by a non-labelled one. Before application to the gel, ethidium 
bromide was added to all samples. Ethidium bromide intercalates into DNA and RNA and 
can be visualised by its fluorescence upon irradiation with UV light. Other intercalators, 
such as SybrGreen, are known to change the running properties of the DNA and/or DNA-
protein-complexes. Even if pre-incubation with ethidium bromide changed the running 
properties of the samples it would be expected to do so proportionally and the result would 
be the same as that obtained with samples stained after the run. The results of the 
experiment are displayed in the left panel of Figure 3.27. To sharpen the visible bands the 
experiment was repeated with an 8% TBE gel, as illustrated in Figure 3.27 in the right 
panel. Not only could the running behaviour of the complexes be improved, but the 
supershift of the ternary complexes is more clearly visualised. 
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The ability of nRBPfull-length in a binary complex with DNA to form ternary complexes with 
NotchRam or NotchRamANK depends on the concentration of NotchRam or NotchRamANK. This 
suggests that one is dealing with an equilibrium corresponding to a relatively low affinity. 
To check the activity of NotchRam and NotchRamANK protein, an experiment similar to the 
one displayed in Figure 3.26 was performed in a non-radioactive EMSA.   
Figure 3.27: Ternary complex formation of nRBPfull-length with oli-Cp22 and proteins derived from human 
Notch1 (Ram and RamANK) analysed on 4% and 8% TBE non-radioactive EMSA gels. Ternary complexes 
were formed by addition of twice the stoichiometric amount of Notch protein to 10 and 5 μg nRBPfull-length in 
the 4 % and 8% TBE PAGE gels. Lanes 1: Binary DNA-nRBPfull-length complex; lanes 2: ternary DNA-
nRBPfull-length-NotchRam complex; lanes 3: ternary DNA-nRBPfull-length-NotchRamANK complex. 
 
As illustrated in Figure 3.28 it was possible to form both ternary complexes with NotchRam 
(Figure 3.28(a)) and NotchRamANK (Figure 3.28(b)). In both cases the ternary complex 
appeared as soon as the corresponding Notch protein was added in 1:1 molar ratio. In this 
condition about 70% of binary complex formed by nRBPfull-length and DNA was transferred 
to a ternary complex. When NotchRam or NotchRamANK was added in 1:2 molar ratio 100% 
nRBPfull-length bound to DNA was present in the ternary complex. This indicates that both 
ternary complex partners exhibit between 50 and 100% biological activity, if one assumes 
that they have the maximum achievable concentration dependent binding affinity. 
The additional band in the Coomassie Brilliant Blue stain in Figure 3.28(b) in the lanes 
where the amount of ternary complex partner exceeds that of binary complex (lanes 5 to 8) 
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corresponds to free excess NotchRamANK protein which could not bind to nRBPfull-length-
DNA. A corresponding band could not be detected for the NotchRam protein in Figure 
3.28(a), but there is a smear with increasing intensity as larger amounts of excess protein 
are added to the binary complex.  
 
 
Figure 3.28: Non-radioactive EMSA successively stained with ethidium bromide (left panel) and Coomassie 
Brilliant Blue (right panel) to study the binding affinity of NotchRam and NotchRamANK to 4.25 nMol binary 
complex formed with oli-Cp22 and nRBPfull-length. The first lane in (a) and the last one in (b) were loaded with 
DNA-  nRBPfull-length without ternary complex partner added. Molar ratios of binary complex:ternary complex 
partner are indicated at the top of each lane. (a) Increasing amounts of NotchRam are added to 5 µg DNA-
nRBPfull-length. The ternary DNA-nRBPfull-length-NotchRam complex is visible as soon as NotchRam is added to 
DNA-nRBPfull-length in 1:1 stoichiometric ratio. (b) Decreasing amounts of NotchRamANK are added to 5 µg 
DNA-nRBPfull-length. As in (a) the ternary DNA-nRBPfull-length-NotchRamANK complex is visible as soon as 
NotchRam is added to DNA-nRBPfull-length in 1:1 stoichiometric ratio.  
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Figure 3.29: Non-radioactive EMSA to determine the amount of protein necessary for NotchRam and 
NotchRamANK to bind to 5 µg nRBPfull-length , which corresponds to 4.25 nMol. nRBPfull-length was incubated 
with the stoichiometric amount of oli-Cp22 to form a 1:1 complex: (a) NotchRam as ligand; (b) NotchRamANK as 
ligand; gels were successively stained with Coomassie Brilliant Blue (left panel) and ethidium bromide (right 
panel); stoichiometric ratios between binary complex and ligand are indicated above the respective lane. A 
control comprising the binary DNA- nRBPfull-length complex was applied in lanes 11. 
 
Luciferase reporter assays and GST pull-down assays have led to the conclusion that the 
ankyrin domain of Notch-IC participates in the binding to RBP-Jκ, albeit weakly compared 
to the Ram domain, but sufficiently to possibly have an effect on transactivation efficiency 
(Kato et al., 1997; Kurooka et al., 1998; Tani et al., 2001). In contrast, in our EMSAs no 
visible difference could be detected in the binding affinity of NotchRam and NotchRamANK. 
As illustrated in Figure 3.28, formation of ternary complex can be detected with both 
Notch constructs as soon as the Notch:RBP-Jκ stoichiometric ratio is 1:1. RBP-Jκ is 
quantitatively bound at all ratios above 1:1. To be able to estimate the real difference in a 
narrower range the experiment illustrated in Figure 3.28 was repeated with a stoichiometric 
range of nRBP-Jfull-length:NotchRam and nRBP-Jfull-length:NotchRamANK of 1:0.5 to 1:2. The 
result is displayed in Figure 3.29, where the small difference between the binding affinities 
becomes even clearer. Here the ternary complex with NotchRamANK is visible at a 
stoichiometric ratio of 1:0.66, whereas the ternary complex with NotchRam can already be 
detected at a ratio of 1:0.5. Visual detection is difficult, however, if only because of the 
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logarithmic sensitivity of the human eye, so that reliable estimations cannot be made in this 
range. 
The affinities of NotchRam and NotchRamANK for RBP-Jκ measured by ITC are nearly 
equal 
To confirm the results obtained with EMSA and obtain more quantitative results, ITC 
experiments were carried out with both Notch proteins. NotchRam and NotchRamANK were 
used to titrate the binary nRBPfull-length-DNA complex according to the protocol described 
in section 2.2.6. During the experiment the heat evolved or absorbed is detected, and as the 
concentration of ligand and protein are known the thermodynamic parameters of the 
reaction can be calculated. 
Each experiment was repeated three times and evaluated as described in section 2.2.6. 
Except for the first experiment conducted with NotchRam as ligand (see table 3.5), which 
yielded a slightly different enthalpy change, all experiments gave similar results for the 
stoichiometry (N) of the reaction, the binding constant and the enthalpy (ΔH) change. As 
expected, the stoichiometry of the reaction was 1:1 in both cases. As the experimental 
errors are of the order of 15 - 20% for the binding constant the small difference observed 
between the two ligands is not significant. 
The results for the experiments conducted with NotchRamANK listed in table 3.6 are based on 
the assumption that there is a single binding site for the ligands. 
If one assumes, however, that there are two binding sites in the case of NotchRamANK, the 
calculated affinities for nRBPfull-length are the same for both the Ram domain and the 
ankyrin repeats, in contrast to previous reports in the literature (Kato et al., 1997; Kurooka 
et al., 1998), which are partly based on in vivo assays. The results obtained do not exclude 
the presence of two similar binding sites, but  the shape of the binding curve is 
incompatible with the existence of two sites with significantly different affinities. 
Three of the experiments were carried out at 25 ºC instead of 20 ºC to detect a possible 
temperature dependence of the parameters characterising the equilibrium but none was 
found. According to tables 3.5 and 3.6 the values for ΔH and Ka are similar, so that major 
differences in the binding properties of NotchRam and NotchRamANK can be excluded. 
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Models of the binary DNA-RBP-Jκ and ternary DNA-RBP-Jκ-NotchRamANK 
complexes obtained by small angle x-ray scattering (SAXS) 
The high sequence identity between the conserved domains of C. elegans Lag-1, for which 
a high resolution crystal structure is available (Koval et al., 2004), and human RBP-Jκ 
suggests that the structures of the two proteins should have a very similar secondary 
structure content and arrangement of elements. Superposition of the conserved domain of   
 
Experiment 
no. 
Ram 1 Ram 2 Ram 3 Ram 4 
T (˚C) 20 20 25 25 
ΔH ±  σ(ΔH) 
[kcal/mole] 
-1.08 x 104 
±160.2 
-1.35 x 104 
±233.2 
-1.26 x 104 
±127 
-1.26 x 104 
±119 
N ± σ(N) 0.988±0.01 1.08±0.008 0.953±0.006 0.952±0.006 
Ka ± σ(Ka) 
[M-1]  
6.93 x 106 
±1.31x106 
1.92 x 107 
±4.4x106 
6.03 x 106 
±1.03x106 
6.52 x 106 
±1.07x106 
Table 3.5: Thermodynamic parameters of the binding of NotchRam to nRBPfull-length-DNA (16 bp). With a 
given temperature T the parameters ΔH (enthalpy change) and N (stoichiometry of the reaction) can be 
calculated. 
 
Experiment no. RA 1 RA 2 RA 3 
T (˚C) 20 20 25 
ΔH ±  σ(ΔH) 
[kcal/mole] 
-1.16 x 104±102.2 -1.14 x 104±103.5 -1.13 x 104±153.0 
N ± σ(N) 0.97±0.005 1.01±0.005 1.05±0.008 
Ka ± σ(Ka) [M-1]  1.21 x 107±2.04x106 7.57 x 106±1.04x106 7.59 x 106±1.6x106 
Table 3.6: Thermodynamic parameters of the binding of NotchRamANK to nRBPfull-length-DNA (16 bp).  
 
RBP-Jκ (aa 28 to 432) with the Lag-1 structure using the program MODELLER 
(http://salilab.org/modeller/) resulted in ten models. As the program can only model the 
same number of amino acids as present in the model structure, the additional N- and C-
terminal parts could not be taken into account. Figure 3.30 represents the calculated model 
with the best statistics superimposed on the Lag-1 structure to visualize the equal overall 
fold. There are considerable differences in the loop regions, which are the least predictable. 
Within the DNA-binding region of RBP-Jκ the differences in the loop regions, which 
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interact mainly with DNA are, however,  smaller than those within non DNA-binding loop 
regions, although the DNA has not been taken into account in the calculation. 
  
 
Figure 3.30: Superposition of the Lag-1-DNA crystal structure (grey) and the best model obtained after 
fitting aa 28 to 432 of human RBP-Jκ (orange) into this crystal structure with MODELLER  
(http://salilab.org/modeller/). The two views differ by a 180º rotation of the molecule. 
 
Since the DNA binding sites of both proteins are conserved to a higher extent than other 
loop regions without comparable known interaction sites, this result appears consistent.  
These predictions were verified by SAXS. This technique provides low-resolution 
information on the overall shape of a molecule and can provide useful insights in 
conformational changes occurring upon binding of interaction partners and the 
participation of defined parts of the molecules in the interaction. 
The experiment was conducted as described in section 2.2.7. The shape, or envelope, of the 
macromolecule in solution can be calculated ab initio from the scattering curve. Additional 
knowledge, if available, can be used to set up restraints in the calculation of the envelope. 
For example, in the presence of a complex of molecules one can specify the requirement or 
exclusion of contacts between amino acids of two different molecules, e. g. as result of 
mutational analyses. 
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After ab initio calculation of the shape of the binary complex with the program DAMMIN 
(Svergun et al., 2001) the DNA-Lag-1 binary complex structure model was used as a 
starting point for the interpretation of the SAXS data. The shape obtained by ab initio 
calculations did not satisfactorily correspond to the Lag-1 model, because DAMMIN does 
not take into account that DNA contributes twice as much to the scattering intensity, which 
artificially increases the size of the resulting envelope. 
The binary RBP-Jκ-DNA complex studied here consists of full-length RBP-Jκ, which 
comprises 39 aa more at the N-terminus and 54 more at the C-terminus than the domain 
conserved in each member of the CSL-family of transcription factors. Calculations with the 
program BUNCH (Petoukhov and Svergun, 2005) confirmed that addition of two bodies 
corresponding to the additional portions in nRBP-Jκ at the N- and the C-terminus 
compared to the model of the binary complex could yield a theoretical scattering curve, 
which fits the experimental data.  
Other information obtained with bioinformatical methods suggested that the additional 
parts present in nRBP-Jfull-length compared to the conserved fragment may be very elongated. 
Secondary structure predictions with full-length RBP-Jκ (figure 3.31) suggest that the N-
terminal first 39 aa, including the His-tag are unfolded. The additional 54 aa present in full-
length human RBP-Jκ are predicted on the basis of comparison with the crystallized Lag-1 
protein part to contain an eight aa long α-helix, with the remaining stretch being unfolded.  
The program SASREF (Petoukhov and Svergun, 2005) is able to calculate theoretical 
scattering curves from molecules with partially known structure. For the additional 
portions to be included into the model, the program creates a number of different models 
and tries to obtain the best fit between the theoretical scattering curve of the complete 
model and the experimental data. Models of the binary complex calculated with SASREF 
show indeed, that a theoretical scattering curve calculated from a combination of the binary 
complex and two additional proteins at the N- and the C-terminus fits when the model has 
very elongated N- and C- termini (figure 3.32: scattering curves, figure 3.33: model). 
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Figure 3.31: Secondary structure prediction for human 6xHis-RBP-Jκ as used for interpretation of the SAXS 
data. Secondary structure elements are highlighted in green (loops), yellow (β-sheets) or light blue (α-helices). 
The probability score for the prediction is listed under the aa sequence. A score of five and above predicts the 
existence of a particular element. 
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Figure 3.32: Fit of the three best model scattering curves of the binary DNA-nRBPfull-length and the ternary 
DNA-nRBPfull-length-NotchRamANK complex to the experimental scattering data. Blue curve: experimental 
scattering of the binary complex; red, green and magenta curves: theoretical scattering patterns of the three 
calculated models. Pale green curve: experimental scattering of the ternary complex; grey, dark blue and 
brown curves: theoretical scattering curves of three calculated models for the ternary complex. The grey and 
brown curves are derived from the model assuming that the ankyrin repeats do not participate in binding 
nRBPfull-length. The dark blue curve is derived from the model assuming the interaction of nRBPfull-length with 
the ankyrin repeats. Theoretical radius of gyration Rg and chi-values for the models of the binary complexes: 
compl07b Rg=2.95 nm, chi: 2.616; compl08b: Rg=2.94 nm, chi: 2.673; compl09b: Rg=2.91 nm, chi: 3.093. 
Theoretical radius of gyration Rg and chi values for the models of the ternary complexes: compl07: Rg=4.01 
nm, chi: 2.460; compl08: Rg=3.15 nm, chi: 3.663; compl09: Rg=4.08 nm, chi: 2.462. 
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Figure 3.33: Model of the binary DNA-nRBPfull-length complex (cmpl07b from Figure 3.31); blue:   
nRBPfull-length fitted onto the Lag-1 crystal structure (PDB-code: 1TTU); gray: 16 bp double-strand DNA 
with a double T- or A-overhang at the 5’-end; red pheres: additional amino acids present in nRBPfull-length, 
but missing in the Lag-1 crystal structure, modeled with SASREF (Petoukhov and Svergun, 2005). 
 
To study conformational changes and the contribution of Ram and the ankyrin repeats to 
the binding to RBP-Jκ a ternary complex of DNA-nRBPfull-length-NotchRamANK was also 
analyzed by SAXS. Comparison of scattering data of the ternary complex with the results 
of model calculations using SASREF was used to investigate the role of the ankyrin repeats 
of NotchRamANK in binding RBP-Jκ, which had been previously found to be at most very 
weak (see section 3.2.2). 
Preliminary calculations showed that a model, where no contribution of the ankyrin repeats 
to the binding of RBP-Jκ was assumed gave a better fit to the experimental data than the 
one requiring an interaction of the ankyrin repeats. After fitting Ram by assuming it to 
adopt mostly α-helical structure and therefore replacing it by a molecule exhibiting such a 
structure, the stretch consisting of the seven ankyrin repeats was located in such a way that 
the entire complex was less compact and more elongated than the first one. More exact 
calculations of the ternary complex were done with SASREF, including the binary 
complex, Notch-Ram and Notch-ANK, to obtain the best fit to the experimental data. 
Because of their low complexity the additional portions of the binary complex have not 
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been taken into account in the calculations for the ternary complex. Even with a very 
flexible Ram domain it was almost impossible to obtain a model where the ANK domain 
participates in the interaction with RBP-Jκ. A superposition of the calculated theoretical 
scattering curves of the different models with the experimental data (see figure 3.32) 
together with the corresponding chi-values clearly indicates that none of the compact 
models assuming the participation of the ankyrin repeats in binding RBP-Jκ fits the 
experimental scattering data (model see figure 3.34). In contrast, an excellent agreement is 
found for elongated models where the ankyrin repeats point away from the interaction site 
of Ram with RBP-Jκ (model in figure 3.35). 
 
 
Figure 3.34: Model of the ternary DNA-nRBPfull-length-NotchRamANK complex assuming the participation of 
the ankyrin repeats in the interaction with nRBPfull-length; models of this type (e.g. cmpl080 in Figure 3.32) 
give a much poorer fit to the experimental data than those in Figure 3.35. Green: nRBPfull-length fitted onto 
the Lag-1 crystal structure (PDB-code: 1TTU); red: α-helical protein structure as dummy molecule 
representing the Ram domain (PDB-code 1HEW); blue: seven ankyrin repeats created from the crystal 
structure of six Notch1 ankyrin repeats plus one additional taken from the same structure (PDB-code: 1YYH). 
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Figure 3.35: Model of the ternary DNA-nRBPfull-length-NotchRamANK complex without participation of the 
ankyrin repeats in the interaction. Models of this type give the best fit to the experimental data (e.g. cmpl070 
in Figure 3.32). Green: nRBPfull-length fitted onto the Lag-1 crystal structure (PDB-code: 1TTU); red: dummy 
molecule representing the Ram domain; blue: seven ankyrin repeats created by extending the crystal structure 
of six Notch1 ankyrin repeats by one additional unit taken from the same structure (PDB-code: 1YYH). 
 
To ensure that SASREF was not used with too much bias information ab initio calculations 
were carried out with the program DAMMIN. The calculated envelope was superimposed 
on the model which gave the best fit using SASREF. The superposition reveals a 
surprisingly accurate fit as illustrated in figure 3.36. 
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Figure 3.36: Superposition of an ab initio calculated envelope of a DNA-nRBPfull-length-NotchRamANK ternary 
complex measured by SAXS and a model created by combining the known structural features. RBP-Jκ is 
coloured green, the 16 bp double-strand DNA with single-strand two-base overhangs at each 5’-end is 
coloured yellow; The part of the complex comprising the Notch Ram domain is coloured magenta, the seven 
ankyrin repeats blue. The envelope calculated ab initio from the experimental scattering curve by the 
program DAMMIN is represented by light blue spheres. 
 
3.2.4 The affinity of EBNA2259-435 to nRBPfull-length is two orders of magnitude higher 
than that of NotchRamANK 
Notch is a cellular transmembrane receptor, which has an intracellular domain that 
translocates to the nucleus upon activation by its ligands. Due to the lack of expressed 
ligands under cell culture conditions no Notch-signalling occurs so that usually only very 
low amounts of Notch-IC can be found in the nucleus. Even after activation only 
comparably few Notch-IC molecules are present in the nucleus, which are rapidly degraded 
to quickly terminate the signal. Binding to any interaction partner can thus be expected to 
be very strong. 
EBNA2 is the viral analogue of Notch-IC and regulates the latency phase of Epstein-Barr 
virus in the cell.  The concentrations of the protein in the nucleus are not known, but 
should be sufficiently high to allow efficient interaction with the appropriate regulatory 
proteins activating the transcription of EBNA2 target genes. 
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Since only the Ram domain and the seven ankyrin repeats (ANK) located near the Ram 
domain of Notch-IC are involved in the binding to RBP-Jκ (Tamura et al., 1995; Tani et al., 
2001) it is sufficient to compare binding to EBNA2259-435 with constructs comprising the 
Ram domain and the Ram domain coupled to ANK. 
EMSAs were therefore carried out with the available Notch constructs NotchRam and 
NotchRamANK and with the EBNA2259-435 construct, which contains the conserved CR5 and 
CR6 regions of EBNA2, the latter of which is involved in RBP-Jκ-binding (Ling et al., 
1993), as well as CR7, fused to an N-terminal GST-tag.   
To exclude a possible participation of the GST-tag in the binding to nRBPfull-length control 
experiments were carried out with all oligonucleotides used, i. e. oli-Cp40, oli-LMP1P36 and 
oli-LMP2AP54. Binding to DNA alone was checked as well as binding to a binary  
nRBPfull-length-DNA complex in comparison with EBNA2259-435. The results of these control 
experiments are shown in Figure 3.37. A supershift of the binary nRBPfull-length-DNA 
complex upon binding of EBNA2259-435 is clearly visible in all three cases, whereas no 
supershift can be observed when purified GST (kindly provided by S. Maier, GSF Munich) 
is added to the binary complex. The experiment also proves that GST alone does not bind 
to DNA. 
As illustrated in Figure 3.26 NotchRam or NotchRamANK do not bind to nRBPfull-length in a 
radioactive EMSA where up to 10 ng nRBPfull-length corresponding to a final concentration 
of about 8 nM are available. In contrast, binding occurs in gels run under the same 
conditions but with a larger amount of the two proteins (5 µg nRBPfull-length and twofold 
excess NotchRam and NotchRamANK) resulting in a final concentration of 4.25 µM nRBPfull-
length (see Figures 3.28 and 3.29). In contrast, binding of EBNA2259-435 to   nRBPfull-length 
occurs even when only very small amounts of protein are put into the reaction, as 
illustrated in Figure 3.37, indicating that its affinity for nRBPfull-length is much higher than 
that of NotchRamANK. 
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Figure 3.37: Radioactive EMSA to estimate the affinity of EBNA2259-435 for a binary DNA-nRBPfull-length 
complex and to examine the capacity of GST to bind to nRBPfull-length or DNA in the absence of other 
components. Binding of GST is tested with radioactively labelled double-stranded DNA oligonucleotides 
derived from the viral Cp, LMP1P and LMP2AP, as indicated at the top of the figure. 5 ng of nRBPfull-length 
were supplemented with equimolar amounts of EBNA2259-435 or GST. Arrows mark the binary complex 
DNA-nRBPfull-length and the complex formed by nRBPfull-length-EBNA2259-435. Since it is impossible to 
distinguish the complex formed with the two binding sites on oli-LMP2AP54 occupied by nRBPfull-length and 
the corresponding complex containing one nRBPfull-length and one EBNA2259-435 spots have not been marked 
by arrows. 
 
To compare the binding affinities of nRBPfull-length and Notch as well as of nRBPfull-length 
and EBNA2259-435 directly, radioactive EMSAs were run with amounts of protein 
comparable to those used for non-radioactive EMSAs stained with ethidium bromide and 
Coomassie Brilliant Blue. The main difficulty in such an experiment arises from the high 
amount of protein that can bind DNA, which gives a signal that is too strong for 
interpretation. To guarantee a detectable and interpretable signal an appropriate amount of 
non-labelled DNA derived from the same promoter, which competes with the radioactively 
labelled DNA for the available nRBPfull-length molecules, must be added. In the following 
experiments an amount of non-labelled DNA binding 95% of the available nRBPfull-length 
molecules was therefore added to each sample.  
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Figure 3.38 shows the interaction of NotchRamANK and EBNA2259-435 with nRBPfull-length 
bound to oli-Cp40. In the case of NotchRamANK-nRBPfull-length the interaction, which is 
revealed by the supershift marked nRBPfull-length-NotchRamANK, is only detectable when 5 µg       
nRBPfull-length (corresponding to a protein concentration of 4.25 μM) and 10 µg Notch 
(9.5μM) or 1 µg nRBP28-432 (0.85 μM) and 2 µg Notch (1.7 μM), respectively, are mixed 
and run on the gel. With amounts below 1 µg, the binary complex nRBPfull-length-DNA is 
visible but the supershift caused by the binding of NotchRamANK disappears. The same 
series was repeated for nRBPfull-length and EBNA2259-435. The supershift caused by the 
binding of EBNA2259-435 to nRBPfull-length-DNA is visible down to 10 ng nRBPfull-length (8.5 
nM) and 20 ng EBNA2259-435 (17.5 nM), respectively. The very different binding behaviour 
of the interaction partners under the same conditions - amounts of proteins per reaction and 
constant 1:2 stoichiometric ratio - indicates that EBNA2259-435 has a higher affinity for 
nRBPfull-length than NotchRamANK. 
 
 
Figure 3.38: Representative EMSA to compare the binding affinity of (a) NotchRamANK and                           
(b)  EBNA2259-435  to     nRBPfull-length. Amounts of nRBPfull-length and NotchRamANK or EBNA2259-435, 
respectively, taken to form complexes are indicated at the top of each lane. A constant 1:2 molar ratio of the 
respective proteins (nRBPfull-length:ternary complex partner) was utilized to form ternary complexes on 
radioactively labelled oli-Cp40 and non-labelled oligonucleotide of the same kind sufficient to bind 95 % of 
the available protein. The band corresponding to the ternary DNA-nRBPfull-length-NotchRamANK complex is no 
longer detectable when less than 500 ng nRBPfull-length and 1 μg NotchRamANK are applied, whereas the band 
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corresponding to the ternary complex DNA-nRBPfull-length-EBNA2259-435 is still visible when only 50 ng 
nRBPfull-length and 100 ng EBNA2259-435 are applied. 
 
 
 
Figure 3.39: Representative EMSA to compare the binding affinity of NotchRamANK (a) and EBNA2259-435 (b) 
to nRBPfull-length. Amounts of nRBPfull-length and NotchRamANK or EBNA2259-435, respectively, taken to form 
complexes are indicated at the top of each lane. A constant 1:2 molar ratio of the respective proteins 
(nRBPfull-length:ternary complex partner) was utilized to form ternary complexes on radioactively labelled oli-
LMP1P36. The band corresponding to the ternary DNA-nRBPfull-length-NotchRamANK complex is no longer 
detectable when less than 1 μg nRBPfull-length and 2 μg NotchRamANK are applied, whereas the band 
corresponding to the ternary complex DNA-nRBPfull-length-EBNA2259-435 is still visible when only 10 ng 
nRBPfull-length and 20 ng EBNA2259-435 are applied. 
 
To test whether this behaviour depended on the oligonucleotide to which nRBPfull-length 
binds, similar experiments were carried out with nRBPfull-length bound to oli-LMP1P36, 
which is known to bind the nRBPfull-length-EBNA2259-435 complex much more tightly than 
oligonucleotides derived from Cp. As illustrated in Figure 3.39 the same tendency could be 
observed with the only difference that the ternary complex formed by nRBPfull-length-
EBNA2259-435-oli-LMP1P36 was still detectable when only 20 ng EBNA2259-435 were put 
into the binding mix. The difference is most striking in the case of oli-LMP2AP54. The left 
panel of Figure 3.40 shows a series of complexes of RBP-Jκ and NotchRamANK at constant 
1:2 molar ratio but with decreasing amounts of the two proteins. At high concentrations 
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both RBP-Jκ binding sites on oli-LMP2AP54 are occupied. The lower the amount of 
protein added, the lower the occupancy of the second binding site on the oligonucleotide. 
Amounts of nRBPfull-length below 10 ng result exclusively in binding to a single site in oli-
LMP2AP54. The supershift caused by binding of NotchRamANK is only visible on one 
binding site.  
Amounts of NotchRamANK below 1 µg do not cause a supershift of nRBPfull-length bound to 
the first binding site, but a faint band corresponding to a supershift can still be observed 
when 10 ng of EBNA2259-435 are added to 5 ng nRBPfull-length. 
 
 
Figure 3.40: Representative EMSA to compare the binding affinity of NotchRamANK (a) and EBNA2259-435 (b) 
to nRBPfull-length. Amounts of nRBPfull-length and NotchRamANK or EBNA2259-435, respectively, taken to form 
complexes are indicated at the top of each lane. A constant 1:2 molar ratio of the respective proteins 
(nRBPfull-length:ternary complex partner) was utilized to form ternary complexes on radioactively labelled oli-
LMP2AP54. The band corresponding to the ternary DNA-nRBPfull-length-NotchRamANK complex is no longer 
detectable when less than 0.5 μg nRBPfull-length and 1 μg NotchRamANK are applied, whereas the band 
corresponding to the ternary complex DNA-nRBPfull-length-EBNA2259-435 is still visible when only 5 ng 
nRBPfull-length and 10 ng EBNA2259-435 are applied. 
 
The EBNA2259-435 protein used for EMSAs was purified using the N-terminal GST-tag to 
bind to glutathione sepharose. This tag was not cleaved off since GST is believed not to 
interfere with the binding of EBNA2259-435 to nRBPfull-length. GST is known to form dimers 
so that two molecules of EBNA2259-435 bind to one nRBPfull-length molecule in any case. This 
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explains why no supershift corresponding to that of NotchRamANK bound to nRBPfull-length on 
the first binding site of LMP2AP is observed. In contrast, the supershift caused by the 
EBNA2259-435 dimer binding to nRBPfull-length occupying both binding sites on LMP2AP is 
still visible when only 5 ng nRBPfull-length and 10 ng EBNA2259-435 are mixed. Native 
EBNA2 possesses four dimerization domains (CR1 to CR4), which leads to the natural 
occurrence of the protein as dimer (Harada et al., 2001; Tsui and Schubach, 1994). This 
function may partly be taken over by the GST-tag in the truncated EBNA2 protein used in 
the present experiments. The possible cooperative binding of the EBNA2259-435 dimer as 
well as the role of the GST-tag as substitute for the lacking dimerization domain of 
EBNA2259-435 still has to be examined.  
Binding may depend on the amount of ternary complex partner, i.e. NotchRamANK or 
EBNA2259-435, in the reaction. Increasing amounts of both proteins added to a constant 
amount of nRBPfull-length should result in a binding behaviour similar to the one observed 
when the amounts of both complex partners are altered in the same way. Figure 3.41(a) 
shows the results of such an experiment carried out with oli-Cp40. Increasing amounts of 
NotchRamANK or EBNA2259-435 were added to 1 µg nRBPfull-length. This corresponds to the 
lowest amount of protein where a supershift could still be observed upon binding of 
NotchRamANK (see Figure 3.38). The left panel in Figure 3.41(a) displays the series with 
NotchRamANK and the right one the series with EBNA2259-435. For NotchRamANK a supershift 
can be observed when 1 µg protein is added to 1 µg nRBPfull-length, whereas addition of 0.5 
µg EBNA2259-435 causes a supershift although a faint band of binary complex remains. This 
comparatively small difference does not correspond to the differences observed in Figures 
3.38, 3.39 and 3.40. If this behaviour is based on different binding constants a smaller 
amount of nRBPfull-length with a similar series of increasing amounts of ternary complex 
partner should reveal the difference more clearly, as confirmed by the results in Figure 
3.41(b), where 100 ng nRBPfull-length were used: The supershift caused by NotchRamANK 
occurs when 1 µg protein is added (corresponding to a concentration of 0.9 μM). In the 
case of EBNA2259-435 already 100 ng protein (90 nM), the same amount as nRBPfull-length 
(85 nM), suffice to cause a supershift upon binding to nRBPfull-length. The band 
corresponding to the supershift appears at a different position than that in Figure 3.28, but 
it is comparable to the one resulting from the trial to form a ternary complex in Figure 3.26. 
The ternary complex DNA-nRBPfull-length-EBNA2259-435 becomes visible when 0.1 µg 
EBNA2259-435 are added. 
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Figure 3.41: Representative EMSA to compare the binding affinity of NotchRamANK and EBNA2259-435 to 
nRBPfull-length bound to oli-Cp40. Constant amounts of nRBPfull-length, 1 µg for (a) and 100 ng for (b), and 
increasing amounts of NotchRamANK (a1 and b1) and EBNA2259-435 (a2 and b2) were applied to form ternary 
complexes. (a) Binding of NotchRamANK to the binary complex is visible when 1 µg NotchRamANK is added to 1 
µg nRBPfull-length, a band corresponding to the ternary DNA-nRBPfull-length-NotchRamANK appears. The ternary 
complex DNA-nRBPfull-length-EBNA2259-435 becomes visible when 0.1 µg EBNA2259-435 are added. (b) Binding 
of NotchRamANK to the binary complex is visible when 1 µg NotchRamANK is added to 1 µg nRBPfull-length, a 
band corresponding to the ternary DNA-nRBPfull-length-NotchRamANK appears upon addition of 100 ng 
EBNA2259-435 and 100 ng nRBPfull-length. 
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EBNA2259-435 can displace NotchRam and NotchRamANK from an nRBPfull-length-DNA 
complex 
To check, whether EBNA2259-435 is visible in the 8% TBE-PAGE system and is able to 
compete with Notch proteins in this system a competition experiment was performed on 
ternary complexes with NotchRam and NotchRamANK. Increasing amounts of EBNA2259-435 
were added to the corresponding ternary complexes from a substoichiometric ratio of 1:0.5 
up to tenfold excess. As indicated by the reduced intensity of the bands of the ternary 
complex in Figure 3.42 EBNA2259-435 can displace both NotchRam and NotchRamANK bound 
to nRBPfull-length. The expected ternary complex of EBNA2259-435 bound to nRBPfull-length-
DNA is not visible as a distinct band in an 8% TBE PAGE gel. The slot of the control lane 
containing 10 μg EBNA2259-435 stains with ethidium bromide although no DNA is present. 
Since the bands for the ternary complex with NotchRam and NotchRamANK are fading, but the 
one for the binary DNA-nRBPfull-length complex does not intensify it is assumed that the 
material in the gel slots stained with ethidium bromide corresponds to a new ternary 
complex formed with EBNA2259-435. The experiment was therefore repeated with 
radioactive EMSAs on 4 % TBE PAGE gels to visualise the band more clearly. 
Direct competition of both ternary complex partners with lower amounts of protein should 
reveal differences in the ability of the two proteins to displace the other one from its 
complex with nRBPfull-length. The result of the corresponding experiment is shown in Figure 
3.43 for Cp. In the left panel (Figure 3.43(a)) increasing amounts of EBNA2259-435 were 
added to a complex between nRBPfull-length and NotchRamANK. The supershifts caused by 
NotchRamANK and EBNA2259-435 are easily distiguishable, as the addition of increasing 
amounts of EBNA2259-435 clearly results in an upward shift of the band containing 
NotchRamANK in favour of the one containing EBNA2259-435. Already 10 ng EBNA2259-435 
added to 1 µg nRBPfull-length and 2 µg NotchRamANK result in a detectable band containing 
the nRBPfull-length-EBNA2259-435 complex bound to the oligonucleotide derived from Cp.  
Displacement becomes detectable upon addition of 1 µg EBNA2259-435 and is completed 
when 5 µg EBNA2259-435 are added, which corresponds to a 1:2.5 stoichiometric ratio 
between NotchRamANK and EBNA2259-435. In contrast, displacement of EBNA2259-435 from a 
ternary complex with nRBPfull-length starts only after addition of 5 µg NotchRamANK and is 
not even completed when a 25-fold excess of NotchRamANK is added (Figure 3.43(b)). 
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Figure 3.42: Non-radioactive EMSA successively stained with ethidium bromide (left panel) and Coomassie 
Brilliant Blue (right panel) to study the ability of EBNA2259-435 to displace NotchRam and NotchRamANK from 
a ternary complex with DNA-nRBPfull-length (DNA: oli-Cp22). Increasing amounts of EBNA2259-435 were 
added to a ternary DNA-nRBPfull-length-NotchRam (a) and DNA-nRBP-NotchRamANK complex (b). In both 
cases the band corresponding to the ternary complex with NotchRam or NotchRamANK is fading with increasing 
amounts of EBNA2259-435. Instead an increasing amount of complex, which cannot enter the gel, 
accumulates in the gel slots. The abbreviations nRBP, RamANK and EBNA2 stand for nRBPfull-length, 
NotchRamANK and EBNA2259-435. 
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Figure 3.43: EMSA demonstrating the increased ability of EBNA2259-435 to displace NotchRamANK from a 
ternary complex with DNA-nRBPfull-length compared to that of NotchRamANK with EBNA2259-435. 1 μg 
nRBPfull-length and 2 μg ternary complex partner were used to form a complex with oli-Cp40. The amount of 
ternary complex partner added to displace the existing one is listed at the top of each lane. (a) Displacement 
of NotchRamANK with increasing amounts of EBNA2259-435; the band corresponding to the ternary complex 
formed with EBNA2259-435 is visible as soon as the smallest amount of EBNA2259-435 is added. (b) 
Displacement of EBNA2259-435 with increasing amounts of NotchRamANK; a band corresponding to the one 
observed when a DNA-nRBPfull-length-NotchRamANK ternary complex is formed (see e.g. Figure 3.38) appears 
as soon as 1 μg NotchRamANK is added. This does not result in a significant reduction in the cooresponding 
band of the DNA-nRBPfull-length-EBNA2259-435 complex. 
 
There is a strong band corresponding to the ternary complex formed with EBNA2259-435 
and a faint one corresponding to the ternary complex with NotchRamANK, which appears as 
soon as 0.5 µg NotchRamANK are added. The ability of NotchRamANK to displace     
EBNA2259-435 from a ternary complex with nRBPfull-length is clearly weaker than the one of 
EBNA2259-435 to displace NotchRamANK. 
The experiment was repeated with oli-LMP1P36 as binding matrix for nRBPfull-length. As 
mentioned above, oli-LMP1P36 has a higher affinity for the nRBPfull-length-EBNA2259-435 
complex than for the complex with NotchRamANK as ternary complex partner. Figure 3.44 
illustrates the result of the experiment, which was done under the same conditions and with 
the same amounts of proteins as indicated in Figure 3.43.  As in the case of  Cp, 10 ng 
EBNA2259-435 added to a 200-fold surplus of NotchRamANK result in a faint band 
corresponding to a supershift of the ternary complex containing EBNA2259-435. Visible 
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displacement of NotchRamANK from nRBPfull-length occurs when 1 µg EBNA2259-435 is added 
and is complete in the presence of a 2.5-fold excess. As already found in the experiment 
shown in Figure 3.43 NotchRamANK is not able to fully displace EBNA2259-435 from  
nRBPfull-length. The first faint band corresponding to a supershift upon formation of a ternary 
complex containing NotchRamANK appears when 1 µg NotchRamANK is added.  
Taken together all these experiments show that EBNA2259-435 has a higher affinity for the 
binary DNA-nRBPfull-length complex than NotchRamANK.  
 
Figure 3.44: Radioactive EMSA demonstrating the higher ability of EBNA2259-435 to displace NotchRamANK 
from a ternary complex with DNA-nRBPfull-length compared to that of NotchRamANK to displace EBNA2259-
435. 1 μg nRBPfull-length and 2 μg ternary complex partner were used to form a complex with oli-LMP1P36. 
The amount of ternary complex partner added to displace the existing one is listed at the top of each lane. (a) 
Displacement of NotchRamANK with increasing amounts of EBNA2259-435; as in Figure 3.43 the band 
corresponding to the ternary complex formed with EBNA2259-435 is visible as soon as the smallest amount of 
EBNA2259-435 is added. (b) Displacement of EBNA2259-435 with increasing amounts of NotchRamANK; a band 
corresponding to the DNA-nRBPfull-length-NotchRamANK ternary complex appears as soon as 1 μg NotchRamANK 
is added. This does not result in a visible decrease of the DNA-nRBPfull-length-EBNA2259-435 complex. 
 
The unexpectedly weaker binding affinity of NotchRamANK to RBP-Jκ compared to that of    
EBNA2259-435 gave reasons to check for hints of changes, which might cause the different 
behaviour. As illustrated in Figure 3.28(b) recombinant NotchRamANK overexpressed and 
purified from bacteria binds quantitatively to RBP-Jκ and a band corresponding to free 
NotchRamANK is only visible when excess NotchRamANK is added to the reaction, indicating 
that the different behaviour is not due to a lack of activity. 
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No indications of a posttranslational modification within the RBP-Jκ binding regions, i. e. 
Ram and the seven ankyrin repeats, of Notch1 could be found in the literature. 
 
Proteins from nuclear extracts display the  tendency to increase the binding affinity of 
NotchRamANK to nRBPfull-length 
The experiments described above were carried out with highly purified recombinant 
proteins. To exclude the possibility that the lower binding affinity might reflect a 
requirement for other cellular proteins for efficient binding of NotchRamANK to nRBPfull-length, 
a similar experiment than the one displayed in Figure 3.41(b) was carried out  with 2 µg 
nuclear extract from RBP-Jκ-/- knockout cells (cell line SM261) added to each sample. If 
any additional proteins were required for stronger binding the supershift band 
corresponding to NotchRamANK bound to nRBPfull-length should be visible in the presence of 
even lower amounts of NotchRamANK. A DG75 nuclear extract, and therefore one from 
SM261 as a cell line derived from DG75, does not contain relevant amounts of Notch1, 
because virtually no Notch-signalling occurs under cell culture conditions, since Notch 
ligands such as Delta or Jagged are not expressed (Hofelmayr et al., 1999). Furthermore, if 
a signal leads to the translocation of Notch1-IC to the nucleus, the protein is rapidly 
degraded, partly because of its PEST domain labelling it for ubiquitination (Öberg et al., 
2001). False positive supershifts can thus be excluded when DG75 nuclear extract is added. 
Figure 3.45 shows the result of the experiment.  
Lanes 4 to 9 display the repeated experiment shown in Figure 3.41(b), left panel, to form a 
nRBPfull-length-DNA-NotchRamANK ternary complex with different amounts of NotchRamANK. 
As soon as 0.2 μg NotchRamANK are added a band appears which corresponds to the ternary 
complex. In lanes 10 to 15 2 μg SM261 nuclear extract are added to the mixtures otherwise 
corresponding to the one in lanes 4 to 9. As clearly visible the band corresponding to the 
ternary complex is visible when only 10 ng NotchRamANK are added. This experiment was 
repeated with different setups to confirm this finding (data not shown). This suggests that 
one or more factors in a nuclear exctract can promote binding of RBP-Jκ and NotchRamANK. 
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Figure 3.45: Radioactive EMSA to compare the affinity of NotchRamANK to nRBPfull-length in the presence 
(lanes 4 to 9) or absence (lanes 10 to 15) of 2 µg nuclear extract from RBP-Jκ-/- knockout cells (cell line 
SM261). Different amount of NotchRamANK are added to 100 ng nRBPfull-length bound to oli-Cp40. The amount 
of NotchRamANK added is indicated at the top of each lane. Control experiments: Lane 1 represents 100 ng 
nRBPfull-length alone, lane 2 2 µg nuclear extract and lane 3 a combination of lanes 1 and 2. 
 
3.2.5 EBNA259-435 has a lower affinity to RBP-Jκ than EBNA291-355 
The RBP-Jκ binding site on EBNA2 was mapped to the conserved region 6 (CR6). The 
present work compared the affinity of the two EBNA2 proteins, comprising CR5 and CR6 
(EBNA291-355) and CR5 to CR7 supplemented by a short additional N-terminal part 
(EBNA259-435). ITC experiments were carried out with EBNA2 proteins as ligands, which 
were titrated to a binary DNA-nRBPfull-length complex. Tables 3.7 and 3.8 list the results of 
three experiments with EBNA291-355 and two with EBNA259-435. Even if there is a larger 
scatter in the values for EBNA291-355, one can still clearly see that the affinities of the two 
proteins for RBP-Jκ differ by one order of magnitude. These data have a higher error than 
those done with Notch proteins as ligand, which may have been caused by the uncleaved 
GST-tag, leading to a homodimer. This also explains the stoichiometric ratio of 1:2 of the 
reaction. Two molecules of GST-EBNA2 bind one molecule RBP-Jκ.  
Obviously regions other than CR6 contribute to the binding of RBP-Jκ. Studies to map the 
region lying within the parts of EBNA2, which are present in EBNA259-435 and also interact 
with RBP-Jκ, are currently under way (S. Maier, personal communication). 
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Otherwise the data obtained for EBNA259-435 supports previous findings about a higher 
affinity of EBNA2 for RBP-Jκ. 
 
Experiment no. CR67_1 CR67_2 CR67_3 
T (˚C) 20 20 20 
ΔH ±  σ(ΔH) [kcal/mole] -7.69 x 104 ± 527 -6.07 x 104 ± 151 -8.14 x 104 ± 412 
N ± σ(N) 0.632 ± 0.03 0.647 ± 0.01 0.584 ± 0.005 
Ka ±  σ(Ka) [M-1]  4.11 x 106  
± 2.92x105 
8.73 x 105  
± 1.21x105 
5.58 x 105  
± 1.56x105 
Table 3.7: Thermodynamic parameters of the binding of EBNA291-355 to nRBPfull-length-DNA (16 bp). With a 
given temperature T the parameters ΔH (enthalpy change) and N (stoichiometry of the reaction) can be 
calculated. 
 
Experiment no. CR57_1 CR57_2 
T (˚C) 20 20 
ΔH ±  σ(ΔH) [kcal/mole] -1.15 x 104 ± 167.3 -1.14 x 104 ± 103.5 
N ± σ(N) 0.499 ± 0.002 0.412 ± 0.004 
Ka ± σ(Ka) [M-1]  1.18 x 108 ± 4.48x107 3.99 x 107± 1.05x107 
Table 3.8: Thermodynamic parameters of the binding of EBNA259-435 to nRBPfull-length-DNA (16 bp). 
Parameters correspond to those described in table 3.7. 
 
3.3 Crystallization trials of RBP-Jκ bound to DNA, peptides derived from 
NotchRam or EBNA2 and NotchRam or NotchRamANK 
 
Crystallization trials were carried out using the vapour diffusion method with the standard 
Hampton Research crystal screens or self-made screens combined with the hanging drop 
method. In the trials that were manually set up a 0.6 μl droplet of solution with different 
protein concentrations (3, 5 and 8 mg/ml) and the same volume of reservoir solution was 
used. The total reservoir volume was 0.5 ml. Trials set up using the high throughput 
crystallization facility had 70 μl reservoir solution and drops composed of 0.3 μl each of 
protein solution and reservoir solution.  
The high throughput facility provides software to evaluate crystal trials. Images of the 
droplets are taken immediately after the setup of the screen and after several time points. 
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Manual evaluation of the screens was carried out under a microscope. Generally, the term 
“hit” is used when small crystals or needles are visible in the drop. In this case the term is 
used if crystalline precipitate or microcrystals, judged by the eye, were found.  
The initial self-made screen combined a pH range from 4.5 to 9 with different 
concentrations of polyethyleneglycols covering a range of molecular mass (PEG1000 to 
PEG10000). 
Section 2.1.4 lists the different oligonucleotides used in the crystallisation trials aiming at 
obtaining crystals of binary and ternary complexes of nRBPfull-length and nRBP28-432. 
Extensive trials with rRBPfull-length expressed in bacteria did not yield any protein crystals.  
Ternary complexes with peptide ligands were formed with two peptides derived from 
EBNA2 comprising 10 or 12 amino acids around the essential WW motif and a 
dodecapeptide and a pentapeptide derived from NotchRam including the amino acids 
essential for binding, which according to the alignment in Figure 1.6 (section 1.3.3) are 
similar to those in EBNA2. To guarantee that the peptides, which by themselves did not 
contain charged amino acids, would be soluble one amino acid was added to the N- and C-
termini of the dodecapeptides. The amino acid side chains were chosen according to an 
alignment of the Ram domain and EBNA2 CR6 (see Figure 1.6 in section 1.3.3).    
Ternary complexes were formed with both Notch constructs, NotchRam and NotchRamANK, 
and used in crystallisation trials. 
Both for nRBP28-432 and nRBPfull-length screens with protein concentrations of 3 mg/ml rarely 
resulted in precipitate, whereas heavy precipitates were generally obtained with 8 mg/ml. 
Depending on the oligonucleotide used up to five times more hits were obtained with 
nRBP28-432 than with nRBPfull-length. Optimization was attempted around all conditions where 
promising results were obtained. 
 
Optimization of the length of the oligonucleotide 
The RBP-Jκ homologue lag-1 was crystallized bound to a 13 bp double-strand 
oligonucleotide with a double T- or A-overhang at each 5’-end (Kovall and Hendrickson, 
2004). The corresponding oligonucleotide adapted to the human RBP-Jκ core binding 
sequence did not bind to rRBPfull-length and bound only very weakly to either nRBP28-432 or 
nRBPfull-length. Initial trials were thus only set up with nRBPfull-length, but they did not yield 
any useful result. Consequently, oligonucleotides with 15 to 23 base pairs, whose affinity is 
sufficiently high, were used for crystallization.  
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 Figure 3.46: Number of promising conditions for binary complexes of nRBP28-432 and nRBPfull-length with 
oligonucleotides of different lengths. 
 
After extensive studies and comparisons of blunt-ended oligonucleotides with 
corresponding oligonucleotides with one or two overhanging bases at each 5’-end, it was 
decided to limit further trials to oligonucleotides with double-overhangs. 
As depicted in Figure 3.46 most hits, defined as the occurrence of apparently micro-
crystalline precipitates or spherulites, were obtained for oligonucleotides with 21 to 23 
base pairs length, but some conditions with 18- or 19-mers yielded additional hits (to 
compare the oligonucleotides used see section 2.1.4). The conditions for different 
oligonucleotides only correspond in very few cases. Generally, suitable conditions for one 
oligonucleotide gave regular or amorphous precipitates for different oligonucleotides. 
 
pH optimum 
The hits for both proteins as well as any oligonucleotide or ligand used to form binary or 
ternary complexes were statistically evaluated to find the pH condition most likely to lead 
to protein crystals. Figure 3.47 shows the number of hits for pH values between  pH 4 and 
pH 9. Promising conditions were found over the entire range with the highest hit frequency 
between pH 6.5 and 7.5 (i.e. near the theoretical pI of 8.3 of full-length RBP-Jκ, calculated 
by ExPASy’s protein parameter tool (Gasteiger et al., 2005)). 
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.  
Figure 3.47: Number of promising conditions between  pH 4 and 9 in steps of 0.5 pH units.  
 
 
Figure 3.48: Number of promising conditions for polyethyleneglycols (PEG) of different molecular mass, 
glycerol and MPD as precipitant. 
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Precipitants 
The most promising conditions obtained with both the Hampton Research and self-made 
screens contained polyethyleneglycols PEG8000 and PEG6000 or PEG3350, which are 
known to promote crystallization of protein-DNA complexes, as precipitant.  Apart from 
PEGs promising conditions contained only glycerol or MPD (Figure 3.48).  
 
Salts and additives 
The Hampton Research screens where usually more than one parameter is altered did not 
give unambiguous indications concerning the optimal salt or salt concentration to be used 
for crystallization of binary or ternary complexes with RBP-Jκ. Table 3.9 lists the nature 
and concentrations of salts found in promising conditions. 
Conditions altered using commercially available additive screens resulted in spermine or 
spermidine as supportive additives. In rare cases ethyleneglycol improved the structure of 
the precipitate. 
 
Influence of peptides 
According to mutational analysis peptides derived from NotchRam should bind to a 
hydrophobic pocket on the surface of RBP-Jκ, which may alter the behaviour of the protein 
in solution. None of the peptides used to form ternary complexes with DNA-RBP-Jκ 
resulted in an increased number of hits nor did they improve the appearance of conditions, 
which were judged promising for the binary complex. A chart listing the total number of 
promising conditions compared with the number obtained with ternary complexes formed 
with peptides is shown in Figure 3.49.  
 
Influence of Notch proteins 
As illustrated in Figure 3.49 a considerable number of promising conditions were obtained 
with ternary complexes formed with NotchRam. In the case of the 17-bp oligonucleotide the 
number increased from zero to 17 conditions. 
Ternary complexes formed with NotchRamANK did not yield any promising conditions, 
which is perhaps not surprising in view of the very elongated model established by SAXS 
as described in section 3.2.3.  
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Salt Concentration range 
[M] 
Ammonium acetate 0.05-0.1 
Ammonium chloride 1.5 
Ammonium nitrate 0.2 
Ammonium sulphate 0.1-2.4 
Calcium acetate 0.2 
Calcium chloride 0.01-0.2 
di-ammonium tartrate 0.7 
Lithium nitrate 0.2 
Lithium sulphate 0.2-1.8 
Magnesium acetate 0.15 
Magnesium chloride 0.01-0.2 
Magnesium formate 0.2-0.5 
Magnesium sulphate 0.005-1.8 
Potassium chloride 0.1-0.2 
Potassium formate 0.1 
Potassium nitrate 0.2 
Potassium sulphate 0.2 
Potassium thiocyanate 0.2-0.5 
Sodium acetate 0.2-1.4 
Sodium citrate 0.2 
Sodium chloride 0.2-3 
Sodium fluoride 0.2 
Sodium formate 4 
Sodium nitrate 1.5 
Sodium thiocyanate 0.2 
Zinc acetate 0.05 
Table 3.9: Salt concentration range of promising crystallization conditions. 
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Figure 3.49: Number of conditions, where crystalline precipitate or spherulites were obtained rather than 
regular or amorphous precipitates as function of the length of the oligonucleotide used for crystallization. The 
number of total hits is compared with the number obtained with ternary complex formed with peptides or 
Notch-Ram. 
 
Despite extensive trials none of the conditions identified could be optimized to yield 
diffracting protein crystals. Most trials resulted in salt or DNA crystals, which both yield 
characteristic diffraction patterns. The surprising increase in hits with NotchRam bound to a 
binary complex formed with a 17-base pair oligonucleotide, which has only recently been 
put into practice, is currently being examined in more detail. 
 
Discussion 
 
 138
4 Discussion 
4.1 Importance of RBP-Jκ in the context of Epstein-Barr virus infections 
 
RBP-Jκ plays an important role in protein expression in many phyla and is ubiquitously 
expressed in all human tissues, where it also serves as anchoring point for the Epstein-Barr 
viral EBNA2 protein. Upon binding of the immediate early EBNA2 protein to RBP-Jκ the 
latency of the virus in the cell and immortalisation of the cell can be established. The 
binding mode of EBNA2 mimics that of a cellular protein, the intracellular domain of 
Notch1 (Notch-IC). Both EBNA2 and Notch1 have been shown to activate or repress 
expression of a similar set of genes, albeit with some differences. The binding sites of the 
two proteins on RBP-Jκ differ slightly, but alignments and mutational analyses have shown 
a conserved ΦWΦP binding motif to be essential for the interactions in both cases.  
RBP-Jκ is known to bind a core DNA sequence, where some bases are essential for the 
binding, but others, mainly located at the border or within the flanking regions of the 
binding sequence may be altered, which results in weaker but still detectable binding. The 
resulting binding sites with different affinities for RBP-Jκ allow cells and viruses to 
differentially regulate responses to signals on the promoters of different target genes, 
displaying multiple variations of RBP-Jκ binding sites. The DNA sequence interacting 
with RBP-Jκ can vary at certain positions, i.e. bases may be exchanged. RBP-Jκ binding 
sites on DNA with different sequences may have different affinities for the protein.  
An important question is whether different DNA binding sequences cause changes in the 
tertiary structure of RBP-Jκ and, if so, how these influence the binding of Notch-IC and 
EBNA2. Ultimately the question is, of course, whether such information can lead to new 
approaches for finding selective ways of inhibiting the binding of EBNA2 to RBP-Jκ 
without affecting that of Notch-IC. 
A good understanding of the mechanism and the consequences of the similar, but 
nevertheless different, binding modes of the two proteins could give rise to new strategies 
against Epstein-Barr virus infections or at least against the malignant tumours, which this 
virus may cause.  
The present work contributes to a better characterisation of the interactions of Notch1 and 
EBNA2 with RBP-Jκ using different, complementary biochemical and biophysical 
methods. 
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4.2 The binding properties of recombinant RBP-Jκ depend on the expression 
system 
 
E. coli is a convenient host to express proteins of different origins in view of their large 
scale purification. A major drawback of this system lies in the possible loss of activity, 
caused by the absence of specific posttranslational modifications, which normally occur in 
higher eucaryotes. As the few mammalian expression systems, which have yet been 
optimised for large scale protein expression, still have major drawbacks the baculovirus 
system using insect cells as expression host has become important in recent years. The 
present work illustrates that the choice of expression host is important not only for 
obtaining soluble protein but can also make a significant difference in the properties of the 
final product.  
After an extensive series of unsuccessful trials to express RBP-Jκ in soluble form in E. coli, 
refolding of the protein expressed into inclusion bodies finally led to a product, which 
specifically bound DNA, but not the Notch derivatives NotchRam and NotchRamANK, which 
were expressed in E. coli as well. The change to the baculovirus expression system yielded 
soluble RBP-Jκ, which bound to shorter oligonucleotides than the refolded protein 
expressed in E. coli. Moreover, it did not only generally bind much more strongly to DNA 
fragments of different lengths, but also bound the Notch proteins NotchRam and 
NotchRamANK with similar strength.  
The molecular mass determined by mass spectrometry differed by only 4 Daltons from the 
theoretical value calculated by the ExPaSY protein parameter tool (Gasteiger et al., 2005). 
As the error on such measurements is of the order of 0.1 Daltons, this difference may be 
significant but cannot be accounted by any known post-synthetic modification. The 
enhanced ability to bind both DNA and interacting proteins suggests that several factors 
play a role. The difference in properties results most probably from the more controlled 
folding process in insect cells compared to the artificial refolding process applied after 
complete denaturation of the protein expressed in E. coli. 
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4.3 The conserved part of RBP-Jκ has the same binding properties for DNA or 
Notch proteins as its full-length counterpart  
 
Alignments of RBP-Jκ homologues from different species revealed a conserved region 
common to all examined RBP-Jκ proteins. Lag-1, the homologue in C. elegans, could be 
successfully crystallised after truncating the protein at the N- and C-termini (Kovall and 
Hendrickson, 2004). For the present work a deleted human RBP-Jκ protein, nRBP28-432, 
was designed according to the conserved part, expressed in insect cells and purified in 
quantities comparable to nRBPfull-length. The truncated protein was tested for its DNA- and 
protein-binding ability. Figure 3.21 reveals no substantial difference in the ability of the 
truncated protein to bind DNA with RBP-Jκ binding sites derived from Epstein-Barr viral 
promoters. None of the protein interaction partners, NotchRam and NotchRamANK, which 
were tested on non-radioactive EMSA (Figure 3.23) exhibited different binding properties, 
supporting the hypothesis that the conserved region is indeed essential and sufficient for 
the binding properties of RBP-Jκ. 
 
4.4 The ankyrin repeats of Notch-IC do not detectably contribute to RBP-Jκ 
binding 
 
We also tried to quantify the contribution of the ankyrin domain (ANK) containing seven 
ankyrin repeats of about 30 amino acids each to the binding affinity of Notch-IC to RBP-Jκ 
with biochemical (EMSA) and biophysical (ITC) methods in a controlled system. Only 
proteins >95% pure in well defined buffer conditions were used for the binding assays, so 
that any influence from unknown sources can be excluded.  
No significant differences in the binding affinity could be detected in non-radioactive 
EMSAs with ternary complexes formed with pure RBP-Jκ, DNA and different amounts of 
NotchRam or NotchRamANK.    
The results obtained with ITC, which are described in section 3.2.3, also clearly indicate 
that there is no significant difference in the enthalpy change (ΔH=-1.1 to -1.3x104 
kcal/mole) and the binding constant (6x106 to 2x107 M-1). As expected, the stoichiometric 
ratio of the reaction is 1:1 for both ternary complex partners. 
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The low resolution model of the ternary DNA-nRBPfull-length-NotchRamANK complex 
obtained with SAXS strongly suggests that the ankyrin repeats do not participate in binding 
RBP-Jκ. The model with the ankyrin domain pointing away from the remaining complex 
gave a much better fit with much lower errors than the one where the ankyrin repeats 
contribute to binding to RBP-Jκ. These quantitative data strongly suggest that the 
contribution of ANK to the binding of RBP-Jκ is negligible.  
All experiments taken together suggest that the system is not as simple as what it is 
reduced to in ITC or even transactivation experiments in vivo. It is likely that successful 
transactivation upon binding of Notch-IC to RBP-Jκ takes places via additional interactions 
to other proteins involved in the transcription initiation process. As ankyrin repeats are 
known to mediate protein-protein interactions and interactions with two histone-
acetyltransferases have already been detected (Kurooka 2000), they might very well be 
involved in this function rather than exerting any strong binding to RBP-Jκ. 
The affinity of NotchRamANK and RBP-Jκ was shown to be concentration dependent (for 
comparison see e.g. Figures 3.26 and 3.28). To evaluate the quantitative results obtained 
with ITC in the context of the expected cellular concentration of RBP-Jκ, this 
concentration was estimated on the basis of Western blot analyses carried out with DG75 
cells. The result of this analysis suggest that under cell culture conditions 25 fg RBP-Jκ can 
be found in a single cell. Under the assumption that most of the protein is located in the 
nucleus the calculated final concentration of RBP-Jκ in the nucleus is 3.75 mM, which 
should be compared with an average concentration of 102 μM assuming RBP-Jκ to be 
evenly distributed within the cell. Most probably the actual concentration lies somewhere 
in between these two surprisingly high values. High physiological concentrations of 
components should suggest a  low affinity in the mM range rather than in the low 
micromolar range as observed in the present work. On the other hand competition of 
coactivators such as Notch-IC and corepressors for possibly different binding sites on 
RBP-Jκ may necessitate such a high affinity to successfully enhance the expression of 
target genes. Assuming a similar concentration for Notch-IC upon activation and 
translocation the interaction should be possible without the help of other components. 
However, Notch signals are known to be comparably weak and quickly abrogated by 
ubiquitination, so that binding without the help of additional components may not occur. 
There are some contradictory results in the literature regarding the role of the Notch1 
ankyrin (ANK) repeats in binding RBP-Jκ and transactivation of its target genes. 
Depending on the method applied ANK displayed a more or less strong binding and 
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transactivation activity. It was even reported that a point mutation within the ANK domain 
of Notch1 (M1 mutation (Kopan et al., 1994)) results in complete abrogation of 
transactivation activity of Notch1-RAMIC, while the Ram domain alone was found to lack 
transactivation ability  (Kato et al., 1997; Kurooka et al., 1998). Ram and ANK are both 
involved in the interaction with RBP-Jκ, whereas ANK was also shown to be necessary for 
transactivation.  
Dumont et al. (2001) found in their study that a GAL4-RamANK fusion protein without 
the novel transactivation domain (TAD) previously identified by Kurooka et al. (1998) is 
unable to transactivate GAL4 responsive reporter genes in two different cell lines. The 
restricted but still significant transactivation of artificial promoter-reporter constructs 
containing multimerized RBP-Jκ binding sites found in promoters of Hes-1 and Hes-5 by 
RamANK indicate the presence of two different transactivation mechanisms: 
Transactivation requires either a transferable TAD possessing the OPA and PEST elements 
(glutamine- rich and proline-, serine and threonine-rich regions, respectively) or the 
concerted action of Ram and ANK within an RBP-Jκ protein complex. 
One obviously has to distinguish between the ability of Notch constructs to interact with 
RBP-Jκ and to transactivate. In general, although the different methods applied by different 
groups partly gave contradictory results, it can be concluded that neither of the two 
functions on its own suffices for expression of RBP-Jκ target genes. 
When this study was effectively completed additional insight in the interaction of the 
ankyrin repeats with RBP-Jκ was gained from the crystal structure of a quaternary complex 
of C. elegans Lag-1 bound to DNA, RamANK and an additional protein fragment derived 
from Mastermind (MAML), another transcriptional coactivator (Wilson and Kovall, 2006) 
and one of the same complex with human proteins without Ram (Nam et al., 2006). The 
crystal structure of the C.elegans proteins, which is depicted in figure 4.1, shows that the 
ankyrin repeats indeed participate in binding RBP-Jκ at three sites in the third, the fifth and 
the seventh repeat, the latter of which contains a C. elegans-specific insertion. Comparison 
of the theoretical scattering curve of the crystal structure of the complex composed of 
proteins from C. elegans, excluding Mastermind, with the experimental SAXS data of the 
according complex with human proteins in solution revealed a poor fit (data not shown), 
making it unlikely that the conformation of ANK in the crystal structure corresponds to 
that of the human proteins in solution.  
In the crystal structure only a small portion of the Ram domain is visible, because large 
parts of the domain seem to be very flexible. This does not contradict the findings that Ram 
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folds up to form mostly alpha-helical structures. However, there is still a considerable 
portion with low complexity, which most likely is responsible for the less rigid structure of 
this protein. 
 
 
Figure 4.1: Crystal structure of the quaternary complex of the C. elegans proteins Lag-1, Notch-RamANK 
and Mastermind on DNA. The ribbon structure of Lag-1 is coloured olive, that of RamANK violet and that of 
Mastermind yellow. The DNA at the bottom of the picture is displayed as sticks representing the bases. 
 
The Mastermind fragment forming two alpha helices is arranged in such a way that it is 
very well imaginable that by binding of this coactivator to the ternary complex in an 
unknown sequence the ankyrin repeats are forced into a conformation, where they interact 
with RBP-Jκ. In this case Mastermind would function as scaffold protein binding RBP-Jκ 
as well as ANK and its presence may determine the binding and therefore possibly the 
functionality of the resulting complex. Since a number of such coactivators exist, the 
conformational changes arising from their binding to RBP-Jκ may well be responsible for 
the differential transactivation activity of RBP-Jκ. Our results gave rise to the suggestion of 
a model of the sequence of binding of RBP-Jκ interaction partners which differs from that 
suggested by Wilson et al. (2006). Figure 4.2 illustrates the differences between this model 
and the one suggested on the basis of the results obtained in the present work. Whereas the 
recently published model suggests an equilibrium of ANK domains docked and undocked 
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on RBP-Jκ after recruitment of Ram (left panel), it is suggested here that ANK can only 
bind after additional recruitment of MAML (right panel), so that MAML, which interacts 
strongly with ANK sets the stage for ANK to interact with RBP-Jκ.  
 
Figure 4.2: Comparison of two models for the sequence of the assembly of Notch-IC, Mastermind (MAML) 
and RBP-Jκ could take place. Left panel: Model as suggested by Wilson et al. (2006); recruitment of Notch-
IC via Ram is followed by docking of ANK to form a high-affinity binding site for MAML. Right panel: 
Model based on the present work suggesting the necessity of MAML to bind prior to the docking of ANK, 
thus creating the corresponding high-affinity binding site for ANK. 
 
 
Our results concerning the possible increase in affinity of RBP-Jκ for Notch after addition 
of cellular extract strongly supports the latter model. So far no information could be 
obtained from the authors about whether crystals of a ternary complex have also been 
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obtained. Both certainly interesting though partly controversial findings encourage to try 
and unravel the binding meachanism in the context of a physiological environment. 
 
4.5 The minimal RBP-Jκ binding site in EBNA2 (CR5 and CR6) does not account 
for its strong binding affinity  
 
Many of the results above are still not well established and should be further examined 
with more controllable methods, but it would not be surprising to find very flexible 
proteins with functional similarities to EBNA2 in different organisms. This would, of 
course, considerably complicate the targeting of the protein in the fight against EBV 
infection resulting in malignant diseases. 
The construct used to determine the stronger binding affinity of EBNA2 to RBP-Jκ 
compared to NotchRamANK comprises aa 258 to 435. The binding properties of full-length 
EBNA2 have not been determined in the present work, since the regions contributing to the 
interaction with RBP-Jκ were mapped to the conserved regions CR5 and CR6. There are 
cases known where the binding of a full-length protein to its interaction partner is weaker 
than that of a truncated version, e.g. because of the presence of autoinhibitory patches in 
regulatory proteins involved in signal transduction. Usually, however, the binding affinity 
increases the smaller the difference in length between the truncation construct and the full-
length protein. An EBNA2 construct comprising the minimal RBP-Jκ binding site 
(EBNA2291-355) does not result in a visible supershift when added to nRBPfull-length-DNA in 
radioactive EMSAs (S. Maier, GSF, personal communication). In contrast, we could detect 
binding of this construct to a binary nRBPfull-length-DNA complex as interaction partner in 
ITC experiments (section 3.2.5). The binding constant is one order of magnitude lower 
than that of NotchRamANK, for which binding to nRBPfull-length-DNA could initially also not 
be visualized on EMSAs. These experiments indicate that one part of EBNA2, which is 
included in EBNA2259-435 but not in EBNA2291-355 and which has not been mapped for the 
interaction with RBP-Jκ contributes to the binding and enhances affinity. 
Secondary structure prediction programs find that a large part of EBNA2 contains low 
complexity regions and few defined secondary structure elements. The stretches containing 
multiple prolines in particular introduce considerable flexibility into the protein chain. 
Although it has been established that most of the poly-proline regions do not contribute to 
Discussion 
 
 146
the transactivation activity of EBNA2 it cannot be excluded that these prolines enable a 
number of other protein-protein-interactions.  
A BLAST similarity search with EBNA2 produces very few homologues in other viruses 
and finds no significant homologies to cellular proteins. The closest match with 39% 
sequence identity is found in herpesvirus papio, a virus infecting baboons, followed by 
cercopithecine herpesviruses 12 and 15. The identical patches include the conserved WW 
binding motif. Other viruses belonging to the family of gamma herpesviruses do not 
express similar proteins, although they may have functional analogues, which may display 
similar structural features despite a very low sequence identity, or even in absence of any 
identity. It is, however, remarkable that as efficient a protein as EBNA2 would not have 
evolved or been transferred to other viruses of the same family. This suggests that EBNA2 
has appeared quite recently in evolution. 
One protein expressed upon infection of cells with human herpesvirus 8 (Kaposi’s 
sarcoma-associated herpesvirus, KHSV) has some non-sequential similarities to EBNA2. 
Like EBV and a number of other members of the herpes virus family, KHSV displays two 
alternative life cycle programs upon infection of host cells: latent and lytic infection. 
Among the products of the limited number of latency genes the gene product LANA 
(Latency-Associated Nuclear Antigen) is most likely critical for establishing latent KHSV 
infection. This high molecular mass protein (222 to 234 kDa) has three distinct domains, 
including a proline-rich one, a characteristic it has in common with EBNA2. Another 
region comprises long glutamic  and aspartic acid-rich repeats as well as a glutamine-rich 
domain. These features are usually found in low complexity regions of proteins, especially 
those involved in transcription control. Among the many interactions with proteins 
involved in transcription (basal transcription factors, histones etc.), which have already 
been mapped, it was found that LANA interacts with CIR, a repressor protein interacting 
with RBP-Jκ. LANA also possesses a DNA-binding domain, which is known to bind to a 
sequence being part of the LMP1 promoter, adding to the common features with EBNA2. 
Most strikingly, both LANA and EBNA2 interact with RBP-Jκ to regulate latency of the 
original virus in the host cells (Lan et al., 2005). 
In contrast to LANA, RTA (Replication and Transcription Activator) is the critical protein 
in the switch of HHV-8 from latency to lytic reactivation. Although RTA is the homologue 
of the EBV BRLF1 gene product, it has some functional similarity with EBNA2, e.g. DNA 
binding as well as interaction with transcription factors. Before the interaction of LANA 
and RBP-Jκ was discovered it has been shown to interact with RBP-Jκ to activate 
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expression of genes, whose products are involved in lytic reactivation (Liang et al., 2002). 
Its promoter contains RBP-Jκ-binding sites, which were shown to be targeted by LANA to 
repress lytic reactivation (Lan et al., 2005). If both interactions are indeed present, there 
must be mechanisms developed for the differential regulation of promoters controlling 
genes with such different impacts on the life cycle of the original virus. These may be 
similar to the ones for EBNA2 and Notch-IC binding to RBP-Jκ: slightly different binding 
sites resulting in different conformational changes enabling RBP-Jκ to bind to the 
appropriate target promoters. 
 
4.6 Impact of the stronger binding affinity of EBNA2259-435 compared to that of 
NotchRamANK on the cellular and Epstein-Barr viral system 
 
EMSAs proved the higher binding affinity of the EBNA2-truncation EBNA2259-435 to  
RBP-Jκ compared to that of NotchRamANK. Depending on the oligonucleotide used for 
complex formation with RBP-Jκ the affinity is 20 to 50 times higher than that of 
NotchRamANK.  
The sequence of the oligonucleotide bound to RBP-Jκ has a strong influence on the 
binding affinity of ternary complex partners of RBP-Jκ. It is possible that the alteration of 
certain bases causes a conformational change in RBP-Jκ sufficient to influence its binding 
affinity to other proteins.  
EBNA2 is necessary to maintain proliferation in EREB2.5 cells, a conditionally 
immortalized lymphoblastoid cell line, where EBNA2 is fused to the hormone-binding 
domain of the estrogen receptor, rendering its activity dependent on estrogen (Kempkes 
1995). Independently it was found that Notch-IC, introduced in different ways, was not 
able to fully substitute for EBNA2 in these cells, when EBNA2 expression was abolished 
by estrogen depletion (Hofelmayr et al., 2001). Another group found, however, that 
expression of very high levels of Notch-IC, obtained by repeated selection for EREB2.5 
cells expressing higher than average levels of Notch-IC could finally rescue EREB2.5 cells 
after inactivation of EBNA2 by estrogen depletion (Gordadze et al., 2001). It was found 
that Notch-IC could not increase the expression of LMP1, another EBV protein necessary 
to maintain proliferation in EREB2.5 cells, after estrogen depletion. In contrast, cells 
expressing very high levels of Notch-IC also expressed LMP1 and other proteins usually 
activated exclusively by EBNA2. These findings could so far not be explained.  
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Taking into account that different RBP-Jκ binding oligonucleotides result in differences in 
affinity between the respective ternary complex partners NotchRamANK and EBNA2259-435 a 
possible explanation can be proposed. LMP1 expression is not activated by Notch-IC, but 
by EBNA2. The RBP-Jκ binding sequence within this promoter corresponds to one used in 
the present study (Figure 3.39), which showed that EBNA2259-435 binds more strongly to 
RBP-Jκ bound to this sequence than NotchRamANK. The transactivation activity of EBNA2 
and the lack of transactivation when Notch replaces EBNA2 could partly be explained by 
the dependence of the binding affinity of RBP-Jκ for the complex partners on the 
oligonucleotide in the complex, but probably even more by the generally stronger binding 
of EBNA2. Binding of two weakly interacting molecules can be enhanced if 1) other 
proteins are mediating the interaction as scaffolds or 2) the concentration of one or both 
interaction partners is increased so that the binding equilibrium is driven towards formation 
of the complex. In the case of Notch-IC overexpressed at unusually high levels exactly this 
could have been the case. The excess supply of Notch-IC shifts the equilibrium, especially 
as RBP-Jκ is anyway generally expressed at moderate levels. 
Both Notch-IC and EBNA2 were shown to act similarly on several promoters, but also 
differences have been found, which, apart from the different binding affinity to RBP-Jκ, 
could arise from their slightly different binding sites on RBP-Jκ resulting in slightly 
different conformational changes in RBP-Jκ. Furthermore, the most intriguing difference 
between EBNA2 and Notch, apart from the PEST sequence labeling Notch for rapid 
breakdown by the ubiquitin-proteasome pathway, lies in the extracellular domain of Notch, 
which enables a tight control of the expression of all Notch1 target genes. EBNA2 does not 
possess any such control element.  
In general, a signaling protein is involved not only in a single isolated pathway but in 
several pathways with different feedback loops, creating a complicated and still largely 
unknown network, which provides the appropriate reaction of cells upon different sets of 
stimuli. In the present case, only one pathway is examined, excluding the possible 
influence of others, which could also involve Notch and/or EBNA2.  
A set of additional interacting proteins at the transcription initiation level is already known 
for both EBNA2 and Notch-IC. Components of the basal transcription machinery interact 
with both proteins (TFIIH, TBP) as well as histone acetyltransferases (EBNA2: p300/CBP 
and PCAF; Notch-IC: p300/CBP, PCAF and GCN5) and proteins binding to RBP-Jκ 
(SKIP).  
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An important question concerns the origin of the generally higher binding affinity of 
EBNA2259-435 compared to NotchRamANK and the impact of this higher affinity on the 
infection process of Epstein-Barr virus. 
 Up to 95% of individuals may be infected by EBV depending on the origin of human 
populations. The high affinity of viral proteins for other cellular proteins may well 
contribute to high levels of infection as the displacement of the usual interaction partners 
puts the infected cells into a latency phase rather than resulting in cell destruction upon 
virus production.  
During latency infected resting B-cells do not express EBV proteins. Even in many of the 
malignant diseases caused by EBV especially EBNA2 is not expressed. It is produced, 
though, in tumours developed by immunocompromised patients, such as those infected 
with HIV. 
The applicability for only a small percentage of patients whose tumours are caused by EBV 
together with the findings in the present work, that EBNA2 has a much stronger affinity for 
RBP-Jκ than Notch-IC raise questions regarding the chances of success of a therapeutic 
attack at this stage of the viral cycle. Since EBNA2 and Notch-IC bind to at least adjacent 
sites on RBP-Jκ and compete for the binding a drug will most likely expel Notch-IC rather 
than EBNA2 from RBP-Jκ.  
 
4.7 Further experiments and outlook 
 
The crystal structure of a ternary complex of RBP-Jκ bound to DNA and NotchRam or 
NotchRamANK would confirm the findings described in this work but also unravel further 
details of the structural changes occurring in NotchRam upon binding RBP-Jκ. The current 
state of the work suggests that the formation of suitable protein crystals with NotchRam as 
ternary complex partner may essentially be a question of time. Since the proteins seem to 
be very flexible and according to the SAXS model the ternary complex with NotchRamANK 
is very extended it may, however, be difficult to obtain crystals which diffract to high 
resolution. 
A three-dimensional structure of EBNA2 would shed light on the contribution of parts of 
the protein apart from CR6 to binding RBP-Jκ, but several hints of its low complexity and 
flexibility accounting for its many different interactions suggest that this problem may also 
require different approaches. A study currently in progress and using radioactive EMSA   
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(S. Maier, personal communication) aims at the comparison of the affinities of truncated 
EBNA2 proteins combining CR5 and CR6 (construct EBNA2291-355) with adjacent regions 
present in the construct KF214 (EBNA259-435), which was mainly used for the present study. 
One cannot exclude that the usage of an even larger part of EBNA2 for binding studies will 
further increase the gap in affinities of EBNA2 and NotchRamANK for RBP-Jκ, thus directing 
the attention to possible causes for this difference. Only the examination of the whole 
interactome, which most likely connects RBP-Jκ signal transduction to different regulatory 
processes such as splicing (in parts already shown with SKIP; see section 1.2.1) will reveal 
the influence of the binding of other proteins on the affinity of NotchRamANK and EBNA2. 
The study of binding sites of different transcription factors within the promoters of Notch-
IC and EBNA2 target genes and their possible interactions with RBP-Jκ on the one hand or 
Notch or EBNA2 on the other hand is another approach, which may lead to an explanation 
for the different binding behaviour.
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Summary 
 
RBP-Jκ serves as interaction partner for both cellular and viral proteins. The protein 
mediates cellular and Epstein-Barr viral signal transduction, which in both cases results in 
dedifferentiation or immortalization of the cell. The intracellular part of the human Notch1 
protein (Notch-IC) and of the Epstein-Barr viral protein EBNA2 binds to RBP-Jκ and 
expels a corepressor complex to activate transcription. The two proteins have similar 
functions and their binding regions on RBP-Jκ lie in close vicinity or partially overlap.  An 
important step towards a better understanding of the biology of both signal transduction 
pathways is to find differences in the properties of Notch and EBNA2, such as binding 
affinities, stability or binding sites on RBP-Jκ.  
The aim of the present work was therefore to characterize the interaction of RBP-Jκ with 
DNA, proteins and relevant peptides using biochemical, biophysical and structural methods. 
Expression and purification protocols were developed, which enabled us to obtain 
sufficiently large amounts of each complex partner. A high biological activity of the 
individual components was obtained by using different expression systems.  
After the characterization of RBP-Jκ expressed in different systems and of potentially more 
soluble truncations, which may be easier to crystallize, using EMSA and CD spectroscopy, 
all subsequent studies were carried out with recombinant RBP-Jκ proteins obtained from 
insect cells.  In comparison with RBP-Jκ proteins expressed in bacteria, these had a higher 
affinity for DNA as well as for Notch proteins. In contrast, according to EMSA, a high 
biological activity of Notch and EBNA2 proteins expressed in bacteria was found.  
There is some controversy in the literature concerning the parts of Notch-IC involved in the 
binding to RBP-Jκ. The detailed characterization of the interaction of RBP-Jκ with the 
strongest interacting component, NotchRam, and the naturally occurring fusion of Ram with 
seven ankyrin repeats, NotchRamANK, using isothermal titration calorimetry (ITC), EMSA 
and small angle x-ray scattering with binary and ternary complexes allowed us to create 
models, which unambiguously exclude the participation of the ankyrin repeats in the 
binding of RBP-Jκ in a system consisting only of the highly  purified components of the 
complex. CD spectroscopy revealed that free Ram is largely unfolded and folds into largely 
α-helical structures upon binding to RBP-Jκ.  
Cell biological methods usually provide indirect information about interactions but do not 
provide quantitative data regarding the strength. The controlled reaction systems developed 
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in the present study enabled us to detect a 20- to 50-fold higher affinity of EBNA291-355 for 
RBP-Jκ compared to NotchRamANK. Interestingly, first results indicate that the CR6 region 
of EBNA2, which is described as the most important region interacting with RBP-Jκ 
cannot account for the higher affinity. 
A precise description of the binding sites of the interaction partners would require crystals 
of RBP-Jκ in complex with proteins from Notch-IC and/or DNA. The many attempts at 
obtaining suitable crystals were hitherto unsuccessful although we were able to narrow 
down the area of likely crystallization conditions. 
The results obtained by different methods help to clarify the role of the interaction partners 
of RBP-Jκ in the context of infections by the Epstein-Barr virus, which may lead to 
malignant tumours because of both the similarities and functional differences of Notch and 
EBNA2. Furthermore, with the results of the present study the discussion of whether a 
therapeutic attack on the level of the RBP-Jκ-EBNA2 interaction is useful has to be 
resumed. 
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Zusammenfassung 
 
RBP-Jκ dient als Interaktionspartner sowohl für zelluläre als auch für virale Proteine. Hier 
treffen sich zelluläre und Epstein-Barr-virale Signalübermittlung, die in beiden Fällen zur 
Dedifferenzierung bzw. Immortalisierung der Zelle führt. Das humane Notch1-Protein 
bindet an RBP-Jκ und verdrängt einen Korepressorkomplex von RBP-Jκ ebenso wie das 
Epstein-Barr-Virus Protein EBNA2. Die Funktionen beider Proteine sind ähnlich, auch die 
Bindestellen an RBP-Jκ liegen nahe beieinander, wenn sie nicht gar überlappen. Einen 
Unterschied in den Eigenschaften beider Proteine zu finden, sei es Bindungsaffinitäten, 
Stabilität oder Bindungsstellen an RBP-Jκ, ist ein wichtiger Schritt auf dem Weg zum 
besseren Verständnis der Biologie beider Signalwege. 
 
Ziel dieser Arbeit war die biochemische, biophysikalische und strukturelle 
Charakterisierung der Interaktionen von RBP-Jκ mit DNA, Proteinen und relevanten 
Peptidfragmenten. Zu diesem Zwecke wurden Expressions- und Aufreinigungsprotokolle 
entwickelt, die es ermöglichen, jeden gewünschten Komplexbestandteils in grossen 
Mengen und hochrein herzustellen. Die Benutzung unterschiedlicher Expressionssysteme 
garantiert die maximale biologische Aktivität der individuellen Komponenten.  
Nach der Charakterisierung von in unterschiedlichen Systemen exprimiertem RBP-Jκ und 
Trunkationen, die eine grössere Löslichkeit bzw. leichtere Kristallisierbarkeit versprachen 
mittels EMSA und CD-Spektroskopie, wurden sämtliche funktionellen Studien mit aus 
Insektenzellen gewonnenen rekombinanten RBP-Jκ-Proteinen durchgeführt, die im 
Vergleich mit den bakteriell exprimierten RBP-Jκ-Proteinen sowohl eine grössere Affinität 
zu DNA, als auch zu Notch-Proteinen aufwiesen. Im Gegensatz dazu wiesen sowohl die 
verwendeten in Bakterien exprimierten Notch- als auch EBNA2-Proteine ihre volle 
Aktivität auf.   
Die Frage, welche Komponenten des intrazellulären Fragments von Notch1 (Notch-IC) 
tatsächlich an der Bindung an RBP-Jκ beteiligt sind, wird in der Literatur kontrovers 
diskutiert. Durch die eindeutige Detektion der rein physikalischen Interaktion von RBP-Jκ 
mit der stärksten bindenden Komponente, Notch-Ram, sowie der natürlich vorkommenden 
Fusion von Ram mit sieben Ankyrin-Domänen, NotchRamANK, mittels isothermaler 
Titrationskalorimetrie, EMSA sowie durch Röntgenkleinwinkelstreuungsexperimente mit 
binären und ternären Komplexen konnten Modelle erstellt werden, die eine Beteiligung der 
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Ankyrin-Domänen an der Bindung an RBP-Jκ eindeutig ausschliessen. CD-
spektroskopische Untersuchungen belegen, dass ungebunden ungefaltetes Notch-Ram sich 
bei der Bindung an RBP-Jκ in vornehmlich α-helikale Strukturen faltet. 
Zellbiologische und daher meist indirekte Nachweismethoden detektieren ausschliesslich 
die Existenz von Interaktionen, sagen aber wenig über deren Intensität aus.  Durch die 
entwickelten kontrollierten Reaktionssysteme konnte mittels EMSA und isothermaler 
Titrationskalorimetrie eine 20- bis 50-fach höhere Affinität des verwendeten EBNA2-
Proteins im Vergleich zu NotchRamANK detektiert werden. Überdies wurden erste Hinweise 
erhalten, dass die für EBNA2 in der Literatur als Hauptinteraktionsdomäne beschriebene 
Region CR6 nicht allein für die um den Faktor 20 bis 50 höhere Affinität zu RBP-Jκ 
verantwortlich sein kann. 
Hinweisen auf die exakte Bindestelle von Notch-IC an RBP-Jκ durch zellbiologische 
Ansätze wurden durch Kristallisationsversuche nachgegangen, die zur Lösung der 
dreidimensionalen Kristallstruktur von RBP-Jκ komplexiert mit Notch-IC-Fragmenten 
und/oder DNA führen sollten. Obwohl dies bislang nicht gelang, konnten die 
Kristallisationsbedingungen soweit eingeengt werden, dass die Lösung des Problems in 
grosse Nähe gerückt ist.  
 
Die erhaltenen Ergebnisse helfen, einen Teil der offenen Fragen zur Charakterisierung der 
RBP-Jκ-Bindungspartner im Zusammenhang mit Infektionen mit dem Epstein-Barr Virus 
zu beantworten, die sowohl durch die Ähnlichkeit als auch durch die funktionellen 
Unterschiede der beiden Proteine zu bösartigen Krebserkrankungen führen können. 
 
References 
 
 155
References 
 
 
Alland, l., Muhle, R., Hou, H. J., Potes, J., Chin, L., Schreiber-Agus, N., and DePinho, R. 
A. (1997). Role for N-CoR and histone deacetylase in Sin3-mediated transcriptional 
repression. Nature 387, 49-55. 
 
Allday, M. J., and Farrell, P. J. (1994). Epstein-Barr virus nuclear antigen EBNA3C/6 
expression maintains the level of latent membrane protein 1 in G1-arrested cells. J Virol 68, 
3491-3498. 
 
Amakawa, R., Jing, W., Ozawa, K., Matsunami, N., Hamaguchi, Y., Matsuda, F., 
Kawaichi, M., and Honjo, T. (1993). Human Jk recombination signal binding protein gene 
(IGKJRB): comparison with its mouse homologue. Genomics 17, 306-315. 
 
Ambrozkova, M., Puta, F., Fukova, I., Skruzny, M., Brabek, J., and Folk, P. (2001). The 
fission yeast ortholog of the coregulator SKIP interacts with the small subunit of U2AF. 
Biochem Biophys Res Commun 284, 1148-1154. 
 
Artavanis-Tsakonas, S., Matsuno, K., and Fortini, M. E. (1995). Notch signaling. Science 
268, 225-232. 
 
Bateman, A., Birney, E., Durbin, R., Eddy, S. R., Howe, K. L., and Sonnhammer, E. L. 
(2000). The Pfam protein families database. Nucleic Acids Res 28, 263-266. 
 
Bigas, A., Martin, D. I., and Milner, L. A. (1998). Notch1 und Notch2 inhibit myeloid 
differentiation in response to different cytokines. Mol Cell Biol 18, 2324-2333. 
 
Bornkamm, G. W., Hudewentz, J., Freese, U. K., and Zimber, U. (1982). Deletion of the 
nontransforming Epstein-Barr virus strain P3HR-1 causes fusion of the large internal 
repeat to the DSL region. J Virol 43, 952-968. 
 
Bray, S., and Furriols, M. (2001). Notch pathway: Making sense of suppressor of hairless. 
Curr Biol 11, R217-221. 
 
Burns, J. A., Butler, J. C., Moran, J., and Whitesides, G. M. (1991). Selective reduction of 
disulfides by tris-(2-carboxyethyl)-phosphine. J Org Chem 56. 
 
Calender, A., Billaud, M., Aubry, J. P., Banchereau, J., Vuillaume, M., and Lenoir, G. M. 
(1987). Epstein-Barr virus (EBV) induces expression of B-cell activation markers on in 
vitro infection of EBV-negative lymphoma cells. Proc Natl Acad Sci U S A 84, 8060-8064. 
 
Chen, Y., Fischer, W. H., and Gill, G. N. (1997). Regulation of the ERBB-2 promoter by 
RBPJkappa and NOTCH. J Biol Chem 272, 14110-14114. 
 
References 
 
 156
Chung, C. N., Hamaguchi, Y., Honjo, T., and Kawaichi, M. (1994). Site-directed 
mutagenesis study on DNA binding regions of the mouse homologue of Suppressor of 
Hairless, RBP-J kappa. Nucleic Acids Res 22, 2938-2944. 
 
Clarke, D. T., and Jones, G. (2004). CD12: a new high-flux beamline for ultraviolet and 
vacuum-ultraviolet circular dichroism on the SRS, Daresbury. J Synchr Rad 11, 142-149. 
 
Cohen, J. I., and Kieff, E. (1991). An Epstein-Barr virus nuclear protein 2 domain essential 
for transformation is a direct transcriptional activator. J Virol 65, 5880-5885. 
 
Cohen, J. I., Wang, F., Mannick, J., and Kieff, E. (1989). Epstein-Barr virus nuclear 
protein 2 is a key determinant of lymphocyte transformation. Proc Natl Acad Sci U S A 86, 
9558-9562. 
 
Cordier, M., Calender, A., Billaud, M., Zimber, U., Rousselet, G., Pavlish, O., Banchereau, 
J., Tursz, T., Bornkamm, G., and Lenoir, G. M. (1990). Stable transfection of Epstein-Barr 
virus (EBV) nuclear antigen 2 in lymphoma cells containing EBV P3HR1 genome induces 
expression of B-cell activation molecules CD21 and CD23. J Virol 64, 1002-1013. 
 
Dambaugh, T., Hennessy, K., Chamnankit, L., and Kieff, E. (1984). U2 region of Epstein-
Barr virus DNA may encode Epstein-Barr nuclear antigen 2. Proc Natl Acad Sci U S A 81, 
7632-7636. 
 
Dillner, J., Kallin, B., Ehlin-Henriksson, B., Rymo, L., Henle, W., Henle, G., and Klein, G. 
(1986). The Epstein-Barr virus determined nuclear antigen is composed of at least three 
different antigens. Int J Cancer 37, 195-200. 
 
Dou, S., Zeng, X., Cortes, P., Erdjument-Bromage, H., Tempst, P., Honjo, T., and Vales, L. 
D. (1994). The recombination signal sequence-binding protein RBP-2N functions as a 
trancriptional repressor. Mol Cell Biol 14, 3310-3319. 
 
Ehebauer, M. T., Chirgadze, D. Y., Hayward, P., Martinez Arias, A., and Blundell, T. L. 
(2005). High-resolution crystal structure of the human Notch 1 ankyrin domain. Biochem J 
392, 13-20. 
 
Ellisen, L. W., Bird, J., West, D. C., Soreng, A. L., Reynolds, T. C., Smith, S. D., and Sklar, 
J. (1991). TAN-1, the human homolog of Drosophila notch gene, is broken by 
chromosomal translocations in T lymphoblastic neoplasms. Cell 66, 649-661. 
 
Fahraeus, R., Jansson, A., Ricksten, A., Sjoblom, A., and Rymo, L. (1990). Epstein-Barr 
virus-encodes nuclear antigen 2 activates the viral latent membrane protein promoter by 
modulation the activity of a negative regulatory element. Proc Natl Acad Sci U S A 87, 
7390-7394. 
 
Fischer, D., Barret, C., Bryson, K., Elofsson, A., Godzik, A., Jones, D., Karplus, K. J., 
Kelley, L. A., MacCallum, R. M., Pawowski, K., et al. (1999). CAFASP-1: critical 
assessment of fully automated structure prediction methods. Proteins Suppl 3, 209-217. 
Fryer, C. J., White, J. B., and Jones, K. A. (2004). Mastermind recruits CycC:CDK8 to 
phosphorylate the Notch ICD and coordinate activation with turnover. Mol Cell 16, 509-
520. 
References 
 
 157
 
Fuchs, K. P., Bommer, G., Dumont, E., Christoph, B., Vidal, M., Kremmer, E., and 
Kempkes, B. (2001). Mutational analysis of the J recombination signal sequence binding 
protein (RBP-J)/Epstein-Barr virus nuclearantigen 2 (EBNA2) and RBP-J/Notch 
interaction. Eur J Biochem 268, 4639-4646. 
 
Gasteiger, E., Hoogland, C., Gattiker, A., Duvaud, S., Wilkins, M. R., Appel, R. D., and 
Bairoch, A. (2005). Protein identification and Analysis Tools on the ExPASy server. In 
The proteomics Protocols Handbook, J. M. Walker, ed. (Totowa, NJ, Humana Press). 
 
Girard, L., Hanna, Z., Beaulieu, N., Hoemann, C. D., Simard, C., Kozak, C. A., and 
Jolicoeur, P. (1996). Frequent provirus insertional mutagenesis of Notch1 in thymomas of 
MMTVD/myc transgenic mice suggests a collaboration of c-myc and Notch1 for 
oncogenesis. Genes Dev 10, 1930-1944. 
 
Goodbourn, S., and Maniatis, T. (1988). Overlapping positive and negative regulatory 
domains of the human beta-interferon gene. Proc Natl Acad Sci U S A 85, 1447-1451. 
 
Gordadze, A. V., Peng, R., Tan, J., Liu, G., Sutton, R., Kempkes, B., Bornkamm, G. W., 
and Ling, P. D. (2001). Notch1IC Partially replaces EBNA2 Function in B Cells 
Immortalized by Epstein-Barr Virus. J Virol 75, 5899-5912. 
 
Grossman, S. R., Johannsen, E., Tong, X., Yalamanchili, R., and Kieff, E. (1994). The 
Epstein-Barr virus nuclear antigen 2 transactivator ist directed to restonse elements by the J 
kappa recombination signal binding protein. Proc Natl Acad Sci U S A 91, 7568-7572. 
 
Guinier, A. (1939). La diffraction des rayons X aux très petits angles: application á l'étude 
des phénomèns. Ann Phys (Paris) 12. 
 
Hammerschmidt, W., and Sugden, B. (1989). Genetic analysis of immortalizing functions 
of Epstein-Barr virus in human B lymphocytes. Nature 340, 393-397. 
 
Harada, S., Yalamanchili, R., and Kieff, E. (2001). Epstein-Barr virus nuclear protein 2 has 
at least two N-terminal domains that mediate selb-association. J Virol 75, 2482-2487. 
 
Hayward, S. D. (2004). Viral interactions with the Notch pathway. Semin Cancer Biol 14, 
387-396. 
 
Helms, W., Lee, H., Ammerman, M., Parks, A. L., Muskavitch, M. A., and Yedvobnick, B. 
(1999). Engineered truncations in the Drosophila mastermind protein disrupt Notch 
pathway function. Dev Biol 215, 358-374. 
 
Henkel, T., Ling, P. D., Hayward, S. D., and Peterson, M. G. (1994). Mediation of Epstein-
Barr virus EBNA2 transactivation by recombination signal-binding protein J kappa. 
Science 265, 92-95. 
 
Hennessy, K., and Kieff, E. (1985). A second nuclear protein is encoded by Epstein-Barr 
virus in latent infection. Science 227, 1238-1240. 
 
References 
 
 158
Hinuma, Y., Konn, M., Yamaguchi, J., Wudarski, D. J., Blakeslee, J. R., Jr., and Grace, J. 
T., Jr. (1967). Immunofluorescence and herpes-type virus particles in the P3HR-1 Burkitt 
lymphoma cell line. J Virol 1, 1045-1051. 
 
Hofelmayr, H., Strobl, L. J., Marschall, G., Bornkamm, G. W., and Zimber-Strobl, U. 
(2001). Activated Notch1 can transiently substitute for EBNA2 in the maintenance of 
proliferation of LMP1-expressing immortalized B cells. J Virol 75, 2033-2040. 
 
Hofelmayr, H., Strobl, L. J., Stein, C., Laux, G., Marschall, G., Bornkamm, G. W., and 
Zimber-Strobl, U. (1999). Activated mouse Notch1 transactivates Epstein-Barr virus 
nuclear antigen 2-regulated viral promoters. J Virol 73, 2770-2780. 
 
Hsieh, J. J., Henkel, T., Salmon, P., Robey, E., Peterson, M. G., and Hayward, S. D. (1996). 
Truncated mammalian Notch1 activates CBF1/RBP-Jk-repressed genes by a mechanism 
resembling that of Epstein-Barr virus EBNA2. Mol Cell Biol 16, 952-959. 
 
Hsieh, J. J., Zhou, S., Chen, L., Young, D. B., and Hayward, S. D. (1999). CIR, a 
corepressor linking the DNA binding factor CBF1 to the histone deacetylase complex. Proc 
Natl Acad Sci U S A 96, 23-28. 
 
Iso, T., Kedes, L., and Hamamori, Y. (2003). HES and HERP families: multiple effectors 
of the Notch signaling pathway. J Cell Physiol 194, 237-255. 
 
Jarriault, S., Brou, C., Logeat, F., Schroeter, E. H., Kopan, R., and Israel, A. (1995). 
Signalling downstream of activated mammalian Notch. Nature 377, 355-358. 
 
Jennings, B., Preiss, A., Delidakis, C., and Bray, S. (1994). The Notch signalling pathway 
is required for Enhancer of split bHLH protein expression during neurogenesis in the 
Drosophila embryo. Development 120, 3537-3548. 
 
Johannsen, E., Koh, E., Mosialos, G., Tong, X., Kieff, E., and Grossman, S. R. (1995). 
Epstein-Barr virus nuclear protein 2 transactivation of the latent membrane protein 1 
promoter is mediated by J kappa and PU.1. J Virol 69, 253-262. 
 
Kannabiran, C., Zeng, X., and Vales, L. D. (1997). The mammalian transcriptional 
repressor RBP (CBF1) regulates interleukin-6 gene expression. Mol Cell Biol 17, 1-9. 
 
Kao, H. Y., Ordentlich, P., Koyano-Nakagawa, N., Tang, Z., Downes, M., Kintner, C. R., 
Evans, R. M., and Kadesch, T. (1998). A histone deacetylase corepressor complex 
regulates the Notch signal transduction pathway. Genes Dev 12, 2269-2277. 
 
Kato, H., Taniguchi, Y., Kurooka, H., Minoguchi, S., Sakai, T., Nomura-Okazaki, S., 
Tamura, K., and Honjo, T. (1997). Involvement of RBP-J in biological functions of mouse 
Notch1 and its derivatives. Development 124, 4133-4141. 
 
Kelley, L. A., MacCallum, R. M., and Sternberg, M. J. (2000). Enhanced genome 
annotation using structural profiles in the program 3D-PSSM. J Mol Biol 299, 499-520. 
Kempkes, B. (2002) Die Rolle des Epstein-Barr Virus nukleären Antigens 2 (EBNA-2) in 
der B-Zellimmortalisierung, Habilitation, Ludwig-Maximilian-Universität, München. 
 
References 
 
 159
Kempkes, B., Pawlita, M., Zimber-Strobl, U., Eissner, G., Laux, G., and Bornkamm, G. W. 
(1995). Epstein-Barr virus nuclear antigen 2-estrogen receptor fusion proteins transactivate 
viral and cellular genes and interact with RBP-J kappa in a conditional fashion. Virology 
214, 675-679. 
 
Kim, Y. J., Noguchi, S., Hayashi, Y. K., Tsukahara, T., Shimizu, K., and Arahata, K. 
(2001). The product of an oculopharyngeal muscular dystrophy gene, poly(A)-binding 
protein 2, interacts with SKIP and stimulates muscle-specific gene expression. Human 
Molecular Genetics 10, 1129-1139. 
 
Knutson, J. J. (1990). The level of c-fgr RNA is increased by EBNA-2, and Epstein-Barr 
virus gene required for B-cell immortalization. J Virol 64, 2530-2536. 
 
Koch, M. H. J., Vachette, P., and Svergun, D. I. (2003). Small angle scattering: a view on 
the properties, structure and structural changes of biological macromolecules in solution. 
Quaterly Reviews of Biophysics 36, 147-227. 
 
Konarev, P. V., Volkov, V. V., Sokolova, A., Koch, M. H. J., and Svergun, D. I. (2003). 
PRIMUS: a Windows PC-based system for small-angle scattering data analysis. J Appl 
Cryst 36, 1277-1282. 
 
Kopan, R., Nye, J. S., and Weintraub, H. (1994). The intracellular domain of mouse Notch: 
a constitutively activated repressor of myogenesis directed at the basic helix-loop-helix 
region of MyoD. Development 120, 2385-2396. 
 
Kopan, R., Schroeter, E. H., Weintraub, H., and Nye, J. S. (1996). Signal transduction by 
activated mNotch: importance of proteolytic processing and its regulation by the 
extracellular domain. Proc Natl Acad Sci U S A 93, 1683-1688. 
 
Kovall, R. A., and Hendrickson, W. A. (2004). Crystal structure of the nuclear effector of 
Notch signaling, CSL, bound to DNA. EMBO J 23, 3441-3451. 
 
Kurooka, H., Kuroda, K., and Honjo, T. (1998). Roles of the ankyrin repeats and C-
terminal region of the mouse notch1 intracellular region. Nucleic Acids Res 26, 5448-5455. 
Lai, E. C. (2002). Keeping a good pathway down: transcriptional repression of Notch 
pathway target genes by CSL proteins. EMBO Rep 3, 840-845. 
 
Lan, K., Kuppers, D. A., and Robertson, E. (2005). Kaposi´s Sarcoma-associated 
Herpesvirus Reactivation is regulated by Interaction of Latency-associated nuclear Antigen 
with Recombination Signal Sequence-Binding protein Jk, the major downstream Effector 
of the Notch Signaling Pathway. J Virol 79, 3468-3478. 
 
Laux, G., Adam, B., Strobl, L. J., and Moreau-Gachelin, F. (1994). The Spi-1/PU.1 and 
Spi-B ets family transcription factors and the recombination signal binding protein RBP-J 
kappa interact with an Epstein-Barr virus nuclear antigen 2 responsive cis-element. EMBO 
J 13, 5624-5632. 
 
Le Roux, A., Kerdiles, B., Walls, D., Dedieu, J. F., and Perricaudet, M. (1994). The 
Epstein-Barr virus determined nuclear antigens EBNA-3A, -3B, and -3C repress EBNA-2-
References 
 
 160
mediated transactivation of the viral terminal protein 1 gene promoter. Virology 205, 596-
602. 
 
Lecourtois, M., and Schweisguth, F. (1995). The neurogenic suppressor of hairless DNA-
binding protein mediates the transcriptional activation of the enhancer of split complex 
genes triggered by Notch signaling. Genes Dev 9, 2598-2608. 
 
Leong, G. M., Subramaniam, N., Issa, L. L., Barry, J. B., Kino, T., Driggers, P. H., 
Hayman, M. J., Eisman, J. A., and Gardiner, E. M. (2004). Ski-interacting protein, a 
bifunctional nuclear receptor coregulator that interacts with N-CoR/SMRT and p300. 
Biochem Biophys Res Commun 315, 1070-1076. 
 
Li, L., Milner, L. A., Deng, Y., Iwata, M., Banta, A., Graf, L., Marcovina, S., Friedman, C., 
Trask, B. J., Hood, L., and Torok-Storb, B. (1998). The human homolog of rat Jagged1 
expressed by marrow stroma inhibits differentiation of 32D cells through intraction with 
Notch1. Immunity 8, 43-55. 
 
Liang, Y., Chang, J., Lynch, S. J., Lukac, D. M., and Ganem, D. (2002). The lytic switch 
protein of KSHV activates gene expression via functional interaction with RBP-Jk (CSL), 
the target of the Notch signaling pathway. Genes Dev 16, 1977-1989. 
 
Ling, P. D., Hsieh, J. J., Ruf, I. K., Rawlins, D. R., and Hayward, S. D. (1994). EBNA-2 
upregulation of Epstein-Barr virus latency promoters and the cellular CD23 promoter 
utilizes a common targeting intermediate, CBF1. J Virol 68, 5375-5383. 
 
Ling, P. D., Rawlins, D. R., and Hayward, S. D. (1993). The Epstein-Barr virus 
immortalizing protein EBNA-2 is targeted to DNA by a cellular enhancer-binding protein. 
Proc Natl Acad Sci U S A 90, 9237-9241. 
 
Lubman, O. Y., Korolev, S. V., and Kopan, R. (2004). Anchoring notch genetics and 
biochemistry; structural analysis of the ankyrin domain sheds light on existing data. Mol 
Cell 13, 619-626. 
 
Maier, M. M., and Gessler, M. (2000). Comparative analysis of the human and mouse 
Hey1 promoter: Hey genes are new Notch target genes. Biochem Biophys Res Commun 
275, 652-660. 
 
Marshall, D., and Sample, C. (1995). Epstein-Barr virus nuclear antigen 3C is a 
transcriptional regulator. J Virol 69, 3624-3630. 
 
Miller, G., Robinson, J., Heston, L., and Lipman, M. (1974). Differences between 
laboratory strains of Epstein-Barr virus based on immortalization, abortive infection, and 
interference. Proc Natl Acad Sci U S A 71, 4006-4010. 
 
Milner, L. A., Bigas, A., Kopan, R., Brashem-Stein, C., Bernstein, I. D., and Martin, D. I. 
(1996). Inhibition of granulocytic differentiation by mNotch1. Proc Natl Acad Sci U S A 
93, 13014-13019. 
 
Miyazawa, K., Mori, A., Yamamoto, K., and Okudaira, H. (1998). Transcriptional roles of 
CCAAT/enhancer binding protein-beta, nuclear factor-kappaB, and C-promoter binding 
References 
 
 161
factor 1 in interleukin (IL)-1beta-induced IL-6 synthesis by human rheumatoid fibroblast-
like synoviocytes. J Biol Chem 273, 7620-7627. 
 
Modrow, S. (2003). Molekulare Virologie (Heidelberg, Spektrum Verlag). 
 
Mueller-Lantzsch, N., Lenoir, G. M., Sauter, M., Takaki, K., Bechet, J. M., Kuklik-Roos, 
C., Wunderlich, D., and Bornkamm, G. W. (1985). Identification of the coding region for a 
second Epstein-Barr virus nuclear antigen (EBNA 2) by transfection of cloned DNA 
fragments. EMBO J 4, 1805-1811. 
 
Mumm, J. S., and Kopan, R. (2000). Notch signaling: from the outside in. Dev Biol 228, 
151-165. 
 
Murray, R. J., Wang, D., Young, L. S., Wang, F., Rowe, M., Kieff, E., and Rickinson, A. B. 
(1988). Epstein-Barr virus-specific cytotoxic T-cell recognition of transfectants expressing 
the virus-coded latent membrane protein LMP. J Virol 62, 3747-3755. 
 
Nagai, K., Yamaguchi, T., Takami, T., Kawasumi, A., Aizawa, M., Masuda, N., Shimizu, 
M., Tominaga, S., Ito, T., Tsukamoto, T., and Osumi, T. (2004). SKIP modifies gene 
expression by affecting both transcription and splicing. Biochem Biophys Res Commun 
316, 512-517. 
 
Nakagawa, O., McFadden, D. G., Nakagawa, M., Yanagisawa, H., Hu, T., Srivastava, D., 
and Olson, E. N. (2000). Members of the HRT family of basic helix-loop-helix proteins act 
as transcriptional repressors downstream of Notch signaling. Proc Natl Acad Sci U S A 97, 
13655-13660. 
 
Nam, Y., Sliz, P., Song, L., Aster, J. C., and Blacklow, S. C. (2006). Structural basis for 
cooperativity in recruitment of MAML coactivators to Notch transcription complexes. Cell 
124, 973-983. 
 
Nam, Y., Weng, A. P., Aster, J. C., and Blacklow, S. C. (2003). Structural requirements for 
assembly of the CSL.intracellular Notch1.Mastermind-like 1 transcriptional activation 
complex. J Biol Chem 278, 21232-21239. 
 
Öberg, C., Li, J., Pauley, A., Wolf, E., Gurney, M., and Lendahl, U. (2001). The Notch 
intracellular domain is ubiquitinated by the mammalian Sel-10 homolog. JBC 276, 35847-
35853. 
 
Oka, C., Nakano, T., Wakeham, A., de la Pompa, J. L., Mori, C., Sakai, T., Okazaki, S., 
Kawaichi, M., Shiota, K., Mak, T. W., and Honjo, T. (1995). Disruption of the mouse 
RBP-J kappa gene results in early embryonic death. Development 121, 3291-3301. 
 
Oswald, F., Kostezka, U., Astrahantseff, K., Bourteele, S., Dillinger, K., Zechner, U., 
Ludwig, L., Wilda, M., Hameister, H., Knochel, W., et al. (2002). SHARP is a novel 
component of the Notch/RBP-Jkappa signalling pathway. EMBO J 21, 5417-5426. 
 
Oswald, F., Liptay, S., Adler, G., and Schmid, R. M. (1998). NF-kappaB2 is a putative 
target gene of activated Notch-1 via RBP-Jkappa. Mol Cell Biol 18, 2077-2088. 
 
References 
 
 162
Petcherski, A. G. and Kimble, J. (2000). Mastermind is a putative activator for Notch. Curr 
Biol. 10, 471-3. 
 
Petoukhov, M. V., and Svergun, D. I. (2005). Global Rigid Body Modeling of 
Macromolecular Complexes against Small-Angle Scattering Data. Biophys J 89, 1237-
1250. 
 
Pierce, M. M., Raman, C. S., and Nall, B. T. (1999). Isothermal Titration Calorimetry of 
Protein-Protein Interactions. Methods 19, 213-221. 
 
Plaisance, S., Vanden Berghe, W., Boone, E., Fiers, W., and Haegeman, G. (1997). 
Recombination signal sequence binding protein Jkappa is constitutively bound to the NF-
kappaB site of the interleukin-6 promoter and acts as a negative regulatory factor. Mol Cell 
Biol 17, 3733-3743. 
 
Porod, G. (1982). General Theory. In Small angle scattering, O. Glatter, and O. Kratky, eds. 
(London, Academic Press). 
 
Provencher, S. W., and Glockner, J. (1981). Estimation of globular protein secondary 
structure from circular dichroism. Biochemistry 20. 
 
Robertson, E. S. (Editor) (2005). Epstein-Barr Virus; Laister Academic Press. 
 
Robertson, K. D., Hayward, S. D., Ling, P. D., Samid, D., and Ambinder, R. F. (1995). 
Transcriptional activation of the Epstein-Barr virus latency C promoter after 5-azacytidine 
treatment: evidence that demethylation at a single CpG site is crucial. Mol Cell Biol 15, 
6150-6159. 
 
Robey, E., Chang, D., Itano, A., Cado, D., Alexander, H., Lans, D., Weinmaster, G., and 
Salmon, P. (1996). An activated form of Notch influences the choice between CD4 and 
CD8 T cell lineages. Cell 87, 483-492. 
 
Roehl, H., Bosenberg, M., Blelloch, R., and Kimble, J. (1996). Roles of the RAM and 
ANK domains in signaling by the C. elegans GLP-1 receptor. Embo J 15, 7002-7012. 
 
Rohn, J. L., Lauring, A. S., Linenberger, M. L., and Overbaugh, J. (1996). Transduction of 
Notch2 in feline leukemia virus.induced thymic lymphoma. J Virol 70, 8071-8080. 
Rost, B. (1996). Methods in Enzymology 266, 525-539. 
 
Sakai, T., Taniguchi, Y., Tamura, K., Minoguchi, S., Fukuhara, T., Strobl, L. J., Zimber-
Strobl, U., Bornkamm, G. W., and Honjo, T. (1998). Functional replacement of the 
intracellular region of the Notch1 receptor by Epstein-Barr virus nuclear antigen 2. J Virol 
72, 6034-6039. 
 
Sample, J., Young, L. S., Martin, T., Chatman, T., Kieff, E., Rickinson, A. B., and Kieff, E. 
(1990). Epstein-Barr virus types 1 and 2 differ in their EBNA3A, EBNA3B, and EBNA3C 
genes. J Virol 64, 4084-4092. 
 
References 
 
 163
Shi, Y., Downes, M., Xie, W., Kao, H. Y., Ordentlich, P., Tsai, C. C., Hon, M., and Evans, 
R. M. (2001). Sharp, an inducible cofactor that integrates nuclear receptor repression and 
activation. Genes Dev 15, 1140-1151. 
Shirakata, Y., Shuman, J. D., and Coligan, J. E. (1996). Purification of a novel MHC class 
I element binding activity from thymus nuclear extracts reveals that thymic RBP-
Jkappa/CBF1 binds to NF-kappaB-like elements. J Immunol 156, 4672-4679. 
 
Smale, S. T., and Kadonaga, J. T. (2003). The RNA Polymerase II Core Promoter. Annu 
Rev Biochem 72, 449-479. 
 
Smoller, D., Friedel, C., Schmid, A., Bettler, D., Lam, L., and Yedvobnick, B. (1990). The 
Drosophila neurogenic locus mastermind encodes a nuclear protein unusually rich in amino 
acid homopolymers. Genes Dev 4, 1688-1700. 
 
Struhl, G., and Adachi, A. (1998). Nuclear access and action of notch in vivo. Cell 93, 549-
560. 
 
Sung, N. S., Kenney, S., Gutsch, D., and Pagano, J. S. (1991). EBNA-2 transactivates a 
lymphoid-specific enhancer in the BamHI C promoter of Epstein-Barr virus. J Virol 65, 
2164-2169. 
 
Svergun, D. I. (1992). Determination of the regularization parameter in indirect 
transformmethods using perceptual criteria. J Appl Cryst 25. 
 
Svergun, D. I. (1999). Restoring low resolution structure of biological macromolecules 
from solution scattering using simulated annealing. Biophys J 76, 2879-2886. 
 
Svergun, D. I., Petoukhov, M. V., and Koch, M. H. J. (2001). Determination of domain 
structure of proteins from X-ray solution scattering. Biophys J 80, 2946-2953. 
 
Tamura, K., Taniguchi, Y., Minoguchi, S., Sakai, T., Tun, T., Furukawa, T., and Honjo, T. 
(1995). Physical interaction between a novel domain of the receptor Notch and the 
transcription factor RBP-J kappa/Su(H). Curr Biol 5, 1416-1423. 
 
Tani, S., Kurooka, H., Aoki, T., Hashimoto, N., and Honjo, T. (2001). The N- and C-
terminal regions of RBP-J interact with the ankyrin repeats of Notch1 RAMIC to activate 
transcription. Nucleic Acids Res 29, 1373-1380. 
 
Taniguchi, Y., Furukawa, T., Tun, T., Han, H., and Honjo, T. (1998). LIM protein KyoT2 
negatively regulates transcription by association with the RBP-J DNA-binding protein. 
Mol Cell Biol 18, 644-654. 
 
Tong, X., Drapkin, R., Reinberg, D., and Kieff, E. (1995a). The 62- and 80-kDa subunits 
of transcription factor IIH mediate the interaction with Epstein-Barr virus nuclear protein 2. 
Proc Natl Acad Sci U S A 92, 3259-3263. 
 
Tong, X., Drapkin, R., Yalamanchili, R., Mosialos, G., and Kieff, E. (1995b). The Epstein-
Barr virus nuclear protein 2 acidic domain forms a complex with a novel cellular 
coactivatior that can interact with TFIIE. Mol Cell Biol 15, 4735-4744. 
 
References 
 
 164
Tsui, S., and Schubach, W. H. (1994). Epstein-Barr virus nuclear protein 2A forms 
oligomers in vitro and in vivo through a region required for B-cell transformation. J Virol 
68, 4287-4294. 
Tun, T., Hamaguchi, Y., Matsunami, N., Furukawa, T., Honjo, T., and Kawaichi, M. 
(1994). Recognition sequence of a highly conserved DNA binding protein RBP-J kappa. 
Nucleic Acids Res 22, 965-971. 
 
Van Stokkum, I. H. M., Spoelder, H. J. W., Bloemendal, M., Van Grondelle, R., and Groen, 
F. C. A. (1990). Estimation of protein secondary structure and error analysis from CD 
spectra. Anal Biochem 191, 110-118. 
 
Wallberg, A. E., Pedersen, K., Lendahl, U., and Roeder, R. G. (2002). p300 and PCAF act 
cooperatively to mediate transcriptional activation from chromatin templates by notch 
intracellular domains in vitro. Mol Cell Biol 22, 7812-7819. 
 
Waltzer, L., Bourillot, P. Y., Sergeant, A., and Manet, E. (1995). RBP-J kappa repression 
activity is mediated by a co-repressor and antagonized by the Epstein-Barr virus 
transcription factor EBNA2. Nucleic Acids Res 23, 4939-4945. 
 
Waltzer, L., Logeat, F., Brou, C., Israel, A., Sergeant, A., and Manet, E. (1994). The 
human J kappa recombination signal sequence binding protein (RBP-J kappa) targets the 
Epstein-Barr virus EBNA2 protein to its DNA responsive elements. EMBO J 13, 5633-
5638. 
 
Wang, F., Gregory, C., Sample, C., Rowe, M., Liebowitz, D., Murray, R., Rickinson, A., 
and Kieff, E. (1990). Epstein-Barr virus latent membrane protein (LMP1) and nuclear 
proteins 2 and 3C are effectors of phenotypic changes in B lymphocytes: EBNA-2 and 
LMP1 cooperatively induce CD23. J Virol 64, 2309-2318. 
 
Wang, F., Gregory, C. D., Rowe, M., Rickinson, A. B., Wang, D., Birkenbach, M., 
Kikutani, H., Kishimoto, T., and Kieff, E. (1987). Epstein-Barr virus nuclear antigen 2 
specifically induces expression of the B-cell activation antigen CD23. Proc Natl Acad Sci 
U S A 84, 3452-3456. 
 
Washburn, T., Schweighoffer, E., Gridley, T., Chang, D., Fowlkes, B. J., Cado, D., and 
Robey, E. (1997). Notch activity influences the alphabeta versus gammadelta T cell lineage 
decision. Cell 88, 833-843. 
 
Wettstein, D. A., Turner, D. L., and Kintner, C. (1997). The Xenopus homolog of 
Drosophila Suppressor of Hairless mediates Notch signaling during primary neurogenesis. 
Development 124, 693-702. 
 
Wilson, J. J., and Kovall, R. A. (2006). Crystal structure of the CSL-Notch-Mastermind 
ternary complex bound to DNA. Cell 124, 985-996. 
 
Woisetschlaeger, M., Yandava, C. N., Furmanski, L. A., Strominger, J. L., and Speck, S. H. 
(1990). Promoter switching in Epstein-Barr virus during the initial stages of infection of B 
lymphocytes. Proc Natl Acad Sci U S A 87, 1725-1729. 
 
References 
 
 165
Wu, D. Y., Krumm, A., and Schubach, W. H. (2000). Promoter-specific targeting of human 
SWI-SNF complex by Epstein-Barr virus nuclear protein 2. J Virol 74, 8893-8903. 
 
Zhao, B., Marshall, D. R., and Sample, C. E. (1996). A conserved domain of the Epstein-
Barr virus nuclear antigens 3A and 3C binds to a discrete domain of Jkappa. J Virol 70, 
4228-4236. 
 
Zhou, S., Fujimuro, M., Hsieh, J. J., Chen, L., Miyamoto, A., Weinmaster, G., and 
Hayward, S. D. (2000). SKIP, a CBF1-associated protein, interacts with the ankyrin repeat 
domain of NotchIC to facilitate NotchIC function. Mol Cell Biol 20, 2400-2410. 
 
Zhou, S., and Hayward, S. D. (2001). Nuclear localization of CBF1 is regulated by 
interactions with the SMRT corepressor complex. Mol Cell Biol 21, 6222-6232. 
 
Zimber-Strobl, U., Strobl, L. J., Meitinger, C., Hinrichs, R., Sakai, T., Furukawa, T., Honjo, 
T., and Bornkamm, G. W. (1994). Epstein-Barr virus nuclear antigen 2 exerts its 
transactivating function through interaction with recombination signal binding protein 
RBP-J kappa, the homologue of Drosophila Suppressor of Hairless. EMBO J 13, 4973-
4982. 
 
Zimber-Strobl, U., Suentzenich, K. O., Laux, G., Eick, D., Cordier, M., Calender, A., 
Billaud, M., Lenoir, G. M., and Bornkamm, G. W. (1991). Epstein-Barr virus nuclear 
antigen 2 activates transcription of the terminal protein gene. J Virol 65, 415-423. 
 
Zweifel, M. E., Leahy, D. J., and Barrick, D. (2005). Structure and Notch receptor binding 
of the tandem WWE domain of Deltex. Structure (Camb) 13, 1599-1611. 
 
Zweifel, M. E., Leahy, D. J., Hughson, F. M., and Barrick, D. (2003). Structure and 
stability of the ankyrin domain of the Drosophila Notch receptor. Protein Sci 12, 2622-
2632. 
 
Acknowledgments 
 
 166
Acknowledgements 
I am grateful to the EMBL for having given me the opportunity to do my PhD in the lively 
international environment of the Hamburg Outstation, which provided a unique scientific 
and cultural experience. I particularly thank Matthias Wilmanns who kindly took me in his 
group, for his support and useful discussions. Special thanks go to Bettina Kempkes from 
GSF in Munich for generously hosting me in her laboratory for extended periods and 
giving me the opportunity to learn most of what I know about cell biology and supporting 
my work at the University of Munich.  
I thank Dr. Dirk Eick and Prof. Patrick Cramer for accepting to provide expert opinions 
about my work. 
Many thanks go to the members of my thesis advisory committee, especially to Paul 
Tucker who kindly read the manuscript and made many useful suggestions.  
Many people have been supporting me in different ways during the last four years. 
The members of Bettina’s laboratory have always welcomed and helped me, whenever I 
was there but often also at a distance. Thanks to Sabine Maier, Claudia Popp and Sarah 
Valencia for fruitful discussions and suggestions and support in the difficult times, which I 
guess, arise during any PhD. I am particularly grateful to Sabine and Andrea Hartmann for 
trying to introduce a structural biologist to the methodology of cell biology. 
At the EMBL Hamburg I thank Eleni Mumtsidu and Young-Hwa Song for reading early 
versions of the manuscript and making useful suggestions. Special thanks go to Eleni for 
her great help with the insect cell culture and to Dimitri Svergun and his group for their 
help in the SAXS data collection and evaluation. Christian Neufeld and Robert Janowski 
introduced me to the software to build and edit structural models.  
I am also grateful to Martin von Bergen from the Max-Planck Group for Structural 
Molecular Biology, who advised me on CD spectroscopy, and Dave Clarke from the SRS 
Daresbury Laboratory, who did the same with synchrotron CD. 
Many thanks go to the entire EMBL staff for their help and kindness during these years. 
Beyond strict work I am grateful to Jack and Stephanie King-Scott, Eleni, Rika Werner and 
Christian Neufeld for their friendship and support – often in edible form - and for the good 
time we had together.  
 
Finally, I would like to thank my mother and my familiy for providing the best place to 
recharge the batteries in every respect in good and bad times.                           
Lebenslauf 
 
 167
Lebenslauf 
 
 
PERSÖNLICHE DATEN 
 
Name     Karen Henning 
Geburtsdatum    05.10.1976 
Geburtsort   Brilon 
Familienstand   ledig 
Nationalität    Deutsch 
 
 
ANSCHRIFT 
 
Straße/Hausnummer   Mansteinstr. 28 
Postleitzahl, Ort   20253 Hamburg 
 
 
SCHULAUSBILDUNG 
 
1983-1987   Martin-Luther-Grundschule Brilon  
1987-1990   Gymnasium Petrinum Brilon 
09.1990 -  06.1996  Friedrich-Spee-Gynmasium Rüthen mit Abschluss Abitur 
 
 
STUDIUM/STUDIENABSCHNITTE 
 
10.1996 – 09.2001   Universität: Friedrich-Schiller-Universität Jena 
Fach: Biochemie 
Abschluss: Diplom 
 
09.2000 – 06.2001   IMB Jena 
    Diplomarbeit im Bereich Strukturbiologie 
   
04.2003 – 01.2006   Ludwig-Maximilians-Universität München 
Fach: Biologie 
Abschluss: Promotion 
 
 
Lebenslauf 
 
 168
 
STIPENDIEN 
  
04.1999 – 09.2001   Konrad-Adenauer-Stiftung 
03.2000 – 07.2000  Erasmus Programm der Europäischen Union 
 
 
SPRACHKENNTNISSE 
 
Deutsch    Muttersprache 
Englisch    Fließend 
Französisch    Konversationsniveau 
Spanisch    Konversationsniveau 
Japanisch    Grundkenntnisse 
 
 
BERUFSERFAHRUNG 
 
07.1999 – 09.1999  UC Berkeley, Berkeley, CA 
    Praktikum am Institute of Cell Biology 
 
03.2000 – 06.2000   Karl-Franzens-Universität Graz,Österreich 
    Praktikum am Institut für Vaskuläre Zellbiologie 
 
 
 
 
 
